srdx-10q_20161231.htm

0001564590-17-000937.txt : 20170203 0001564590-17-000937.hdr.sgml : 20170203 20170203141516 ACCESSION NUMBER: 0001564590-17-000937 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 77 CONFORMED PERIOD OF REPORT: 20161231 FILED AS OF DATE: 20170203 DATE AS OF CHANGE: 20170203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SURMODICS INC CENTRAL INDEX KEY: 0000924717 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 411356149 STATE OF INCORPORATION: MN FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-23837 FILM NUMBER: 17571545 BUSINESS ADDRESS: STREET 1: 9924 W 74TH ST CITY: EDEN PRAIRIE STATE: MN ZIP: 55344 BUSINESS PHONE: 9525007000 MAIL ADDRESS: STREET 1: 9924 WEST 74TH ST CITY: EDEN PRAIRIE STATE: MN ZIP: 55344 FORMER COMPANY: FORMER CONFORMED NAME: BSI CORP DATE OF NAME CHANGE: 19970506 10-Q 1 srdx-10q_20161231.htm SRDX-Q1-20161231 srdx-10q_20161231.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2016

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________ to ______________

Commission File Number: 0-23837

Surmodics, Inc.

(Exact name of registrant as specified in its charter)

MINNESOTA

41-1356149

(State of incorporation)

(I.R.S. Employer

Identification No.)

9924 West 74th Street

Eden Prairie, Minnesota 55344

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (952) 500-7000

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐		Accelerated filer	☒
Non-accelerated filer	☐	(Do not check if a smaller reporting company)	Smaller reporting company	☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant’s Common Stock, $.05 par value per share, outstanding as of January 31, 2017 was 13,266,526.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION
Item 1.	Unaudited Condensed Financial Statements	Error! Bookmark not defined.
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	22
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	29
Item 4.	Controls and Procedures	30
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	32
Item 1A.	Risk Factors	32
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	32
Item 3.	Defaults Upon Senior Securities	32
Item 4.	Mine Safety Disclosures	32
Item 5.	Other Information	32
Item 6.	Exhibits	33

SIGNATURES

EX-12

EX-31.1

EX-31.2

EX-32.1

EX-32.2

EX-101 INSTANCE DOCUMENT

EX-101 SCHEMA DOCUMENT

EX-101 CALCULATION LINKBASE DOCUMENT

EX-101 DEFINITION LINKBASE DOCUMENT

EX-101 LABEL LINKBASE DOCUMENT

EX-101 PRESENTATION LINKBASE DOCUMENT

PART I. FINANCIAL INFORMATION

Item 1. Unaudited Condensed Financial Statements

Surmodics, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

	December 31,			September 30,
	2016			2016
(in thousands, except share and per share data)	(Unaudited)
ASSETS
Current Assets:
Cash and cash equivalents	$	17,653		$	24,987
Available-for-sale securities		27,474			21,954
Accounts receivable, net of allowance for doubtful accounts of $10 and $19 as of December 31, 2016 and September 30, 2016, respectively		6,504			6,869
Inventories		3,472			3,579
Income tax receivable		358			697
Prepaids and other		1,183			472
Total Current Assets		56,644			58,558
Property and equipment, net		20,186			19,601
Deferred tax assets		4,286			5,027
Intangible assets, net		21,094			22,525
Goodwill		25,694			26,555
Other assets		721			628
Total Assets	$	128,625		$	132,894

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	1,611		$	1,622
Accrued liabilities:
Compensation		1,364			5,418
Due to customers		340			881
Accrued other		1,563			1,109
Contingent consideration		925			925
Deferred revenue		131			180
Total Current Liabilities		5,934			10,135
Contingent consideration, less current portion		13,366			13,592
Deferred revenue, less current portion		258			188
Other long-term liabilities		1,884			2,146
Total Liabilities		21,442			26,061
Commitments and Contingencies (Note 15)
Stockholders’ Equity:
Series A Preferred stock- $.05 par value, 450,000 shares authorized; no shares issued and outstanding		—			—
Common stock- $.05 par value, 45,000,000 shares authorized; 13,268,530 and 13,208,443 shares issued and outstanding, respectively		663			660
Additional paid-in capital		7,009			6,754
Accumulated other comprehensive (loss) income		(935	)		1,273
Retained earnings		100,446			98,146
Total Stockholders’ Equity		107,183			106,833
Total Liabilities and Stockholders’ Equity	$	128,625		$	132,894

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Surmodics, Inc. and Subsidiaries

Condensed Consolidated Statements of Income

		Three Months Ended
		December 31,
		2016			2015
(In thousands, except per share data)	(Unaudited)
Revenue:
Product sales		$	7,701		$	7,181
Royalties and license fees			8,001			7,954
Research, development and other			2,059			1,406
Total revenue			17,761			16,541
Operating costs and expenses:
Product costs			2,628			2,366
Research and development			5,970			3,634
Selling, general and administrative			4,862			3,648
Acquisition transaction, integration and other costs			—			2,491
Acquired intangible asset amortization			596			354
Contingent consideration accretion expense			437			109
Total operating costs and expenses			14,493			12,602
Operating income			3,268			3,939
Other income (loss):
Investment income, net			85			1
Foreign exchange gain (loss)			674			(135	)
Other income (loss), net			759			(134	)
Income before income taxes			4,027			3,805
Income tax provision			(1,727	)		(1,152	)
Net income		$	2,300		$	2,653

Basic net income per share		$	0.17		$	0.20
Diluted net income per share		$	0.17		$	0.20
Weighted average number of shares outstanding:
Basic			13,200			12,966
Diluted			13,446			13,186

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Surmodics, Inc. and Subsidiaries

Condensed Consolidated Statements of Comprehensive Income

	Three Months Ended
	December 31,
	2016			2015
(In thousands)	(Unaudited)
Net income	$	2,300		$	2,653
Other comprehensive (loss) income:
Unrealized holding gains (losses) on available-for-sale securities, net of tax		46			(2	)
Foreign currency translation adjustments		(2,254	)		408
Other comprehensive (loss) income		(2,208	)		406
Comprehensive income	$	92		$	3,059

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Surmodics, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

	Three Months Ended
	December 31,
	2016			2015
(in thousands)	(Unaudited)
Operating Activities:
Net income	$	2,300		$	2,653
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		1,282			909
Stock-based compensation		789			684
Contingent consideration accretion		437			109
Unrealized foreign exchange (income) loss		(663	)		135
Deferred taxes		742			753
Other		(5	)		(3	)
Change in operating assets and liabilities, net of acquisitions:
Accounts receivable		345			2,194
Inventories		73			(83	)
Prepaids and other		(746	)		(75	)
Accounts payable and accrued liabilities		(2,713	)		(1,354	)
Income taxes		82			356
Deferred revenue		28			—
Net cash provided by operating activities		1,951			6,278
Investing Activities:
Purchases of property and equipment		(1,545	)		(384	)
Purchases of available-for-sale securities		(12,541	)		—
Maturities of available-for-sale securities		7,071			—
Payments for acquisition, net of cash acquired		—			(18,166	)
Net cash used in investing activities		(7,015	)		(18,550	)
Financing Activities:
Issuance of common stock		13			10
Payments for taxes related to net share settlement of equity awards		(2,129	)		(353	)
Payment of deferred financing costs		(38	)		—
Payment of contingent consideration		—			(305	)
Net cash used in financing activities		(2,154	)		(648	)
Effect of exchange rate changes on cash		(116	)		—
Net change in cash and cash equivalents		(7,334	)		(12,920	)
Cash and Cash Equivalents:
Beginning of period		24,987			55,588
End of period	$	17,653		$	42,668
Supplemental Information:
Cash paid for income taxes	$	897		$	42
Noncash transactions from investing and financing activities:
Acquisition of property and equipment on account	$	227		$	54
Deferred financing costs in accounts payable		45			—
Contingent consideration and debt assumed in Creagh Medical transaction		—			9,857
Issuance of performance shares, restricted and deferred stock units		2,414			1,073

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Surmodics, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

Period Ended December 31, 2016

(Unaudited)

1. Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S.”) (“GAAP”) and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, needed to fairly present the financial results of Surmodics, Inc. and subsidiaries (“Surmodics” or the “Company”) for the periods presented. These financial statements include some amounts that are based on management’s best estimates and judgments. These estimates may be adjusted as more information becomes available, and any adjustment could be significant. The impact of any change in estimates is included in the determination of net income in the period in which the change in estimate is identified. The results of operations for the three months ended December 31, 2016 are not necessarily indicative of the results that may be expected for the entire 2017 fiscal year.

In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), the Company has omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited consolidated financial statements of the Company. These unaudited condensed consolidated financial statements should be read together with the audited consolidated financial statements for the fiscal year ended September 30, 2016, and footnotes thereto included in the Company’s Form 10-K as filed with the SEC on December 2, 2016.

2. New Accounting Pronouncements

Accounting Standards to be Implemented

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) Update No. 2014-09, Revenue from Contracts with Customers (ASC Topic 606). Principles of this guidance require entities to recognize revenue in a manner that depicts the transfer of goods or services to customers in amounts that reflect the consideration an entity expects to be entitled to in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting standard will be effective for the Company beginning in the first quarter of fiscal year 2019 (October 1, 2018) using one of two prescribed retrospective methods. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s business model and consolidated results of operations, cash flows and financial position. The Company expects to complete its evaluation during fiscal 2017. Based on a preliminary assessment, the Company currently estimates the impact may be material due to the potential acceleration of minimum license fees and a one quarter acceleration of royalty revenue pursuant to our hydrophilic license agreements.

In February 2016, the FASB issued Accounting Standards Update ASU 2016-02, Leases (ASC Topic 842). The new guidance primarily affects lessee accounting, while accounting by lessors will not be significantly impacted by the update. The update maintains two classifications of leases: finance leases, which replace capital leases, and operating leases. Lessees will need to recognize a right-of-use asset and a lease liability on the statement of financial position for those leases previously classified as operating leases under the old guidance. The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for direct costs. The accounting standard will be effective for the Company beginning the first quarter of fiscal year 2020 (October 1, 2019) and will be applied using a modified retrospective approach. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s results of operations, cash flows and financial position.

In June 2016, the FASB issued ASU No 2016-13, Financial Instruments – Credit Losses (ASC Topic 326), Measurement of Credit Losses on Financial Statements. This ASU requires a financial asset (or a group of financial assets) measured at an amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The accounting standard will be effective for the Company beginning in the first quarter of fiscal 2020 (October 1, 2019). Early adoption is permitted and the guidance will be applied using a modified retrospective approach. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s results of operations, cash flows and financial position.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new guidance clarifies requirements for presentation and classification of the following items within the statement of cash flows: debt prepayments, settlement of zero coupon debt instruments, contingent consideration payments, insurance proceeds, securitization transactions and distributions from equity method investees. The update also addresses classification of transactions that have characteristics of more than one class of cash flows. The accounting standard will be effective for the Company beginning in the first quarter of fiscal 2018. Early adoption is permitted, including adoption in an interim period, and the guidance will be applied retrospectively. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s condensed consolidated statements of cash flows.

In January 2017, the FASB issued ASU No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The new guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The accounting standard will be effective for the Company beginning in its fiscal 2020. Early adoption is permitted, and the guidance will be applied prospectively. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s condensed consolidated financial statements.

Accounting Standards Implemented

In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (ASC Topic 718): Improvements to Employee Share-Based Payment Accounting. The accounting standard intends to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The accounting standard is effective for the Company beginning in the first quarter of fiscal 2018 (October 1, 2017), and early adoption is permitted. The Company elected to early-adopt this accounting standard in the fourth quarter of fiscal 2016, for the fiscal year ended September 30, 2016. As a result of the adoption, the Company records excess tax benefits and certain tax deficiencies as income tax expense or benefit in the condensed consolidated statements of income, whereas such excess tax benefits or tax deficiencies were previously recorded in additional paid-in capital. As this guidance was applied retroactively to the beginning of the fiscal year ended September 30, 2016, previously reported quarterly income tax and net income for interim periods therein were adjusted for the effects of the adoption. This resulted in an adjustment to reduce the income tax provision and increase net income by $0.1 million in the three months ended December 31, 2015, with a corresponding increase in net income per basic and diluted share of $0.01 per share.

The guidance also requires presentation of excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. Prior to the adoption of ASU No. 2016-09, cash flows resulting from the tax benefits generated by tax deductions in excess of the compensation cost recognized for those options (excess tax benefits) are classified as financing cash flows. During the three months ended December 31, 2015, the Company realized tax benefits from stock options resulting in approximately $0.1 million of gross excess tax benefits, which are included as a component of cash flows from operating activities for the three months ended December 31, 2015 in the accompanying condensed consolidated statements of cash flows. This amount was previously reported as a component of cash flows from financing activities, but has been reclassified to conform to current accounting guidance.

No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s condensed consolidated financial statements.

3. Business Combinations

For all business combinations, the Company records all assets and liabilities of the acquired business, including goodwill and other identified intangible assets, at their respective fair values as of the acquisition date. Contingent consideration, if any, is recognized at its fair value on the acquisition date and changes in fair value are recognized in earnings until settlement. Acquisition-related transaction costs are expensed as incurred.

Creagh Medical Ltd.

through September 30, 2018. The payment of the milestones, if any, will occur in the quarter ending December 31, 2018. Total transaction, integration and other costs associated with the Creagh Medical acquisition aggregated $2.4 million for the quarter ended December 31, 2015. The operating results of Creagh Medical have been included in the Company’s Medical Device segment since the acquisition date. The Company realized $0.5 million of revenue and a loss of $0.3 million from the Creagh Medical operations for the three months ended December 31, 2015.

Creagh Medical designs and manufactures high-quality percutaneous transluminal angioplasty (“PTA”) balloon catheters. Since 2006, Creagh Medical has grown its technical and product capability with PTA products approved throughout the world, including Europe, the United States, and Japan. With these resources, the Company is uniquely positioned to offer a total solutions approach from product design and development through in-house extrusion, balloon forming, top-assembly and packaging and regulatory capabilities to approved products for exclusive distribution.

The purchase price of Creagh Medical consisted of the following:

(Dollars in thousands)
Cash paid	$	18,449
Debt assumed		761
Contingent consideration		9,064
Total purchase price		28,274
Less cash and cash equivalents acquired		(251	)
Total purchase price, net of cash acquired	$	28,023

The following table summarizes the final allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the Creagh Medical acquisition:

	Fair Value (Dollars in thousands)			Estimated Useful Life (In years)
Current assets	$	896		N/A
Property and equipment		634		1.0-10.0
Trade name		75		N/A
Developed technology		1,787		7.0
In-process research and development		942		N/A
Customer relationships		11,119		7.0-10.0
Other noncurrent assets		81		N/A
Current liabilities		(942	)	N/A
Deferred tax liabilities		(9	)	N/A
Net assets acquired		14,583
Goodwill		13,440		N/A
Total purchase price, net of cash acquired	$	28,023

The Creagh Medical goodwill, which is a result of acquiring and retaining the Creagh Medical existing workforce and expected synergies from integrating their business into the Company’s Medical Device segment, is not deductible for tax purposes.

NorMedix, Inc.

On January 8, 2016, the Company acquired 100% of the shares of NorMedix, Inc. (“NorMedix”), a privately owned design and development company focused on ultra thin-walled, minimally invasive catheter technologies based in Plymouth, Minnesota. The acquisition was financed with cash on hand and contingent seller financing. The Company acquired NorMedix for up to $14.0 million, including an upfront payment of $7.0 million, and up to $7.0 million based on achievement of revenue and value-creating operational milestones through September 30, 2019. Contingent consideration associated with the NorMedix transaction is payable as earned. This acquisition strengthened the Company’s vascular device expertise and Research and Development (“R&D”) capabilities and was a significant component of the Company’s strategy to offer whole-product solutions to medical device customers, while continuing its commitment to consistently deliver innovation in coating technologies. Total transaction, integration and other costs associated with the NorMedix acquisition aggregated $0.1 million for the three months ended December 31, 2015. The operating results for NorMedix have been included in the Medical Device segment since the acquisition date.

The purchase price of NorMedix consisted of the following:

(Dollars in thousands)
Cash paid	$	6,905
Contingent consideration		3,520
Total purchase price		10,425
Less cash and cash equivalents acquired		(17	)
Total purchase price, net of cash acquired	$	10,408

The following table summarizes the final allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the NorMedix acquisition:

	Fair Value (Dollars in thousands)			Estimated Useful Life (In years)
Net current assets	$	113		N/A
Property and equipment		60		N/A
Developed technology		6,850		10.0-14.0
Customer relationships		900		4.0
Deferred tax asset		690		N/A
Other noncurrent asset		13		N/A
Accounts payable		(187	)	N/A
Deferred tax liabilities		(2,483	)	N/A
Net assets acquired		5,956
Goodwill		4,452		N/A
Total purchase price, net of cash acquired	$	10,408

The NorMedix goodwill is a result of acquiring and retaining the NorMedix existing workforce and expected synergies from integrating their business into the Medical Device segment. The goodwill is not deductible for tax purposes.

On a pro forma basis, as if the Creagh medical and NorMedix acquisitions had occurred as of the beginning of fiscal 2016, the Company’s consolidated revenues and net income would have been $17.6 million and $4.2 million for the three months ended December 31, 2015, with basic and diluted earnings per share of $0.32. This unaudited pro forma financial information includes adjustments for additional amortization expense on identifiable intangible assets of $0.4 million and contingent consideration accretion expense of $0.3 million, eliminating non-recurring transactional professional fees of $2.5 million, and tax effect impact of $0.3 million. The tax impact of the adjustments in all periods reflects no tax benefit from contingent consideration accretion as well as a significant portion of our transaction related costs in fiscal 2016 as they are not deductible for tax purposes. Further, Creagh Medical amortization expense does not reflect an Irish tax benefit as we acquired a net operating loss carryforward as of the acquisition date that was offset in the aggregate by deferred tax liabilities and valuation allowance. Therefore, the amortization of Creagh Medical intangible assets results in a decrease in deferred tax liabilities with a corresponding increase to a deferred tax valuation allowance. NorMedix amortization expense reflects a tax benefit based on our incremental U.S. tax rate.

4. Fair Value Measurements

The accounting guidance on fair value measurements defines fair value, establishes a framework for measuring fair value under GAAP, and expands disclosures about fair value measurements. The guidance is applicable for all financial assets and financial liabilities and for all nonfinancial assets and nonfinancial liabilities recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and also considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance.

Fair Value Hierarchy

Accounting guidance on fair value measurements requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1 — Quoted (unadjusted) prices in active markets for identical assets or liabilities.

The Company did not have any Level 1 assets as of December 31, 2016 and September 30, 2016.

Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability.

The Company’s Level 2 assets as of December 31, 2016 and September 30, 2016 consisted of money market funds, commercial paper instruments and corporate bonds.

Level 3 — Unobservable inputs to the valuation methodology that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation.

Level 3 liabilities at December 31, 2016 and September 30, 2016 consist of contingent consideration obligations for the achievement of revenue and value-creating milestones related to the acquisitions of Creagh Medical and NorMedix discussed in Note 3.

In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

In instances where the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability.

The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2016:

(Dollars in thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)			Total Fair Value as of December 31, 2016
Assets
Cash equivalents	$	—	$	13,775	$	—		$	13,775
Available-for-sale securities		—		27,474		—			27,474
Total assets	$	—	$	41,249	$	—		$	41,249

Liabilities
Contingent consideration	$	—	$	—	$	(14,291	)	$	(14,291	)
Total liabilities	$	—	$	—	$	(14,291	)	$	(14,291	)

The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2016:

(Dollars in thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)			Total Fair Value as of September 30, 2016
Assets
Cash equivalents	$	—	$	22,160	$	—		$	22,160
Available-for-sale securities		—		21,954				$	21,954
Total assets	$	—	$	44,114	$	—		$	44,114

Liabilities
Contingent consideration	$	—	$	—	$	(14,517	)	$	(14,517	)
Total liabilities	$	—	$	—	$	(14,517	)	$	(14,517	)

The following table summarizes the changes in the contingent consideration liabilities measured at fair value using Level 3 inputs for the three months ended December 31, 2016 and 2015:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016			2015
Beginning balance	$	14,517		$	—
Additions		—			9,064
Fair value adjustments		—			—
Settlements		—			—
Interest accretion		437			109
Foreign currency translation (gain) loss		(663	)		135
Ending balance	$	14,291		$	9,308

There were no transfers of assets or liabilities to or from amounts measured using Level 3 fair value measurements during fiscal 2017 or 2016.

Valuation Techniques

The valuation techniques used to measure the fair value of assets are as follows:

Cash equivalents — These assets are classified as Level 2 and are carried at historical cost which is a reasonable estimate of fair value because of the relatively short time between origination of the instrument and its expected realization.

Available-for-sale securities — Fair market values for these assets are based on quoted vendor prices and broker pricing in active markets underlying the securities where all significant inputs are observable. To ensure the accuracy of quoted vendor prices and broker pricing, the Company performs regular reviews of investment returns to industry benchmarks and sample tests of individual securities to validate quoted vendor prices with other available market data.

Contingent consideration — The contingent consideration liabilities were determined based on discounted cash flow analyses that included revenue estimates, probability of strategic milestone achievement and a discount rate, which are considered significant unobservable inputs. For the revenue-based milestones, the Company discounted forecasted revenue by 14.1% to 22.8%, which represents the Company’s weighted average cost of capital for each transaction, adjusted for the short-term nature of the cash flows. The resulting present value of revenue was used as an input into an option pricing approach, which also considered the Company’s risk of non-payment of the revenue-based milestones. Non-revenue milestones were projected to have a 65-95% probability of achievement and related payments were discounted using the Company’s estimated cost of debt, or 5.6% to 6.7%. To the extent that actual results differ from these estimates, the fair value of the contingent consideration liabilities could change significantly. The contingent consideration liability related to the Creagh Medical acquisition is denominated in Euros and is not hedged. The Company recorded a foreign currency gain of $0.7 million and a loss of $0.1 million for the three months ended

December 31, 2016 and 2015, respectively, related to this contingent consideration as this obligation was marked to period-end exchange rates.

5. Investments

Investments consisted principally of commercial paper securities and are classified as available-for-sale as of December 31, 2016 and September 30, 2016. Available-for-sale securities are reported at fair value with unrealized gains and losses, net of tax, excluded from the condensed consolidated statements of income and reported in the condensed consolidated statements of comprehensive income as well as a separate component of stockholders’ equity in the condensed consolidated balance sheets, except for other-than-temporary impairments, which are reported as a charge to current earnings. A loss would be recognized when there is an other-than-temporary impairment in the fair value of any individual security classified as available-for-sale, with the associated net unrealized loss reclassified out of accumulated other comprehensive income with a corresponding adjustment to other income (loss). This adjustment results in a new cost basis for the investment. Interest earned on debt securities, including amortization of premiums and accretion of discounts, is included in other income. Realized gains and losses from the sales of debt securities, which are included in other income, are determined using the specific identification method.

The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows:

	December 31, 2016
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial paper and corporate bonds	$	27,487	$	—	$	(13	)	$	27,474
Total	$	27,487	$	—	$	(13	)	$	27,474

	September 30, 2016
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial paper and corporate bonds	$	22,019	$	—	$	(65	)	$	21,954
Total	$	22,019	$	—	$	(65	)	$	21,954

The following table summarizes sales of available-for-sale debt securities:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016		2015
Proceeds from maturities	$	7,071	$	—
Gross realized gains	$	—	$	—
Gross realized losses	$	—	$	—

6. Inventories

Inventories are principally stated at the lower of cost or market using the specific identification method and include direct labor, materials and overhead, with cost of product sales determined on a first-in, first-out basis. Inventories consisted of the following components:

	December 31,		September 30,
(Dollars in thousands)	2016		2016
Raw materials	$	1,724	$	1,766
Work-in process		449		492
Finished products		1,299		1,321
Total	$	3,472	$	3,579

7. Other Assets

Other assets consist of the following:

	December 31,		September 30,
(Dollars in thousands)	2016		2016
ViaCyte, Inc.	$	479	$	479
Other noncurrent assets		242		149
Other assets, net	$	721	$	628

The Company has invested a total of $5.3 million in ViaCyte, Inc. (“ViaCyte”), a privately-held California-based biotechnology firm that is developing a unique treatment for diabetes using coated islet cells, the cells that produce insulin in the human body. The balance of the investment of $0.5 million, which is net of previously recorded other-than-temporary impairments of $4.8 million is accounted for under the cost method and represents less than a 1% ownership interest. The Company does not exert significant influence over ViaCyte’s operating or financial activities.

The carrying value of each cost method investment is reviewed quarterly for changes in circumstances or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost method investments is not adjusted if there are no identified events or changes in circumstances that may have a material adverse effect on the fair value of the investment.

8. Intangible Assets

Intangible assets consist principally of acquired patents and technology, customer lists and relationships, licenses and trademarks. The Company recorded amortization expense of $0.6 million and $0.4 million for the three months ended December 31, 2016 and 2015, respectively.

Intangible assets consisted of the following:

	December 31, 2016
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	16,979	$	(6,434	)	$	10,545
Core technology		8.0		530		(530	)		—
Developed technology		11.8		8,610		(800	)		7,810
Non-compete		5.0		230		(69	)		161
Patents and other		16.5		2,322		(1,312	)		1,010
Subtotal				28,671		(9,145	)		19,526
Unamortized intangible assets:
In-process research and development				927		—			927
Trademarks and trade names				641		—			641
Total			$	30,239	$	(9,145	)	$	21,094

	September 30, 2016
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	17,692	$	(6,123	)	$	11,569
Core technology		8.0		530		(530	)		—
Developed technology		11.8		8,724		(618	)		8,106
Non-compete		5.0		230		(58	)		172
Patents and other		16.5		2,321		(1,275	)		1,046
Subtotal				29,497		(8,604	)		20,893
Unamortized intangible assets:
In-process research and development				987		—			987
Trademarks and trade names				645		—			645
Total			$	31,129	$	(8,604	)	$	22,525

Based on the intangible assets in service as of December 31, 2016, excluding any possible future amortization associated with acquired in-process research and development (“IPR&D”), which has not met technological feasibility as of December 31, 2016, estimated amortization expense for the remainder of fiscal 2017 and each of the next five fiscal years is as follows:

(Dollars in thousands)
Remainder of 2017	$	1,864
2018		2,439
2019		2,439
2020		2,264
2021		2,125
2022		2,085

Future amortization amounts presented above are estimates. Actual future amortization expense may be different as a result of future acquisitions, impairments, completion or abandonment of IPR&D intangible assets, changes in amortization periods, or other factors.

indefinite-lived intangible asset until completion of the IPR&D project or abandonment. Upon completion of the development project (generally when regulatory approval to market the product is obtained), an impairment assessment is performed prior to amortizing the asset over its estimated useful life. If the IPR&D projects are abandoned, the related IPR&D assets would be written off.

9. Goodwill

Goodwill represents the excess of the cost of an acquired entity over the fair value assigned to the assets purchased and liabilities assumed in connection with a business acquisition. Goodwill is not amortized but is subject, at a minimum, to annual tests for impairment in accordance with accounting guidance for goodwill. The carrying amount of goodwill is evaluated annually, and between annual evaluations if events occur or circumstances change indicating that the carrying amount of goodwill may be impaired.

Goodwill as of December 31, 2016 and September 30, 2016 totaled $25.7 million and $26.6 million, respectively. Goodwill in the Medical Device reporting unit represents the gross value from the acquisitions of Creagh Medical and NorMedix in fiscal 2016. Goodwill in the In Vitro Diagnostics reporting unit represents the gross value from the acquisition of BioFX Laboratories, Inc. (“BioFX”) in fiscal 2007.

Goodwill was not impaired in either reporting unit based on the outcome of the fiscal 2016 annual impairment test, and there have been no events or circumstances that have occurred in the first quarter of fiscal 2017 to indicate that goodwill has been impaired.

The change in the carrying amount of goodwill by segment for the three months ended December 31, 2016 was as follows:

(Dollars in thousands)	In Vitro Diagnostics		Medical Device			Total
Balance as of September 30, 2016	$	8,010	$	18,545		$	26,555
Translation adjustment		—		(861	)		(861	)
Balance as of December 31, 2016	$	8,010	$	17,684		$	25,694

10. Stock-based Compensation

The Company has stock-based compensation plans under which it grants stock options, restricted stock awards, performance share awards, restricted stock units and deferred stock units. Accounting guidance requires all share-based payments to be recognized as an operating expense, based on their fair values, over the requisite service period.

The Company’s stock-based compensation expenses were allocated to the following expense categories:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016		2015
Product costs	$	13	$	6
Research and development		125		59
Selling, general and administrative		651		619
Total	$	789	$	684

As of December 31, 2016, approximately $6.2 million of total unrecognized compensation costs related to non-vested awards is expected to be recognized over a weighted average period of approximately 2.5 years. The unrecognized compensation costs above include $2.6 million, remaining to be expensed over the life of the awards, based on payout levels associated with performance share awards that are currently anticipated to be fully expensed because the performance conditions are expected to exceed minimum threshold levels.

Stock Option Awards

The Company uses the Black-Scholes option pricing model to determine the weighted average grant date fair value of stock options granted. The weighted average per-share fair values of stock options granted during the three months ended December 31, 2016 and 2015 were $7.59 and $6.87, respectively. The assumptions used as inputs in the model were as follows:

	Three Months Ended
	December 31,
	2016			2015
Risk-free interest rates		1.7	%		2.0	%
Expected life (years)		4.6			4.6
Expected volatility		34.4	%		36.7	%
Dividend yield		0.0	%		0.0	%

The risk-free interest rate assumption was based on the U.S. Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award. The expected life of options granted was determined based on the Company’s experience. Expected volatility was based on the Company’s stock price movement over a period approximating the expected term. Based on management’s judgment, dividend yields were expected to be 0.0% for the expected life of the options. The Company also estimated forfeitures of options granted, which were based on historical experience.

Non-qualified stock options are granted at fair market value on the date of grant. Non-qualified stock options expire in seven to ten years or upon termination of employment or service as a Board member. With respect to members of our Board, non-qualified stock options generally become exercisable on a pro-rata basis within the one-year period following the date of grant. With respect to our employees, non-qualified stock options generally become exercisable with respect to 25% of the shares on each of the first four anniversaries following the grant date. The stock-based compensation table above includes stock option expenses recognized related to these awards, which totaled $0.3 million and $0.3 million during the three months ended December 31, 2016 and 2015, respectively.

The total pre-tax intrinsic value of options exercised during the three months ended December 31, 2016 and 2015 was less than $0.1 million in each period. The intrinsic value represents the difference between the average exercise price and the fair market value of the Company’s common stock on the last day of the respective fiscal period end.

Restricted Stock Awards

The Company has entered into restricted stock agreements with certain key employees, covering the issuance of common stock (“Restricted Stock”). Under accounting guidance, these shares are considered to be non-vested shares. The Restricted Stock is released to the key employees if they are employed by the Company at the end of the vesting period. Compensation expense has been recognized for the estimated fair value of the common shares and is being charged to income over the vesting term. The stock-based compensation expense table includes Restricted Stock expenses recognized related to these awards, which totaled $0.1 million in each of the three months ended December 31, 2016 and 2015, respectively.

Performance Share Awards

The Company has entered into performance share agreements with certain key employees and executives, covering the issuance of common stock (“Performance Shares”). Performance Shares vest upon the achievement of all or a portion of certain performance objectives (which may include financial or project objectives), which must be achieved during the performance period. The Organization and Compensation Committee of the Board of Directors (the “Committee”) approves the performance objectives used for our executive compensation programs, which objectives were cumulative revenue and cumulative earnings before interest, income taxes, depreciation and amortization (“EBITDA”) for the three-year performance periods for awards granted in fiscal 2015 (2015 – 2017), fiscal 2016 (2016 – 2018) and fiscal 2017 (2017 – 2019). Assuming that the minimum performance level is attained, the number of shares that may actually vest will vary based on performance from 20% (minimum) to 200% (maximum) of the target number of shares. Shares will be issued to participants as soon as practicable following the end of each performance period, subject to Committee approval and verification of results. Awards granted in fiscal 2014 were finalized in the three months ended December 31, 2016 and resulted in the issuance of 38,505 shares (maximum was 78,606 shares) based on the performance objectives relative to actual results achieved during the performance period. The per share compensation cost for each award is fixed on the grant date. Compensation expense is recognized in each period based on management’s best estimate of the achievement level of actual and forecasted results, as appropriate, compared with the specified performance objectives and the related impact on the number

of Performance Shares expected to vest. The stock-based compensation expense table includes the Performance Shares expenses recognized related to these awards, which totaled $0.2 million for both the three months ended December 31, 2016 and 2015.

The fair values of the Performance Shares, at target, were $1.2 million, $1.3 million and $0.9 million in each fiscal year for awards granted in fiscal 2017, 2016 and 2015, respectively.

The aggregate number of shares that could be awarded to our executives if the minimum, target and maximum performance goals are met, based on the fair value at the date of grant is as follows:

Performance Period	Minimum Shares		Target Shares		Maximum Shares
Fiscal 2015 – 2017		8,440		42,199		84,398
Fiscal 2016 – 2018		13,268		66,338		132,676
Fiscal 2017 – 2019		10,437		52,185		104,370

1999 Employee Stock Purchase Plan

Under the 1999 Employee Stock Purchase Plan (“Stock Purchase Plan”), the Company is authorized to issue up to 600,000 shares of common stock. All full-time and part-time U.S. employees can choose to have up to 10% of their annual compensation withheld, with a limit of $25,000, to purchase the Company’s common stock at purchase prices defined within the provisions of the Stock Purchase Plan. As of December 31, 2016 and September 30, 2016, there was $0.1 million of employee contributions included in accrued liabilities in the condensed consolidated balance sheets. Stock compensation expense recognized related to the Stock Purchase Plan for the three months ended December 31, 2016 and 2015 totaled less than $0.1 million in each period. The stock-based compensation table includes the Stock Purchase Plan expenses.

Restricted Stock and Deferred Stock Units

During the three months ended December 31, 2016 and 2015, the Company awarded 6,570 and 8,916 restricted stock units (“RSUs”), respectively, under the 2009 Equity Incentive Plan to non-employee directors and certain key employees in foreign jurisdictions. Forfeiture of 74 RSUs occurred in the first quarter of fiscal 2017. As of December 31, 2016 and September 30, 2016, 35,378 and 32,101 RSUs were outstanding, respectively, with an estimated fair market value of $0.9 million for both periods. RSU awards are not considered issued or outstanding common stock of the Company until they vest. The estimated fair value of the RSUs was calculated based on the closing market price of Surmodics’ common stock on the date of grant. Compensation expense has been recognized for the estimated fair value of the common shares and is being charged to income over the vesting term. The stock-based compensation table includes RSU expenses recognized related to these awards, which totaled less than $0.1 million for both the three months ended December 31, 2016 and 2015.

Directors can also elect to receive their annual fees for services to the Board in deferred stock units (“DSUs”). Certain directors elected this option beginning on January 1, 2013 with deferral elections made annually. During the three months ended December 31, 2016 and 2015, 1,971 and 1,842 units, respectively, were issued with a total fair value of less than $0.1 million in each period. As of December 31, 2016 and September 30, 2016, outstanding DSUs totaled 23,048 and 21,077, respectively, with an estimated fair value of $0.6 million for both periods. These DSUs are fully vested. Stock-based compensation expense related to DSU awards, totaled less than $0.1 million for the three months ended December 31, 2016 and 2015, respectively.

11. Revolving Credit Facility

On November 2, 2016, the Company amended and restated the revolving credit facility. The new agreement increased the available principal to $30.0 million and extended the maturity of the previous facility by three years to November 2019. In addition, the agreement includes a $5.0 million multi-currency overdraft facility in Ireland. Borrowings under the credit facility, if any, will bear interest at a benchmark rate plus a margin ranging from 1.00% to 1.75% based on the Company’s leverage ratio, as defined in the loan agreement. A facility fee is payable quarterly on unused commitments at a rate of 0.15% per annum. The Company has the option to increase the credit facility in increments of $5.0 million up to an additional $20.0 million, subject to approval of the lender. The Company’s obligations under the credit facility are secured by substantially all of its assets, other than intellectual property and real estate, as well as the majority of its equity interest in its subsidiaries.

In connection with the credit facility, the Company is required to comply with certain financial and non-financial covenants. As of December 31, 2016, the Company has no debt outstanding and was in compliance with all financial covenants.

12. Net Income Per Share Data

Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and common equivalent shares outstanding during the period. The Company’s potentially dilutive common shares are those that result from dilutive common stock options, non-vested stock relating to restricted stock awards, restricted stock units, deferred stock units and performance shares.

The following table sets forth the denominator for the computation of basic and diluted net income per share (in thousands):

	Three Months Ended
	December 31,
	2016		2015
Net income available to common shareholders	$	2,300	$	2,653
Basic weighted average shares outstanding		13,200		12,966
Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units, deferred stock units and performance shares		246		220
Diluted weighted average shares outstanding		13,446		13,186

The calculation of weighted average diluted shares outstanding excludes outstanding stock options associated with the right to purchase 0.3 million and 0.4 million shares of common stock for the three months ended December 31, 2016 and 2015, respectively, as their inclusion would have had an antidilutive effect on diluted net income per share.

The Company’s Board of Directors has authorized the repurchase of up to $30.0 million of the Company’s outstanding common stock. This authorization does not have an expiration date.

13. Income Taxes

The Company recorded income tax provisions of $1.7 million and $1.2 million for the three months ended December 31, 2016 and 2015, respectively, representing effective tax rates of 42.9% and 30.3%, respectively. The Company’s effective tax reflects the impact of state income taxes, permanent tax items and discrete tax benefits. The effective income tax rate for the three month periods ended December 31, 2016 and 2015 differs from the U.S. federal statutory tax rate of 35.0% primarily due to transaction costs and contingent consideration accretion associated with the Creagh Medical and NorMedix acquisitions, the domestic production manufacturing deduction and the U.S. federal research and development income tax credit , operating losses in a jurisdiction where tax benefits are offset by a valuation allowance, and discrete tax expense related to expiring stock option awards.

The total amount of unrecognized tax benefits, excluding interest and penalties that, if recognized, would affect the effective tax rate is $1.2 million as of both December 31, 2016 and September 30, 2016. Currently, the Company does not expect the liability for unrecognized tax benefits to change significantly in the next 12 months with the above balances classified on the condensed consolidated balance sheets in other long-term liabilities. Interest and penalties related to unrecognized tax benefits are recorded in income tax provision.

The Company files income tax returns, including returns for its subsidiaries, in the U.S. federal jurisdiction and in various state jurisdictions as well as several non-U.S. jurisdictions. Uncertain tax positions are related to tax years that remain subject to examination. The Internal Revenue Service (“IRS”) completed an examination of the Company’s U.S. income tax return for fiscal 2012 in the fourth quarter of fiscal 2014 with a payment made associated with a timing adjustment. U.S. income tax returns for years prior to fiscal 2013 are no longer subject to examination by federal tax authorities. For tax returns for state and local jurisdictions, the Company is no longer subject to examination for tax years generally before fiscal 2006. For tax returns for non-U.S. jurisdictions, the Company is no longer subject to income tax examination for years prior to 2011. Additionally, the Company has been indemnified of liability for any taxes relating to Creagh Medical and NorMedix for periods prior to the respective acquisition dates, pursuant to the terms of the related share purchase agreements. As of December 31, 2016 and September 30, 2016 there were no undistributed earnings in foreign subsidiaries.

14. Segment and Geographical Information

The Company’s management evaluates performance and allocates resources based on reported results for two reportable segments, based on the criteria set forth in FASB ASC Topic 280, Segment Reporting, as follows: (1) the Medical Device unit, which is comprised of manufacturing balloons and catheters used for a variety of interventional cardiology, peripheral and other applications, surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device, with end markets that include coronary, peripheral, and neurovascular, and urology, among others, and (2) the In Vitro Diagnostics unit, which consists of component products and technologies for diagnostic immunoassay as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, antigens and surface coatings.

During fiscal 2016, the Company acquired Creagh Medical and NorMedix, which are included in the Medical Device segment subsequent to the respective acquisition dates, as further discussed in Note 3.

The tables below present segment revenue, operating income and depreciation and amortization, as follows:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016			2015
Revenue:
Medical Device	$	13,757		$	12,247
In Vitro Diagnostics		4,004			4,294
Total revenue	$	17,761		$	16,541

Operating income:
Medical Device	$	3,719		$	3,830
In Vitro Diagnostics		1,456			1,643
Total segment operating income		5,175			5,473
Corporate		(1,907	)		(1,534	)
Total operating income	$	3,268		$	3,939

Depreciation and amortization:
Medical Device	$	1,004		$	487
In Vitro Diagnostics		103			222
Corporate		175			200
Total depreciation and amortization	$	1,282		$	909

The Corporate category includes expenses that are not fully allocated to Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to functions, such as executive management, corporate accounting, legal, human resources and Board of Directors. Corporate may also include expenses, such as litigation, which are not specific to a segment and thus not allocated to the operating segments.

Asset information by operating segment is not presented because the Company does not provide its chief operating decision maker assets by operating segment, as the data is not readily available or significant to the decision making process.

15. Commitments and Contingencies

Litigation. From time to time, the Company has been, and may become, involved in various legal actions involving its operations, products and technologies, including intellectual property and employment disputes. The outcomes of these legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages as well as other relief, including injunctions barring the sale of products that are the subject of the lawsuit, which if granted, could require significant expenditures or result in lost revenue. The Company records a liability in the condensed consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate, the minimum amount of the range is accrued. If a loss is possible but not known or probable, and can be reasonably estimated, the

estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded.

InnoCore Technologies BV. In March 2006, the Company entered into a license agreement whereby Surmodics obtained an exclusive license to a drug delivery coating for licensed products within the vascular field which included peripheral, coronary and neurovascular biodurable stent products. The license requires an annual minimum payment of 200,000 euros (equivalent to $211,000 using a euro to US dollar exchange rate of 1.0536 to the Euro as of December 31, 2016) until the last patent expires which is currently estimated to be September 2027. The total minimum future payments associated with this license are approximately $2.7 million. The license is currently utilized by one of the Company’s drug delivery customers.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis provides information management believes is useful in understanding the operating results, cash flows and financial condition of Surmodics, Inc. and subsidiaries (referred to as “Surmodics,” the “Company,” “we,” “us,” “our” and other like terms). The discussion should be read in conjunction with both the unaudited condensed consolidated financial statements and related notes included in this Form 10-Q and our audited consolidated financial statements and related notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations each included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2016. This discussion contains various “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We refer readers to the statement entitled “Forward-Looking Statements” located at the end of this Item 2.

Overview

Surmodics is a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry. In fiscal 2017, our business performance has been driven by growth in our core Medical Device business as well incremental increases in product sales and contract research and development services from the fiscal 2016 acquisitions of Creagh Medical Ltd. (“Creagh Medical”) and NorMedix, Inc. (“NorMedix”) in our Medical Device segment (together the “Fiscal 2016 Acquisitions”). Revenues in the Medical Device business are driven by product sales, hydrophilic coatings royalties, and contract research development services. Medical Device segment revenue grew 12% in the first three months of fiscal 2017, stemming from higher product sales, royalties, research, development and other revenue. Our In Vitro Diagnostics (“IVD”) business is driven by product sales of diagnostic technology. Revenue from the IVD segment decreased 7% in the first three months of fiscal year 2017 compared with the same prior-year period as the business was impacted by strong fourth quarter fiscal 2016 sales in several product categories as well as a decline from a significant microarray customer that had previously been acquired by one of its competitors.

We continue to derive our revenue from three primary sources: (1) product revenues from the sale of reagent chemicals to licensees, the sale of stabilization products, antigens, substrates and surface coatings to the diagnostic and biomedical research markets as well as the sale of medical devices and related products (such as balloons and catheters) to original equipment manufacturer (OEM) suppliers and distributors; (2) royalties and license fees from licensing our proprietary surface modification and device drug delivery technologies to customers; the vast majority (typically in excess of 90%) of revenue in the “royalties and license fees” category is in the form of royalties; and (3) research and commercial development fees generated on customer projects. Revenue fluctuates from quarter to quarter depending on, among other factors: our customers’ success in selling products incorporating our technologies; the timing of introductions of licensed products by our customers; the timing of introductions of products that compete with our customers’ products; the number and activity level associated with customer development projects; the number and terms of new license agreements that are finalized each quarter; and the value of reagent chemicals and other products sold to customers.

We have several U.S. and international issued patents and pending international patent applications protecting various aspects of proprietary surface modification technologies, including compositions, methods of manufacture and methods of coating devices. The expiration dates for these patents and the anticipated expiration dates of patent applications that cover our hydrophilic coating technologies range from fiscal 2020 to fiscal 2035. Among these, our third generation of PhotoLink hydrophilic technology is protected by a family of patents that expired in November 2015 (in the U.S.) and October 2016 (in certain other countries). The royalty revenue associated with our third generation technology was approximately 17% of our fiscal 2016 revenue. Approximately 24% of our total revenue in fiscal 2016 was generated from fourth generation hydrophilic coating technologies, which are protected by a family of patents that begin to expire in fiscal 2020. Of the license agreements using our early generation technologies, most will continue to generate royalty revenue at a reduced royalty rate beyond patent expiration. The remainder of our hydrophilic royalty revenues are derived from other Surmodics coatings that are protected by a number of patents that extend to at least fiscal 2035. While we are actively seeking to convert our customers to one of our advanced generations of our hydrophilic coating technology, there can be no assurance that we will be successful in doing so, or that those customers that have converted, or will convert, will sell products utilizing our technology which will generate earned royalty revenue for us.

Overview of Research and Development Activities

Since fiscal 2013, with our investment in our drug-coated balloon (“DCB”) platform, we have been focused on a strategy to develop and manufacture proprietary medical device products that combine our surface modification coatings with medical devices or delivery systems (“whole-product solutions”). Our aim is to provide customers earlier access to highly differentiated whole-product solutions that address unmet clinical needs, and partner with them on successful commercialization. During fiscal 2016, we made significant progress on our whole-product solutions strategy with the Fiscal 2016 Acquisitions, as well as the initiation of an in-

human early feasibility study of the Surmodics SurVeil^®drug-coated balloon (“Surveil DCB”). The development of the SurVeil DCB is a major step forward in our strategy to offer whole-product solutions for the medical device industry. We received preliminary results from the feasibility study in December 2016 and, based on the findings to date, are expecting to launch the next phase of clinical study by the end of fiscal 2017. To facilitate this, in January 2017 we engaged a clinical research organization (“CRO”) to plan and manage the clinical trial.

We prioritize our internal R&D programs in our segments based on a number of factors, including a program’s strategic fit, commercial impact, potential competitive advantage, technical feasibility, and the amount of investment required. The measures and metrics used to monitor a program’s progress vary based on the first-in-human program, and typically include many of the same factors discussed above with respect to our customer R&D programs. We typically make decisions to continue or terminate a program based on research results (relative to the above measures and metrics) and other factors, including our own strategic and/or business priorities, and the amount of additional investment required.

With respect to cost components, R&D expenses consist of labor, materials and overhead costs (for example, utilities, depreciation, and indirect labor) for both customer R&D and internal R&D programs. We manage our R&D organization in a flexible manner, balancing workloads/resources between customer R&D and internal R&D programs primarily based on the level of customer program activity. Therefore, costs incurred for customer R&D and internal R&D can shift as customer activity increases or decreases.

Critical Accounting Policies

Critical accounting policies are those policies that require the application of management’s most challenging subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Critical accounting policies involve judgments and uncertainties that are sufficiently likely to result in materially different results under different assumptions and conditions. For the quarter ended December 31, 2016, there were no significant changes in our critical accounting policies.

For a detailed description of our critical accounting policies, see Management’s Discussion and Analysis of Financial Condition and Results of Operations under Item 7 in our Annual Report on Form 10-K for the fiscal year ended September 30, 2016.

Results of Operations – Three Months Ended December 31

Revenue. Revenue during the first quarter of fiscal 2017 was $17.8 million, an increase of $1.2 million, or 7.4%, compared with the first quarter of fiscal 2016. The change in revenue, as detailed in the table below, is further explained in the narrative below.

	Three Months Ended December 31,				%
(Dollars in thousands)	2016		2015		Change
Revenue
Medical Device	$	13,757	$	12,247		12.3	%
In Vitro Diagnostics		4,004		4,294		(6.8	)%
Total Revenue	$	17,761	$	16,541		7.4	%

Medical Device. Medical Device revenue was $13.8 million in the first quarter of fiscal 2017, an increase of 12.3% compared with $12.2 million for the first quarter of fiscal 2016. The change in total revenue was attributable to increases in revenue of $0.8 million from higher product sales and $0.7 million from higher research and development services. These increases include $0.9 million of incremental revenue from the Fiscal 2016 Acquisitions. License and royalty revenue for the first quarter of fiscal 2017 was up slightly from the prior year. Royalty revenue was stronger than expected as our customers reported a higher mix of revenue in royalty-bearing jurisdictions outside of the United States as well as products that have migrated to more advanced generations of hydrophilic coatings. The patent covering our third-generation hydrophilic coatings in countries outside of the U.S. expired on October 31, 2016. For fiscal 2017, we expect royalty revenue to decline between $4.0 million to $5.0 million as the result of one-time items that occurred in fiscal 2016 and the impact of patent expirations governing our third-generation patents.

In Vitro Diagnostics. In Vitro Diagnostics revenue was $4.0 million in the first quarter of fiscal 2017, a decrease of 6.8% compared with $4.3 million for first quarter of fiscal 2016. The decrease in the first quarter of fiscal 2017 was primarily due to reduced sales to a significant microarray customer that had previously been acquired by one of its competitors. We expect a decline in revenue from the microarray customer to adversely impact our IVD business through our third quarter of fiscal 2017.

Costs and Operating Expenses

The following is a summary of major costs and expenses as a percent of total revenue:

	Three Months Ended December 31,
	2016					2015
(Dollars in thousands)	Amount		% Total Revenue			Amount		% Total Revenue
Product costs	$	2,628		15	%	$	2,366		14	%
Research and development		5,970		34			3,634		22
Selling, general and administrative		4,862		27			3,648		22
Acquired intangible asset amortization		596		3			354		2
Contingent consideration accretion expense		437		2			109		1
Acquisition transaction, integration and other costs		—		—			2,491		15

Product costs. Product costs were $2.6 million and $2.4 million for the three months ended December 31, 2016 and 2015, respectively, or 15% and 14% of total revenue in each respective period. Product gross margins (defined as product sales less related product costs) were 65.9% and 67.1% of product sales for the three months ended December 31, 2016 and 2015, respectively. The reduction in product gross margins was largely a result of a $0.1 million loss from a damaged shipment from a vendor, which was partially offset by improved product mix in our Medical Device segment.

Research and development (R&D) expenses. R&D expenses were $5.9 million and $3.6 million for the first quarter of fiscal 2016 and 2015, respectively, or 33.6% and 22.0% of total revenue in each respective period. The fiscal 2017 increase in total R&D expenses from fiscal 2016 was primarily the result of higher spending for our DCB and proprietary product development activities. Fiscal 2017 included $1.1 million of incremental R&D expenses from our Fiscal 2016 Acquisitions. We expect R&D expense to increase in the remainder of fiscal 2017 compared with fiscal 2016 as we invest in our whole-products solutions strategy and continue to invest in our DCB development activities, including the commencement of a clinical study. We anticipate fiscal 2017 R&D expense will be approximately high-thirty to low-forty percent of revenue.

Selling, general and administrative (SG&A) expenses. SG&A expenses were $4.9 million and $3.6 million for the first quarter of fiscal 2016 and 2015, respectively, or 27.7% and 22.1% of total revenue for each respective period. The increase in SG&A expenses as a percent of total revenue reflects $0.4 million of incremental expenses attributable to our Fiscal 2016 Acquisitions as well as additional infrastructure needed to support our whole-products solutions strategy. We expect fiscal 2017 SG&A expenses as a percent of revenue will be approximately high twenty percent of revenue.

Acquisition transaction, integration and other costs. In the first quarter of fiscal 2016, we incurred $2.5 million in acquisition transaction, integration and other costs related to our Fiscal 2016 Acquisitions.

Intangible asset amortization. As part of our Fiscal 2016 Acquisitions, we acquired certain intangible assets which are being amortized over periods ranging from four to 14 years. In addition, we own certain intangible assets related to the BioFx acquisition in fiscal 2007. We recorded $0.6 million in amortization expense related to these acquisitions in the first quarter of fiscal 2017 as compared to $0.4 million in the prior-year quarter. The increase is the result of the Fiscal 2016 Acquisitions. Acquired intangible asset amortization, is estimated to total $2.5 million in fiscal 2017.

Contingent consideration accretion expense. For the first quarter of fiscal 2017, we recorded $0.4 million of contingent consideration expense related to our contingent consideration liabilities from the Fiscal 2016 Acquisitions, due to the passage of time (i.e. accretion). Accretion expense increased $0.3 million from the prior-year quarter, as Creagh Medical was acquired in the middle of the first quarter of fiscal 2016 and NorMedix was acquired in the second quarter of fiscal 2016. Based on the most recent projections related to the Fiscal 2016 Acquisitions, we estimate contingent consideration accretion expense to be approximately $2.0 million in fiscal 2017. In addition, if there are changes in the amount, probability or timing of achievement of contingent consideration milestones, there may be adjustments, which could be material, in the statement of income to reflect changes in the fair value of contingent consideration liabilities.

Other income (loss), net. Major classifications of other income, net are as follows:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016		2015
Investment income, net	$	85	$	1
Foreign exchange gain (loss)		674		(135	)
Other (loss) income, net	$	759	$	(134	)

Other income (loss) was $0.8 million and $(0.1) million in the three months ended December 31, 2016 and 2015, respectively. The foreign exchange gain (loss) in the quarters ended December 31, 2016 and 2015 related to the change in exchange rates associated with the Euro-denominated contingent consideration liability from the fiscal 2016 Creagh Medical acquisition, which is scheduled to be paid in the first quarter of fiscal 2019.

Income tax provision. The income tax provision was $1.7 million and $1.3 million for the three months ended December 31, 2016 and 2015, respectively, representing an effective tax rate of 42.9% and 30.3%, respectively. The difference between the U.S. federal statutory tax rate of 35.0% and our effective tax rate for the three months ended December 31, 2016 and 2015 is primarily due to transaction costs and contingent consideration accretion associated with the Fiscal 2016 Acquisitions, the domestic production manufacturing deduction and the US federal research and development tax credit. Discrete items largely consist of state income tax reserve reversals related to the expiration of statutory filing requirements in each period, as well as the effects of expirations and cancellations of stock option awards, as further discussed below. The effective income tax rate for the three months ended December 31, 2016 differs from the three months ended December 31, 2015 primarily due to contingent consideration accretion and foreign currency gains (losses) associated with the Fiscal 2016 Acquisitions, as well as operating losses in Ireland, where tax benefits are offset by a valuation allowance.

Additionally, new guidance related to accounting for excess tax benefits (ASU No. 2016-09, Compensation – Stock Compensation (ASC Topic 718): Improvements to Employee Share-Based Payment Accounting) was adopted in fiscal 2016, resulting in recognition of a tax expense (benefit) from tax deficiencies (excess tax benefits) realized from share awards vested, expired, cancelled and exercised of $0.3 million and ($0.1 million) for the three months ended December 31, 2016 and 2015, respectively. Prior to adoption of the guidance, excess tax benefits and tax deficiencies were recorded within additional paid-in capital on the condensed consolidated balance sheets. The adoption of ASU-2016-09 will increase volatility in the Company’s effective tax rate.

We expect to incur between $2.5 million and $3.5 million in income tax expense for fiscal 2017. Amortization expense from the Creagh Medical acquisition does not reflect an Irish income tax benefit as we acquired a net operating loss carryforward as of the acquisition date that was offset in the aggregate with deferred tax liabilities and a valuation allowance. Therefore, taxable income or losses in Ireland will result in no reported tax impacts in fiscal 2017.

Segment Operating Results

Operating income for each of our reportable segments is as follows:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016			2015			% Change
Operating income:
Medical Device	$	3,719		$	3,830			(3	)%
In Vitro Diagnostics		1,456			1,643			(11	)%
Total segment operating income		5,175			5,473
Corporate		(1,907	)		(1,534	)		24	%
Total operating income	$	3,268		$	3,939			(17	)%

Medical Device. Operating income was $3.7 million in the first quarter of fiscal 2017, compared with $3.8 million in the first quarter of fiscal 2016. Operating income decreased as higher revenues were offset by $1.0 million of amortization and contingent consideration accretion expenses associated with the Fiscal 2016 Acquisitions, as well as an increase in R&D expenses of $2.3 million related to our investment in our drug-coated balloon and proprietary medical device product development programs. Operating income as a percentage of revenue was 27.0% and 31.2% in the first quarter of fiscal 2017 and 2016, respectively.

In Vitro Diagnostics. Operating income was $1.5 million in the first quarter of fiscal 2017, compared with $1.6 million in the first quarter of fiscal 2016. Product sales decreased $0.3 million and the related product gross margins of 61.0% in the first quarter of fiscal 2017 were down from 65.4% in the first quarter of fiscal 2016. Product gross margins decreased as a result of sales mix, as well as a $0.1 million cost associated with a casualty loss incurred in the first quarter of fiscal 2017 related to a damaged shipment. Allocated corporate expenses decreased by $0.1 million in the first quarter of fiscal 2017 compared with the first quarter of fiscal 2016, as the Medical Device segment absorbed more overhead costs due to increased operating activities in fiscal 2017. The operating income as a percentage of revenue was 36.3% and 38.3% in the first quarter of fiscal 2017 and 2016, respectively.

Corporate. The Corporate category includes expenses for administrative corporate functions, such as executive, corporate accounting, legal, human resources and Board of Directors related fees and expenses, which have not been fully allocated to the Medical Device and In Vitro Diagnostics segments. Corporate also includes expenses, such as litigation, which are not specific to a segment and thus not allocated to our operating segments. The unallocated Corporate operating loss was $1.9 million and $1.5 million in the three months ended December 31, 2016 and 2015, respectively.

Liquidity and Capital Resources

As of December 31, 2016, we had working capital of $50.7 million, an increase of $2.3 million from September 30, 2016. Working capital is defined by us as current assets minus current liabilities. The increase from the prior-year end is primarily a result of cash generated from operating activities and reductions in current liabilities. Our cash and cash equivalents and available-for-sale investments totaled $45.1 million at December 31, 2016, a decrease of $1.8 million from $46.9 million at September 30, 2016. This change was principally associated with $2.0 million of cash flow from operations was offset by $2.1 million of stock purchases to pay employee taxes and $1.5 million of investments in capital equipment during the first quarter of fiscal 2017.

The Company’s investment policy excludes ownership of collateralized mortgage obligations, mortgage-backed derivatives and other derivative securities without prior written approval of the Board of Directors. Our investments primarily consist of money market and commercial paper investments. Our investment policy requires that no more than 5% of investments be held in any one credit or issue, excluding U.S. government and government agency obligations. The primary investment objective of the portfolio is to provide for the safety of principal and appropriate liquidity while generating an above benchmark (“Merrill Lynch 1-3 Year Government-Corporate Index”) total rate of return on a pre-tax basis. Management plans to continue to direct its investment advisors to manage the Company’s securities investments primarily for the safety of principal for the foreseeable future as it continues to assess other investment opportunities and uses of its cash and securities investments, including those described below.

On November 4, 2013, we entered into a three year, $20.0 million secured revolving credit facility. On November 2, 2016, we amended and restated the secured revolving credit facility pursuant to an Amended and Restated Credit Agreement (the "Credit Agreement") with Wells Fargo Bank, National Association (the "Bank"). The Credit Agreement increases availability under the secured revolving line of credit from $20.0 million to $30.0 million and extends the maturity of the previous facility by three years. The Company's obligations under the Credit Agreement are secured by substantially all of its and its subsidiaries' assets, other than intellectual property and real estate. The Company has also pledged the majority of the stock of its subsidiaries to secure such obligations. Interest expense under the Credit Agreement is reduced as compared to the Company's prior secured revolving credit facility and accrues at a benchmark rate, plus an applicable margin ranging from 1.00% to 1.75%. A facility fee is payable quarterly on unused commitments at a rate of 0.15% per annum. The interest rate margins are determined based on the Company's ratio of total funded debt to EBITDA (as defined in the Credit Agreement).

We generated cash flows from operating activities of approximately $2.0 million and $6.3 million in the first quarter ended December 31, 2016 and 2015, respectively. The following table depicts our cash flows provided by operating activities:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016			2015
Net income	$	2,300		$	2,653
Depreciation and amortization		1,282			909
Stock-based compensation		789			684
Contingent consideration accretion		437			109
Unrealized foreign exchange (income) loss		(663	)		135
Deferred taxes		742			753
Net other operating activities		(5	)		(3	)
Net change in other operating assets and liabilities		(2,931	)		1,038
Net cash provided by operating activities	$	1,951		$	6,278

Operating Activities. Net cash flow from operating activities has provided us with significant sources of liquidity. During the first three months of fiscal 2017, operating cash flow was primarily generated by net income as adjusted for non-cash expenses (benefits) for depreciation and amortization, unrealized foreign exchange income, stock-based compensation and deferred taxes; reduced by net other operating activities, which includes the excess tax benefit from stock-based compensation. Net income in the first quarter of fiscal 2017 was negatively impacted by increased depreciation, intangible amortization and contingent consideration expenses associated with the Fiscal 2016 Acquisitions. Additionally, net changes in operating assets and liabilities for the first quarter of fiscal 2017 had a negative impact on cash flows of $2.9 million compared to $1.0 million positive impact in fiscal 2016. Fiscal 2016 benefited from $2.1 million of customer collections in excess of billings, compared to $0.3 million in fiscal 2017, due to a $2.4 million customer payment due in the fourth quarter of fiscal 2015 that was paid in October 2015. Additionally, payments of incentive compensation and operating expenses increased by $1.3 million in fiscal 2017 from fiscal 2016 and increases in other current assets reduced cash by $0.7 million in fiscal 2017 compared to $0.1 million in fiscal 2016.

Investing Activities. We used cash in investing activities of $7.0 million in the first quarter of fiscal 2017 compared with cash used in investing activities of $18.6 million in the first quarter of fiscal 2016. We acquired Creagh Medical in the first quarter of fiscal 2016 with an initial payment, net of cash acquired, of $18.2 million. We invested $1.5 million in property and equipment in the first quarter of fiscal 2017, compared with $0.4 million in the prior-year period. In the first quarter of fiscal 2017, we invested $5.5 million in available-for-sale debt securities, net of maturities of other investments.

Financing Activities. We used cash in financing activities of $2.2 million and $0.5 million in the first quarter of fiscal 2017 and 2016, respectively. In the first quarter of fiscal 2017, we paid $2.1 million to purchase common stock to pay employee taxes resulting from the exercise of stock options in the fourth quarter of 2016 as well as the issuance of common shares associated with our fiscal 2014-2016 performance share program. In the first quarter of fiscal 2016, we paid contingent consideration of $0.3 million related to a prior-year acquisition and used cash of $0.4 million to purchase common stock to pay employee taxes resulting primarily from the issuance of common shares associated with our fiscal 2013-2015 performance share program.

We believe that our existing cash, and cash equivalents and investments, which totaled $45.1 million as of December 31, 2016, together with cash flow from operations and our $30.0 million credit facility, will provide liquidity sufficient to meet our cash needs and fund our operations and planned capital expenditures for the next twelve months. There can be no assurance, however, that Surmodics’ business will continue to generate cash flows at current levels, and disruptions in financial markets may negatively impact our ability to access capital in a timely manner and on attractive terms. In the event Creagh Medical begins to generate taxable income in future years, repatriation of its earnings may result in substantial U.S. tax cost. Our current plans do not foresee a need to repatriate funds that are designated as permanently reinvested in order to fund our operations or meet currently anticipated liquidity and capital investment needs.

Customer Concentrations. Our licensed technologies provide royalty revenue, which represents the largest revenue stream to the Company. We have licenses with a diverse base of customers and certain customers have multiple products using our technology. Medtronic plc (“Medtronic”) is our largest customer comprising 25% of our consolidated revenue for fiscal 2016 and 22% of our consolidated revenue for the first quarter of fiscal 2017. Medtronic has several separately licensed products that generate royalty revenue for Surmodics, none of which represented more than 4% of Surmodics’ total revenue. No other individual customer using licensed technology constitutes more than 6% of Surmodics’ total revenue.

Share Purchase Activity

The Company’s Board of Directors has authorized the repurchase of up to an additional $30.0 million of the Company’s outstanding stock in open-market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, tender offers or by any combination of such methods. The authorization has no fixed expiration date.

Off-Balance Sheet Arrangements

As of December 31, 2016 and September 30, 2016, the Company did not have any off-balance sheet arrangements with any unconsolidated entities.

Forward-Looking Statements

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include expectations concerning our growth strategy, including our ability to sign new license agreements and broaden our hydrophilic coatings royalty revenue, product development programs, various milestone achievements, research and development expenses, future cash flow and sources of funding, short-term liquidity requirements, future property and equipment investment levels, the impact of potential lawsuits or claims, the impact of Medtronic, as well as other significant customers, including new diagnostic kit customers, our ability to recognize the expected benefits of our recent acquisitions and our ability to implement a PMA Clinical trial of the Surmodics SurVeil® Drug Coated Balloon on any particular time frame. Without limiting the foregoing, words or phrases such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “possible,” “project,” “will” and similar terminology, generally identify forward-looking statements. Forward-looking statements may also represent challenging goals for us. These statements, which represent the Company’s expectations or beliefs concerning various future events, are based on current expectations that involve a number of risks and uncertainties that could cause actual results to differ materially from those of such forward-looking statements. We caution that undue reliance should not be placed on such forward-looking statements, which speak only as of the date made. Some of the factors which could cause results to differ from those expressed in any forward-looking statement are set forth under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2016. We disclaim any intent or obligation to update publicly these forward-looking statements, whether because of new information, future events or otherwise.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from our forward-looking statements, such factors include, among others:

•

our reliance on a small number of significant customers, including our largest customer, Medtronic, which causes our financial results and stock price to be subject to factors affecting those significant customers and their products, the timing of market introduction of their or competing products, product safety or efficacy concerns and intellectual property litigation could adversely affect our growth strategy and the royalty revenue we derive;

•

general economic conditions which are beyond our control, such as the impact of recession, customer mergers and acquisitions, business investment and changes in consumer confidence;

•

a decrease in our available cash could impact short-term liquidity requirements and expected capital and other expenditures;

•

the difficulties and uncertainties associated with the lengthy and costly new product development and foreign and domestic regulatory approval processes, such as delays, difficulties or failures in achieving acceptable clinical results or obtaining foreign or U.S. Food and Drug Administration marketing clearances or approvals, which may result in lost market opportunities or postpone or preclude product commercialization by licensees or ourselves;

•

the development of new products or technologies by competitors, technological obsolescence and other changes in competitive factors;

•

our ability to successfully develop, obtain regulatory approval for, and commercialize our Surmodics SurVeil Drug Coated Balloon product, including our reliance on a clinical research organization to manage the PMA clinical trial;

•

our ability to perform successfully certain product development activities, the related R&D expense impact and governmental and regulatory compliance activities which we have not previously undertaken in any significant manner;

•

our ability to successfully convert our customers from the third generation of our PhotoLink^® hydrophilic technology protected by a family of patents which expired in November 2015 (in the U.S.) and October 2016 (in certain other countries) to one of our advanced generation technologies and to offset any decline in revenues from customers that we are unlikely to convert;

•

our ability to identify and execute new acquisition opportunities as well as the process of integrating acquired businesses poses numerous risks, including an inability to assimilate acquired operations, personnel, technology, information systems, and internal control systems and products; a lack of understanding of tax, legal and cultural differences; diversion of management’s attention; difficulties and uncertainties in transitioning the customers or other business relationships from the acquired entity to us; the loss of key employees of acquired companies; and

•

other factors described in “Risk Factors” and other sections of Surmodics’ Annual Report on Form 10-K for the fiscal year ended September 30, 2016, which you are encouraged to read carefully.

Many of these factors are outside the control and knowledge of us, and could result in increased volatility in period-to-period results. Investors are advised not to place undue reliance upon our forward-looking statements and to consult any further disclosures by us on this subject in our filings with the SEC.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Our investment policy requires investments with high credit quality issuers and limits the amount of credit exposure to any one issuer. Our investments consist principally of interest-bearing corporate debt securities with varying maturity dates, which are less than one year. Because of the credit criteria of our investment policies, the primary market risk associated with these investments is interest rate risk. We do not use derivative financial instruments to manage interest rate risk or to speculate on future changes in interest rates. As of December 31, 2016, we held $27.5 million in available-for-sale debt securities, all with maturity dates of less than one year, therefore interest rate fluctuations would have an insignificant impact on the results of operations or cash flows. Our policy also allows the Company to hold a substantial portion of funds in cash and cash equivalents, which are defined as financial instruments with original maturities of three months or less and may include money market instruments, certificates of deposit, repurchase agreements, corporate bonds and commercial paper instruments.

Management believes that a reasonable change in raw material prices would not have a material impact on future earnings or cash flows because the Company’s inventory exposure is not material.

With the Creagh Medical acquisition in November 2015, we are exposed to increasing Euro currency risk with respect to our manufacturing operations in Ireland. In a period where the U.S. dollar is strengthening or weakening as compared to the Euro, our revenues and expenses denominated in Euro’s are translated into U.S. dollars at a lower or higher value than they would be in an otherwise constant currency exchange rate environment. All sales transactions are denominated in U.S. dollars or Euros. We generate royalty revenue from the sale of customer products in foreign jurisdictions. Royalties generated in foreign jurisdictions by customers are converted and paid in U.S. dollars per contractual terms. Substantially all of our purchasing transactions are denominated in U.S. Dollars or Euros. Further, we are subject to foreign currency risk associated with the payment of up to €12 million of Creagh Medical contingent consideration in approximately December 2018. For the first three months of fiscal 2017, we have recorded a foreign currency exchange gain of $0.7 million related to this future payment. A 10% increase or decrease in the U.S. Dollar to Euro exchange rate could have a $1.0 million impact on this payment based on the exchange rate as of December 31, 2016. To date, we have not entered into any foreign currency forward exchange contracts or other derivative financial instruments to hedge the effects of adverse fluctuations in foreign currency exchange.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company’s management, under the supervision and with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of December 31, 2016. Based on that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) were not effective as of December 31, 2016 due to the material weakness in internal control over financial reporting described below.

Material Weakness in Internal Control over Financial Reporting

In April 2016, the Company concluded its internal control over financial reporting was not effective due to a material weakness in the design and operating effectiveness of its transactional and review controls related to the recognition of royalty revenue. The ineffectiveness of these internal controls did not result in a restatement of previously issued interim or annual consolidated financial statements. This material weakness has not been remediated as of December 31, 2016, and could result in a misstatement of royalty revenue and related accounts and disclosures that could be material to the condensed consolidated financial statements. Accordingly, management concluded that the Company’s internal control over financial reporting was not effective as of December 31, 2016. Although the Company has already made progress in remediation of this issue, as indicated below, sufficient time needs to pass before management can conclude that newly implemented controls are operating effectively and that the material weaknesses has been adequately remediated.

Notwithstanding the material weakness in our internal control over financial reporting, we have concluded that the interim condensed consolidated financial statements and other financial information included in this Quarterly Report on Form 10-Q, fairly present in all material respects our financial condition, results of operations and cash flows as of, and for, the periods presented.

The foregoing has been approved by our management, including our Chief Executive Officer and Chief Financial Officer, who have been involved with the reassessment and analysis of our internal control over financial reporting.

Changes in Internal Controls over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) during the three months ended December 31, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Status of Material Weakness Remediation

With oversight from the Audit Committee, the Company’s management has designed and implemented certain changes in processes and controls for the purpose of remediating the material weakness described above and to enhance the Company’s internal control over financial reporting as follows:

•

Enhanced the evaluation and analysis of royalties reported and/or paid by customers to determine the proper amount of revenue to be recognized based on terms of the relevant license agreement, including comparison of amounts reported by customers to management’s expectations.

•

Established quarterly meetings of a cross-functional team from our Medical Device business development, accounting and legal departments to review and evaluate license agreements and royalty revenue in order to identify circumstances that could impact recognition of royalty revenue with an emphasis on the review of the analysis generated from the preceding control, new or amended licenses, licenses impacted by expired or expiring patents, non-routine royalty revenue as well as the status of current customer inquiries related to reported and unpaid royalty revenue.

•

Augmented proactive communications with customers and internal departments related to patent expirations, license terms and license utilization.

•

Established a process for ongoing monitoring, review and conclusion of customer investigations or inquiries. These matters are identified from a review of customer license agreements, customer utilization of the Company’s technology, royalty revenue reporting and discussions with customers, among other things.

We believe these remediation measures will strengthen our internal control over financial reporting and remediate the material weakness identified. These additional controls were designed and implemented in the third and fourth quarters of fiscal 2016, but have not operated for an appropriate amount of time for management to determine their operational effectiveness. Accordingly, management has determined that the material weakness has not been remediated as of December 31, 2016. During the remainder of fiscal 2017, management will test and evaluate the effectiveness of these new processes and procedures to ascertain whether they are designed and operating effectively to provide reasonable assurance that they will prevent or detect a material error in the financial statements. Management may deem it necessary to enhance other existing controls and/or implement additional controls as the evaluation progresses.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

There have been no material developments in the legal proceedings previously disclosed in the Company’s Form 10-K for the fiscal year ended September 30, 2016.

Item 1A. Risk Factors

In our report on Form 10-K for the fiscal year ended September 30, 2016, filed with the SEC on December 2, 2016, we identify under “Part 1, Item 1A. Risk Factors.” important factors which could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Form 10-Q.

There have been no material changes in our risk factors subsequent to the filing of our Form 10-K for the fiscal year ended September 30, 2016.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table presents information with respect to purchases of common stock of the Company made during the three months ended December 31, 2015, by the Company or on behalf of the Company or any “affiliated purchaser” of the Company, as defined in Rule 10b-18(a)(3) under the Exchange Act.

Period	Total Number of Shares Purchased		Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs		Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs(1)
10/1/16 — 10/31/16		—	N/A		—	$	30,000,000
11/1/16 — 11/30/16		—	N/A		—	$	30,000,000
12/1/16 — 12/31/16		—	N/A		—	$	30,000,000
Total		—	N/A		—	$	30,000,000

(1)	As of December 31, 2016, the Company has an aggregate of $30 million available for future common stock repurchases under authorizations previously issued by the Board of Directors.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit		Description
2.1		Share Purchase Agreement by and among Surmodics, Inc. and the shareholders of Creagh Medical Ltd. named therein dated as of November 20, 2015 (excluding certain schedules and exhibits, which Surmodics, Inc. agrees to furnish to the Securities and Exchange Commission upon request) – incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K filed on November 27, 2015, SEC File No. 0-23837.

2.2		Put and Call Option Agreement by and among Surmodics, Inc. and the shareholders of Creagh Medical Ltd. named therein dated as of November 20, 2015 (excluding schedules and exhibits, which Surmodics, Inc. agrees to furnish to the Securities and Exchange Commission upon request) – incorporated by reference to Exhibit 2.2 of the Company’s Current Report on Form 8-K filed on November 27, 2015, SEC File No. 0-23837.

2.3		Stock Purchase Agreement by and among Surmodics, Inc., the shareholders of NorMedix, Inc. and Gregg Sutton, as Seller’s Agent dated as of January 8, 2016 (excluding schedules and exhibits, which Surmodics, Inc. agrees to furnish to the Securities and Exchange Commission upon request) – incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K filed on January 13, 2016, SEC File No. 0-23837.
3.1		Restated Articles of Incorporation, as amended incorporated by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q filed on July 29, 2016, SEC File No. 0-23837.

3.2		Restated Bylaws of Surmodics, Inc., as amended December 18, 2015 – incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K filed on December 23, 2015.

10.1		Amended and Restated Credit Agreement dated November 2, 2016, by and between Surmodics, Inc., and Wells Fargo Bank, National Association — incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on November 7, 2016, SEC File No. 0 23837.

10.2		Amended and Restated Revolving Line of Credit Note dated November 2, 2016 — incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on November 7, 2016, SEC File No. 0 23837.

12*		Computation of Ratio of Earnings to Fixed Charges.

31.1*		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*		Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101*		Financial statements from the Quarterly Report on Form 10-Q for Surmodics, Inc. for the quarterly period ended December 31, 2016, filed on February 3, 2017, formatted in Extensible Business Reporting Language (XBRL): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Income, (iii) Condensed Consolidated Statements of Comprehensive Income, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.

*	Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


February 3, 2017	Surmodics, Inc.

	By:	/s/ Andrew D.C. LaFrence
		Andrew D.C. LaFrence
		Vice President of Finance, Information Systems and
		Chief Financial Officer
		(duly authorized signatory and principal financial officer)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

EXHIBIT INDEX TO FORM 10-Q

For the Quarter Ended December 31, 2016

SURMODICS, INC.

Exhibit		Description
2.1		Share Purchase Agreement by and among Surmodics, Inc. and the shareholders of Creagh Medical Ltd. named therein dated as of November 20, 2015 (excluding certain schedules and exhibits, which Surmodics, Inc. agrees to furnish to the Securities and Exchange Commission upon request) – incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K filed on November 27, 2015, SEC File No. 0-23837.

2.2		Put and Call Option Agreement by and among Surmodics, Inc. and the shareholders of Creagh Medical Ltd. named therein dated as of November 20, 2015 (excluding schedules and exhibits, which Surmodics, Inc. agrees to furnish to the Securities and Exchange Commission upon request) – incorporated by reference to Exhibit 2.2 of the Company’s Current Report on Form 8-K filed on November 27, 2015, SEC File No. 0-23837.

2.3		Stock Purchase Agreement by and among Surmodics, Inc., the shareholders of NorMedix, Inc. and Gregg Sutton, as Seller’s Agent dated as of January 8, 2016 (excluding schedules and exhibits, which Surmodics, Inc. agrees to furnish to the Securities and Exchange Commission upon request) – incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K filed on January 13, 2016, SEC File No. 0-23837.

3.1		Restated Articles of Incorporation, as amended — incorporated by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q filed on July 29, 2016, SEC File No. 0-23837.

3.2		Restated Bylaws of Surmodics, Inc., as amended on December 18, 2015— incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on December 23, 2015, SEC File No. 0-23837.

10.1		Amended and Restated Credit Agreement dated November 2, 2016, by and between Surmodics, Inc., and Wells Fargo Bank, National Association — incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on November 7, 2016, SEC File No. 0 23837.

10.2		Amended and Restated Revolving Line of Credit Note dated November 2, 2016 — incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on November 7, 2016, SEC File No. 0 23837.

12*		Computation of Ratio of Earnings to Fixed Charges.

31.1*		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*		Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS*		XBRL Instance Document

101.SCH*		XBRL Taxonomy Extension Schema Document

101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*		XBRL Taxonomy Extension Label Linkbase Document

101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

*	Filed herewith

EX-12 2 srdx-ex12_130.htm EX-12 srdx-ex12_130.htm

Exhibit 12

Surmodics, Inc.

Computation of Ratio of Earnings to Fixed Charges

	Three Months Ended		Fiscal Year Ended September 30,
	December 31, 2016		2016		2015		2014		2013		2012
Earnings
Pre-tax income from continuing operations	$	4,027,000	$	16,947,641	$	18,241,415	$	18,471,862	$	20,359,694	$	16,305,540

Add:
Fixed charges (build up below)		454,708		1,607,212		40,136		38,189		19,257		19,797
Amortization of capitalized interest		—		—		—		—		—		—
Distributed income of equity investees		—		—		—		—		—		—
Pre-tax losses of equity investees for which charges arising from guarantees are included in fixed charges		—		—		—		—		—		—

Subtract:
Interest capitalized		—		—		—		—		—		—
Preference security dividend requirement		—		—		—		—		—		—
Non-controlling interest in pre-tax income of subsidiaries that have not incurred fixed charges		—		—		—		—		—		—
Total Earnings Available for Fixed Charges	$	4,481,708	$	18,554,853	$	18,281,551	$	18,510,051	$	20,378,951	$	16,325,337

Fixed charges
Interest expensed and capitalized	$	—	$	—	$	—	$	—	$	—	$	—
Amortized premiums, discounts and capitalized expenses related to indebtedness (a)		436,870		1,518,851		17,822		16,337		—		—
Estimate of interest within rental expense (b)		17,838		88,361		22,314		21,852		19,257		19,797
Preference security dividend requirements of consolidated subsidiaries		—		—		—		—		—		—
Total Fixed Charges	$	454,708	$	1,607,212	$	40,136	$	38,189	$	19,257	$	19,797

Ratio of earnings to fixed charges (c)	9.86x		11.54x		455.49x		484.70x		1058.24x		824.65x

^(a)Interest expense consists of interest on indebtedness, including accretion expense related to contingent consideration obligations.

^(b)Includes that portion of rental expense that management believes is representative of the interest component.

^(c)We had no preferred stock outstanding during the periods presented and accordingly, the ratio of earnings to combined fixed charges and preferred stock dividends is equal to the ratio of earnings to fixed charges and is not disclosed separately.

EX-31.1 3 srdx-ex311_173.htm EX-31.1 srdx-ex311_173.htm

EXHIBIT 31.1

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Gary R. Maharaj, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Surmodics, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: February 3, 2017	Signature:	/s/ Gary R. Maharaj
		Gary R. Maharaj
		President and
		Chief Executive Officer

EX-31.2 4 srdx-ex312_175.htm EX-31.2 srdx-ex312_175.htm

EXHIBIT 31.2

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Andrew D. C. LaFrence, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Surmodics, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: February 3, 2017

Signature:

/s/ Andrew D.C. LaFrence

Andrew D.C. LaFrence

Vice President of Finance and Information Systems and

Chief Financial Officer

EX-32.1 5 srdx-ex321_174.htm EX-32.1 srdx-ex321_174.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Surmodics, Inc. (the “Company”) on Form 10-Q for the quarter ended December 31, 2016, as filed with the Securities and Exchange Commission (the “Report”), I, Gary R. Maharaj, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 3, 2017	Signature:	/s/ Gary R. Maharaj
		Gary R. Maharaj
		President and
		Chief Executive Officer

EX-32.2 6 srdx-ex322_176.htm EX-32.2 srdx-ex322_176.htm

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Surmodics, Inc. (the “Company”) on Form 10-Q for the quarter ended December 31, 2016, as filed with the Securities and Exchange Commission (the “Report”), I, Andrew D. C. LaFrence, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 3, 2017	Signature:	/s/ Andrew D.C. LaFrence
		Andrew D.C. LaFrence
		Vice President of Finance and Information Systems and
		Chief Financial Officer

EX-101.INS 7 srdx-20161231.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares pure iso4217:EUR srdx:Segment iso4217:EUR iso4217:USD 0000924717 2016-10-01 2016-12-31 0000924717 2017-01-31 0000924717 2016-12-31 0000924717 2016-09-30 0000924717 2015-10-01 2015-12-31 0000924717 2015-09-30 0000924717 2015-12-31 0000924717 srdx:CreaghMedicalLtdMember 2015-10-01 2015-12-31 0000924717 srdx:CreaghMedicalLtdMember 2016-10-01 2016-12-31 0000924717 srdx:NorMedixIncMember 2016-10-01 2016-12-31 0000924717 srdx:AccountingStandardsUpdateTwoThousandSixteenZeroNineMember 2015-10-01 2015-12-31 0000924717 srdx:CreaghMedicalLtdMember 2015-11-20 0000924717 us-gaap:MaximumMember srdx:CreaghMedicalLtdMember 2015-11-19 2015-11-20 0000924717 srdx:CreaghMedicalLtdMember 2015-11-19 2015-11-20 0000924717 srdx:CreaghMedicalLtdMember 2016-12-31 0000924717 srdx:CreaghMedicalLtdMember us-gaap:TradeNamesMember 2016-12-31 0000924717 srdx:CreaghMedicalLtdMember us-gaap:DevelopedTechnologyRightsMember 2016-12-31 0000924717 srdx:CreaghMedicalLtdMember us-gaap:InProcessResearchAndDevelopmentMember 2016-12-31 0000924717 srdx:CreaghMedicalLtdMember us-gaap:CustomerRelationshipsMember 2016-12-31 0000924717 srdx:CreaghMedicalLtdMember us-gaap:DevelopedTechnologyRightsMember 2016-10-01 2016-12-31 0000924717 us-gaap:MinimumMember srdx:CreaghMedicalLtdMember 2016-10-01 2016-12-31 0000924717 us-gaap:MaximumMember srdx:CreaghMedicalLtdMember 2016-10-01 2016-12-31 0000924717 us-gaap:MinimumMember srdx:CreaghMedicalLtdMember us-gaap:CustomerRelationshipsMember 2016-10-01 2016-12-31 0000924717 us-gaap:MaximumMember srdx:CreaghMedicalLtdMember us-gaap:CustomerRelationshipsMember 2016-10-01 2016-12-31 0000924717 srdx:NorMedixIncMember 2016-01-08 0000924717 srdx:NorMedixIncMember us-gaap:MaximumMember 2016-01-07 2016-01-08 0000924717 srdx:NorMedixIncMember 2016-01-07 2016-01-08 0000924717 srdx:NorMedixIncMember 2015-10-01 2015-12-31 0000924717 srdx:NorMedixIncMember 2016-12-31 0000924717 srdx:NorMedixIncMember us-gaap:DevelopedTechnologyRightsMember 2016-12-31 0000924717 srdx:NorMedixIncMember us-gaap:CustomerRelationshipsMember 2016-12-31 0000924717 srdx:NorMedixIncMember us-gaap:CustomerRelationshipsMember 2016-10-01 2016-12-31 0000924717 srdx:NorMedixIncMember us-gaap:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2016-10-01 2016-12-31 0000924717 srdx:NorMedixIncMember us-gaap:MaximumMember us-gaap:DevelopedTechnologyRightsMember 2016-10-01 2016-12-31 0000924717 srdx:CreaghMedicalAndNorMedixMember 2015-10-01 2015-12-31 0000924717 us-gaap:ProFormaMember srdx:CreaghMedicalAndNorMedixMember 2015-10-01 2015-12-31 0000924717 us-gaap:FairValueInputsLevel2Member us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000924717 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000924717 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2016-12-31 0000924717 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2016-12-31 0000924717 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000924717 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000924717 us-gaap:FairValueInputsLevel3Member srdx:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000924717 srdx:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000924717 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0000924717 us-gaap:FairValueInputsLevel2Member us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0000924717 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0000924717 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2016-09-30 0000924717 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AvailableforsaleSecuritiesMember 2016-09-30 0000924717 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0000924717 us-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0000924717 us-gaap:FairValueInputsLevel3Member srdx:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0000924717 srdx:ContingentConsiderationMember us-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0000924717 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-09-30 0000924717 srdx:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2016-09-30 0000924717 srdx:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2015-10-01 2015-12-31 0000924717 srdx:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2016-10-01 2016-12-31 0000924717 srdx:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2016-12-31 0000924717 srdx:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2015-12-31 0000924717 2015-10-01 2016-09-30 0000924717 us-gaap:ScenarioForecastMember 2016-10-01 2017-09-30 0000924717 srdx:ContingentConsiderationMember srdx:NonRevenueBasedMilestonesMember us-gaap:MinimumMember 2016-10-01 2016-12-31 0000924717 srdx:ContingentConsiderationMember srdx:NonRevenueBasedMilestonesMember us-gaap:MaximumMember 2016-10-01 2016-12-31 0000924717 srdx:ContingentConsiderationMember srdx:RevenueBasedMilestonesMember us-gaap:MinimumMember 2016-10-01 2016-12-31 0000924717 srdx:ContingentConsiderationMember srdx:RevenueBasedMilestonesMember us-gaap:MaximumMember 2016-10-01 2016-12-31 0000924717 us-gaap:MinimumMember 2016-10-01 2016-12-31 0000924717 us-gaap:MaximumMember 2016-10-01 2016-12-31 0000924717 srdx:ContingentConsiderationMember 2016-10-01 2016-12-31 0000924717 srdx:ContingentConsiderationMember 2015-10-01 2015-12-31 0000924717 srdx:CommercialPaperAndCorporateBondSecuritiesMember 2016-12-31 0000924717 srdx:CommercialPaperAndCorporateBondSecuritiesMember 2016-09-30 0000924717 srdx:ViaCyteIncMember 2016-12-31 0000924717 srdx:ViaCyteIncMember 2016-09-30 0000924717 us-gaap:OtherNoncurrentAssetsMember 2016-12-31 0000924717 us-gaap:OtherNoncurrentAssetsMember 2016-09-30 0000924717 srdx:ViaCyteIncMember 2016-10-01 2016-12-31 0000924717 us-gaap:MaximumMember srdx:ViaCyteIncMember 2016-12-31 0000924717 srdx:CustomerListsAndRelationshipsMember 2016-10-01 2016-12-31 0000924717 srdx:CoreTechnologyMember 2016-10-01 2016-12-31 0000924717 us-gaap:DevelopedTechnologyRightsMember 2016-10-01 2016-12-31 0000924717 us-gaap:NoncompeteAgreementsMember 2016-10-01 2016-12-31 0000924717 srdx:PatentsAndOtherMember 2016-10-01 2016-12-31 0000924717 us-gaap:InProcessResearchAndDevelopmentMember 2016-12-31 0000924717 us-gaap:TrademarksAndTradeNamesMember 2016-12-31 0000924717 srdx:CustomerListsAndRelationshipsMember 2016-12-31 0000924717 srdx:CoreTechnologyMember 2016-12-31 0000924717 us-gaap:DevelopedTechnologyRightsMember 2016-12-31 0000924717 us-gaap:NoncompeteAgreementsMember 2016-12-31 0000924717 srdx:PatentsAndOtherMember 2016-12-31 0000924717 srdx:DefiniteLivedIntangibleAssetsMember 2016-12-31 0000924717 srdx:CustomerListsAndRelationshipsMember 2015-10-01 2016-09-30 0000924717 srdx:CoreTechnologyMember 2015-10-01 2016-09-30 0000924717 us-gaap:DevelopedTechnologyRightsMember 2015-10-01 2016-09-30 0000924717 us-gaap:NoncompeteAgreementsMember 2015-10-01 2016-09-30 0000924717 srdx:PatentsAndOtherMember 2015-10-01 2016-09-30 0000924717 us-gaap:InProcessResearchAndDevelopmentMember 2016-09-30 0000924717 us-gaap:TrademarksAndTradeNamesMember 2016-09-30 0000924717 srdx:CustomerListsAndRelationshipsMember 2016-09-30 0000924717 srdx:CoreTechnologyMember 2016-09-30 0000924717 us-gaap:DevelopedTechnologyRightsMember 2016-09-30 0000924717 us-gaap:NoncompeteAgreementsMember 2016-09-30 0000924717 srdx:PatentsAndOtherMember 2016-09-30 0000924717 srdx:DefiniteLivedIntangibleAssetsMember 2016-09-30 0000924717 srdx:InVitroDiagnosticsMember 2016-09-30 0000924717 srdx:MedicalDeviceMember 2016-09-30 0000924717 srdx:MedicalDeviceMember 2016-10-01 2016-12-31 0000924717 srdx:InVitroDiagnosticsMember 2016-12-31 0000924717 srdx:MedicalDeviceMember 2016-12-31 0000924717 us-gaap:CostOfSalesMember 2016-10-01 2016-12-31 0000924717 us-gaap:CostOfSalesMember 2015-10-01 2015-12-31 0000924717 us-gaap:ResearchAndDevelopmentExpenseMember 2016-10-01 2016-12-31 0000924717 us-gaap:ResearchAndDevelopmentExpenseMember 2015-10-01 2015-12-31 0000924717 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-10-01 2016-12-31 0000924717 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-10-01 2015-12-31 0000924717 srdx:BoardOfDirectorMember srdx:NonqualifiedStockOptionsMember us-gaap:MinimumMember 2016-10-01 2016-12-31 0000924717 srdx:BoardOfDirectorMember srdx:NonqualifiedStockOptionsMember us-gaap:MaximumMember 2016-10-01 2016-12-31 0000924717 srdx:BoardOfDirectorMember srdx:NonqualifiedStockOptionsMember 2016-10-01 2016-12-31 0000924717 srdx:EmployeeMember srdx:NonqualifiedStockOptionsMember srdx:VestingAnniversaryMember 2016-10-01 2016-12-31 0000924717 srdx:EmployeeMember srdx:NonqualifiedStockOptionsMember 2016-10-01 2016-12-31 0000924717 srdx:NonqualifiedStockOptionsMember 2016-10-01 2016-12-31 0000924717 srdx:NonqualifiedStockOptionsMember 2015-10-01 2015-12-31 0000924717 us-gaap:MaximumMember 2015-10-01 2015-12-31 0000924717 us-gaap:RestrictedStockMember 2016-10-01 2016-12-31 0000924717 us-gaap:RestrictedStockMember 2015-10-01 2015-12-31 0000924717 2014-10-01 2015-09-30 0000924717 srdx:PeriodTwentyFifteenThroughTwentySeventeenMember 2016-10-01 2016-12-31 0000924717 srdx:PeriodTwentySixteenThroughTwentyEighteenMember 2016-10-01 2016-12-31 0000924717 srdx:PeriodTwentySeventeenThroughTwentyNineteenMember 2016-10-01 2016-12-31 0000924717 us-gaap:ShareBasedCompensationAwardTrancheOneMember us-gaap:MinimumMember 2016-10-01 2016-12-31 0000924717 us-gaap:ShareBasedCompensationAwardTrancheOneMember us-gaap:MaximumMember 2016-10-01 2016-12-31 0000924717 us-gaap:PerformanceSharesMember 2016-10-01 2016-12-31 0000924717 us-gaap:PerformanceSharesMember 2015-10-01 2015-12-31 0000924717 us-gaap:MaximumMember us-gaap:PerformanceSharesMember 2016-10-01 2016-12-31 0000924717 srdx:PeriodTwentySeventeenThroughTwentyNineteenMember us-gaap:ScenarioForecastMember us-gaap:PerformanceSharesMember 2016-10-01 2017-09-30 0000924717 srdx:PeriodTwentySixteenThroughTwentyEighteenMember us-gaap:PerformanceSharesMember 2015-10-01 2016-09-30 0000924717 srdx:PeriodTwentyFifteenThroughTwentySeventeenMember us-gaap:PerformanceSharesMember 2014-10-01 2015-09-30 0000924717 us-gaap:MaximumMember srdx:EmployeeStockPurchasePlanMember 2016-12-31 0000924717 us-gaap:MaximumMember srdx:EmployeeStockPurchasePlanMember 2016-10-01 2016-12-31 0000924717 srdx:EmployeeStockPurchasePlanMember 2016-10-01 2016-12-31 0000924717 srdx:EmployeeStockPurchasePlanMember 2016-12-31 0000924717 srdx:EmployeeStockPurchasePlanMember 2016-09-30 0000924717 us-gaap:MaximumMember srdx:EmployeeStockPurchasePlanMember 2015-10-01 2015-12-31 0000924717 srdx:EquityIncentivePlan2009Member us-gaap:RestrictedStockUnitsRSUMember 2016-10-01 2016-12-31 0000924717 srdx:EquityIncentivePlan2009Member us-gaap:RestrictedStockUnitsRSUMember 2015-10-01 2015-12-31 0000924717 srdx:EquityIncentivePlan2009Member us-gaap:RestrictedStockUnitsRSUMember us-gaap:MaximumMember 2016-10-01 2016-12-31 0000924717 srdx:EquityIncentivePlan2009Member us-gaap:RestrictedStockUnitsRSUMember us-gaap:MaximumMember 2015-10-01 2015-12-31 0000924717 srdx:EquityIncentivePlan2009Member us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0000924717 srdx:EquityIncentivePlan2009Member us-gaap:RestrictedStockUnitsRSUMember 2016-09-30 0000924717 srdx:EquityIncentivePlan2009Member us-gaap:RestrictedStockUnitsRSUMember 2015-10-01 2016-09-30 0000924717 srdx:DeferredStockUnitsMember srdx:EquityIncentivePlan2009Member us-gaap:DirectorMember 2016-10-01 2016-12-31 0000924717 srdx:DeferredStockUnitsMember srdx:EquityIncentivePlan2009Member us-gaap:DirectorMember 2015-10-01 2015-12-31 0000924717 srdx:DeferredStockUnitsMember srdx:EquityIncentivePlan2009Member us-gaap:DirectorMember us-gaap:MaximumMember 2016-10-01 2016-12-31 0000924717 srdx:DeferredStockUnitsMember srdx:EquityIncentivePlan2009Member us-gaap:DirectorMember us-gaap:MaximumMember 2015-10-01 2015-12-31 0000924717 srdx:DeferredStockUnitsMember srdx:EquityIncentivePlan2009Member us-gaap:DirectorMember 2016-12-31 0000924717 srdx:DeferredStockUnitsMember srdx:EquityIncentivePlan2009Member us-gaap:DirectorMember 2016-09-30 0000924717 srdx:DeferredStockUnitsMember srdx:EquityIncentivePlan2009Member us-gaap:DirectorMember 2015-10-01 2016-09-30 0000924717 us-gaap:RevolvingCreditFacilityMember 2016-11-02 0000924717 us-gaap:RevolvingCreditFacilityMember 2016-11-01 2016-11-02 0000924717 us-gaap:RevolvingCreditFacilityMember srdx:MulticurrencyOverdraftFacilityMember country:IE 2016-11-02 0000924717 us-gaap:RevolvingCreditFacilityMember us-gaap:MinimumMember 2016-11-01 2016-11-02 0000924717 us-gaap:RevolvingCreditFacilityMember us-gaap:MaximumMember 2016-11-01 2016-11-02 0000924717 us-gaap:RevolvingCreditFacilityMember srdx:MulticurrencyOverdraftFacilityMember country:IE us-gaap:MaximumMember 2016-11-02 0000924717 us-gaap:RevolvingCreditFacilityMember 2016-10-01 2016-12-31 0000924717 us-gaap:RevolvingCreditFacilityMember 2016-12-31 0000924717 srdx:AcceleratedShareRepurchaseProgramMember 2014-11-05 0000924717 srdx:MedicalDeviceMember us-gaap:OperatingSegmentsMember 2016-10-01 2016-12-31 0000924717 srdx:MedicalDeviceMember us-gaap:OperatingSegmentsMember 2015-10-01 2015-12-31 0000924717 srdx:InVitroDiagnosticsMember us-gaap:OperatingSegmentsMember 2016-10-01 2016-12-31 0000924717 srdx:InVitroDiagnosticsMember us-gaap:OperatingSegmentsMember 2015-10-01 2015-12-31 0000924717 us-gaap:OperatingSegmentsMember 2016-10-01 2016-12-31 0000924717 us-gaap:OperatingSegmentsMember 2015-10-01 2015-12-31 0000924717 us-gaap:CorporateNonSegmentMember 2016-10-01 2016-12-31 0000924717 us-gaap:CorporateNonSegmentMember 2015-10-01 2015-12-31 0000924717 us-gaap:PatentsMember 2016-10-01 2016-12-31 10-Q false 2016-12-31 2017 Q1 SRDX SURMODICS INC 0000924717 --09-30 Accelerated Filer 13266526

17653000

24987000

27474000

21954000

6504000

6869000

3472000

3579000

358000

697000

1183000

472000

56644000

58558000

20186000

19601000

4286000

5027000

21094000

22525000

25694000

26555000

721000

628000

128625000

132894000

1611000

1622000

1364000

5418000

340000

881000

1563000

1109000

925000

131000

180000

5934000

10135000

13366000

13592000

258000

188000

1884000

2146000

21442000

26061000

663000

660000

7009000

6754000

-935000

1273000

100446000

98146000

107183000

106833000

128625000

132894000

10000

19000

0.05

450000

0.05

45000000

13268530

13208443

13268530

13208443

7701000

7181000

8001000

7954000

2059000 1406000

17761000

16541000

2628000

2366000

5970000

3634000

4862000

3648000

2491000

596000 354000

437000

109000

14493000

12602000

3268000

3939000

85000

1000

674000

-135000

759000

-134000

4027000

3805000

1727000

1152000

2300000

2653000

0.17

0.20

0.17

0.20

13200000

12966000

13446000

13186000

46000

-2000

-2254000

408000

-2208000

406000

92000

3059000

1282000

909000

789000

684000

437000

109000

663000

-135000

742000

753000

5000

3000

-345000

-2194000

-73000

83000

746000

75000

-2713000

-1354000

82000

356000

28000

1951000

6278000

1545000

384000

12541000

7071000

18166000

-7015000

-18550000

13000

10000

2129000

353000

38000

305000

-2154000

-648000

-116000

-7334000

-12920000

55588000

42668000

897000

42000

227000 54000 45000

9857000

2414000 1073000

<div> 4. Fair Value Measurements The accounting guidance on fair value measurements defines fair value, establishes a framework for measuring fair value under GAAP, and expands disclosures about fair value measurements. The guidance is applicable for all financial assets and financial liabilities and for all nonfinancial assets and nonfinancial liabilities recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and also considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value Hierarchy Accounting guidance on fair value measurements requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: Level 1 — Quoted (unadjusted) prices in active markets for identical assets or liabilities. The Company did not have any Level 1 assets as of December 31, 2016 and September 30, 2016.   Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. The Company’s Level 2 assets as of December 31, 2016 and September 30, 2016 consisted of money market funds, commercial paper instruments and corporate bonds. Level 3 — Unobservable inputs to the valuation methodology that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation. Level 3 liabilities at December 31, 2016 and September 30, 2016 consist of contingent consideration obligations for the achievement of revenue and value-creating milestones related to the acquisitions of Creagh Medical and NorMedix discussed in Note 3. In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs. Assets and Liabilities Measured at Fair Value on a Recurring Basis In instances where the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability. The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2016:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.8%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Active Markets <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">for Identical <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Instruments <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Significant Other Observable Inputs <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Significant Unobservable Inputs <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Total Fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Value as of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.8%;"> Assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.8%;"> Cash equivalents</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,775</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,775</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.8%; border-bottom:solid 0.75pt transparent;"> Available-for-sale securities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,474</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,474</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.8%; border-bottom:double 2.5pt transparent;"> Total assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,249</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,249</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.8%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%; border-top:double 2.5pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%; border-top:double 2.5pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.8%;"> Liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.8%; border-bottom:solid 0.75pt transparent;"> Contingent consideration</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,291</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,291</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.8%; border-bottom:double 2.5pt transparent;"> Total liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,291</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,291</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> )</td> </tr> </table></div> The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2016:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.74%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Active Markets <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">for Identical <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Instruments <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Significant Other Observable Inputs <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Significant Unobservable Inputs <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.24%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Total Fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Value as of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%;"> Assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%;"> Cash equivalents</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,160</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,160</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.74%; border-bottom:solid 0.75pt transparent;"> Available-for-sale securities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,954</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,954</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.74%; border-bottom:double 2.5pt transparent;"> Total assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,114</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,114</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-top:double 2.5pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%; border-top:double 2.5pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%;"> Liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.74%; border-bottom:solid 0.75pt transparent;"> Contingent consideration</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,517</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,517</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.74%; border-bottom:double 2.5pt transparent;"> Total liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,517</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,517</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> )</td> </tr> </table></div> The following table summarizes the changes in the contingent consideration liabilities measured at fair value using Level 3 inputs for the three months ended December 31, 2016 and 2015:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.98%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.98%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.98%;"> Beginning balance</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,517</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.98%;"> Additions</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,064</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.98%;"> Fair value adjustments</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.98%;"> Settlements</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.98%;"> Interest accretion</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">437</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.98%; border-bottom:solid 0.75pt transparent;"> Foreign currency translation (gain) loss</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(663</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.98%; border-bottom:double 2.5pt transparent;"> Ending balance</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,291</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,308</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div> There were no transfers of assets or liabilities to or from amounts measured using Level 3 fair value measurements during fiscal 2017 or 2016. Valuation Techniques <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The valuation techniques used to measure the fair value of assets are as follows: Cash equivalents — These assets are classified as Level 2 and are carried at historical cost which is a reasonable estimate of fair value because of the relatively short time between origination of the instrument and its expected realization. Available-for-sale securities — Fair market values for these assets are based on quoted vendor prices and broker pricing in active markets underlying the securities where all significant inputs are observable. To ensure the accuracy of quoted vendor prices and broker pricing, the Company performs regular reviews of investment returns to industry benchmarks and sample tests of individual securities to validate quoted vendor prices with other available market data. Contingent consideration — The contingent consideration liabilities were determined based on discounted cash flow analyses that included revenue estimates, probability of strategic milestone achievement and a discount rate, which are considered significant unobservable inputs. For the revenue-based milestones, the Company discounted forecasted revenue by 14.1% to 22.8%, which represents the Company’s weighted average cost of capital for each transaction, adjusted for the short-term nature of the cash flows. The resulting present value of revenue was used as an input into an option pricing approach, which also considered the Company’s risk of non-payment of the revenue-based milestones.  Non-revenue milestones were projected to have a 65-95% probability of achievement and related payments were discounted using the Company’s estimated cost of debt, or 5.6% to 6.7%.  To the extent that actual results differ from these estimates, the fair value of the contingent consideration liabilities could change significantly. The contingent consideration liability related to the Creagh Medical acquisition is denominated in Euros and is not hedged.  The Company recorded a foreign currency gain of $0.7 million and a loss of $0.1 million for the three months ended December 31, 2016 and 2015, respectively, related to this contingent consideration as this obligation was marked to period-end exchange rates.</div>

<div> 5. Investments Investments consisted principally of commercial paper securities and are classified as available-for-sale as of December 31, 2016 and September 30, 2016. Available-for-sale securities are reported at fair value with unrealized gains and losses, net of tax, excluded from the condensed consolidated statements of income and reported in the condensed consolidated statements of comprehensive income as well as a separate component of stockholders’ equity in the condensed consolidated balance sheets, except for other-than-temporary impairments, which are reported as a charge to current earnings. A loss would be recognized when there is an other-than-temporary impairment in the fair value of any individual security classified as available-for-sale, with the associated net unrealized loss reclassified out of accumulated other comprehensive income with a corresponding adjustment to other income (loss). This adjustment results in a new cost basis for the investment.  Interest earned on debt securities, including amortization of premiums and accretion of discounts, is included in other income. Realized gains and losses from the sales of debt securities, which are included in other income, are determined using the specific identification method. The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows:     <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:solid 0.75pt transparent;"> Commercial paper and corporate bonds</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,487</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,474</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:double 2.5pt transparent;"> Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,487</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,474</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:solid 0.75pt transparent;"> Commercial paper and corporate bonds</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,954</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:double 2.5pt transparent;"> Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,954</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>   The following table summarizes sales of available-for-sale debt securities:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from maturities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,071</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross realized gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross realized losses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> 7. Other Assets     Other assets consist of the following: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> ViaCyte, Inc.</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">479</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">479</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> Other noncurrent assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> Other assets, net</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">721</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div> The Company has invested a total of $5.3 million in ViaCyte, Inc. (“ViaCyte”), a privately-held California-based biotechnology firm that is developing a unique treatment for diabetes using coated islet cells, the cells that produce insulin in the human body. The balance of the investment of $0.5 million, which is net of previously recorded other-than-temporary impairments of $4.8 million is accounted for under the cost method and represents less than a 1% ownership interest. The Company does not exert significant influence over ViaCyte’s operating or financial activities. The carrying value of each cost method investment is reviewed quarterly for changes in circumstances or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost method investments is not adjusted if there are no identified events or changes in circumstances that may have a material adverse effect on the fair value of the investment.</div>

<div> 8. Intangible Assets Intangible assets consist principally of acquired patents and technology, customer lists and relationships, licenses and trademarks. The Company recorded amortization expense of $0.6 million and $0.4 million for the three months ended December 31, 2016 and 2015, respectively. Intangible assets consisted of the following: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Original Life (Years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Gross Carrying Amount</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Amortization</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Net</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;"> Definite-lived intangible assets:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer lists and relationships</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,979</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,434</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,545</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Core technology</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">530</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(530</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developed technology</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,610</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(800</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,810</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-compete</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents and other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,322</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,312</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,010</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,671</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,145</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,526</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;"> Unamortized intangible assets:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-process research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">927</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">927</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trademarks and trade names</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">641</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">641</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,239</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,145</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,094</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.42%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.42%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Original Life (Years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Gross Carrying Amount</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-top:solid 0.75pt #000000;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Amortization</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-top:solid 0.75pt #000000;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Net</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.42%;"> Definite-lived intangible assets:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.42%;"> Customer lists and relationships</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,692</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,123</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,569</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.42%;"> Core technology</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">530</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(530</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.42%;"> Developed technology</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,724</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(618</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,106</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.42%;"> Non-compete</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.42%; border-bottom:solid 0.75pt transparent;"> Patents and other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,321</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,275</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,046</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.42%;"> Subtotal</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,497</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,604</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,893</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.42%;"> Unamortized intangible assets:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.42%;"> In-process research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">987</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">987</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.42%; border-bottom:solid 0.75pt transparent;"> Trademarks and trade names</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">645</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">645</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.42%; border-bottom:double 2.5pt transparent;"> Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.96%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,129</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,604</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,525</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div> Based on the intangible assets in service as of December 31, 2016, excluding any possible future amortization associated with acquired in-process research and development (“IPR&D”), which has not met technological feasibility as of December 31, 2016, estimated amortization expense for the remainder of fiscal 2017 and each of the next five fiscal years is as follows: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> Remainder of 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,864</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,439</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,439</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,264</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,125</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,085</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Future amortization amounts presented above are estimates. Actual future amortization expense may be different as a result of future acquisitions, impairments, completion or abandonment of IPR&D intangible assets, changes in amortization periods, or other factors. The Company defines IPR&D as the value of technology acquired for which the related projects have substance and are incomplete. IPR&D acquired in a business acquisition is recognized at fair value and requires the IPR&D to be capitalized as an indefinite-lived intangible asset until completion of the IPR&D project or abandonment. Upon completion of the development project (generally when regulatory approval to market the product is obtained), an impairment assessment is performed prior to amortizing the asset over its estimated useful life. If the IPR&D projects are abandoned, the related IPR&D assets would be written off. </div>

<div> Accounting Standards to be Implemented In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) Update No. 2014-09, Revenue from Contracts with Customers (ASC Topic 606).  Principles of this guidance require entities to recognize revenue in a manner that depicts the transfer of goods or services to customers in amounts that reflect the consideration an entity expects to be entitled to in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting standard will be effective for the Company beginning in the first quarter of fiscal year 2019 (October 1, 2018) using one of two prescribed retrospective methods. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s business model and consolidated results of operations, cash flows and financial position. The Company expects to complete its evaluation during fiscal 2017. Based on a preliminary assessment, the Company currently estimates the impact may be material due to the potential acceleration of minimum license fees and a one quarter acceleration of royalty revenue pursuant to our hydrophilic license agreements. In February 2016, the FASB issued Accounting Standards Update ASU 2016-02, Leases (ASC Topic 842).  The new guidance primarily affects lessee accounting, while accounting by lessors will not be significantly impacted by the update.  The update maintains two classifications of leases: finance leases, which replace capital leases, and operating leases. Lessees will need to recognize a right-of-use asset and a lease liability on the statement of financial position for those leases previously classified as operating leases under the old guidance. The liability will be equal to the present value of lease payments.  The asset will be based on the liability, subject to adjustment, such as for direct costs. The accounting standard will be effective for the Company beginning the first quarter of fiscal year 2020 (October 1, 2019) and will be applied using a modified retrospective approach. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s results of operations, cash flows and financial position. In June 2016, the FASB issued ASU No 2016-13, Financial Instruments – Credit Losses (ASC Topic 326), Measurement of Credit Losses on Financial Statements. This ASU requires a financial asset (or a group of financial assets) measured at an amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The accounting standard will be effective for the Company beginning in the first quarter of fiscal 2020 (October 1, 2019). Early adoption is permitted and the guidance will be applied using a modified retrospective approach. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s results of operations, cash flows and financial position. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new guidance clarifies requirements for presentation and classification of the following items within the statement of cash flows: debt prepayments, settlement of zero coupon debt instruments, contingent consideration payments, insurance proceeds, securitization transactions and distributions from equity method investees. The update also addresses classification of transactions that have characteristics of more than one class of cash flows. The accounting standard will be effective for the Company beginning in the first quarter of fiscal 2018. Early adoption is permitted, including adoption in an interim period, and the guidance will be applied retrospectively. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s condensed consolidated statements of cash flows. In January 2017, the FASB issued ASU No. 2017-04, Intangibles—Goodwill and Other  (Topic 350): Simplifying the Test for Goodwill Impairment. The new guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The accounting standard will be effective for the Company beginning in its fiscal 2020. Early adoption is permitted, and the guidance will be applied prospectively. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s condensed consolidated financial statements. Accounting Standards Implemented In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (ASC Topic 718): Improvements to Employee Share-Based Payment Accounting. The accounting standard intends to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The accounting standard is effective for the Company beginning in the first quarter of fiscal 2018 (October 1, 2017), and early adoption is permitted. The Company elected to early-adopt this accounting standard in the fourth quarter of fiscal 2016, for the fiscal year ended September 30, 2016. As a result of the adoption, the Company records excess tax benefits and certain tax deficiencies as income tax expense or benefit in the condensed consolidated statements of income, whereas such excess tax benefits or tax deficiencies were previously recorded in additional paid-in capital. As this guidance was applied retroactively to the beginning of the fiscal year ended September 30, 2016, previously reported quarterly income tax and net income for interim periods therein were adjusted for the effects of the adoption. This resulted in an adjustment to reduce the income tax provision and increase net income by $0.1 million in the three months ended December 31, 2015, with a corresponding increase in net income per basic and diluted share of $0.01 per share. The guidance also requires presentation of excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. Prior to the adoption of ASU No. 2016-09, cash flows resulting from the tax benefits generated by tax deductions in excess of the compensation cost recognized for those options (excess tax benefits) are classified as financing cash flows. During the three months ended December 31, 2015, the Company realized tax benefits from stock options resulting in approximately $0.1 million of gross excess tax benefits, which are included as a component of cash flows from operating activities for the three months ended December 31, 2015 in the accompanying condensed consolidated statements of cash flows. This amount was previously reported as a component of cash flows from financing activities, but has been reclassified to conform to current accounting guidance. No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s condensed consolidated financial statements.</div>

<div> The purchase price of Creagh Medical consisted of the following: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.74%;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.74%;"> Cash paid</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,449</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.74%;"> Debt assumed</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">761</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.74%; border-bottom:solid 0.75pt transparent;"> Contingent consideration</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,064</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.74%;"> Total purchase price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.12%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,274</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.74%; border-bottom:solid 0.75pt transparent;"> Less cash and cash equivalents acquired</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(251</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.74%; border-bottom:double 2.5pt transparent;"> Total purchase price, net of cash acquired</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.12%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,023</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>  </div>

<div> The following table summarizes the final allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the Creagh Medical acquisition: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.62%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Fair Value <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(In years)</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.62%;"> Current assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">896</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.62%;"> Property and equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">634</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0-10.0</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.62%;"> Trade name</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.62%;"> Developed technology</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,787</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.0</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.62%;"> In-process research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">942</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.62%;"> Customer relationships</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,119</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.0-10.0</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.62%;"> Other noncurrent assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.62%;"> Current liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(942</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.62%; border-bottom:solid 0.75pt transparent;"> Deferred tax liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.62%;"> Net assets acquired</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,583</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.62%; border-bottom:solid 0.75pt transparent;"> Goodwill</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,440</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.62%; border-bottom:double 2.5pt transparent;"> Total purchase price, net of cash acquired</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,023</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.68%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The purchase price of NorMedix consisted of the following: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.68%;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.68%;"> Cash paid</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,905</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.68%; border-bottom:solid 0.75pt transparent;"> Contingent consideration</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,520</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.68%;"> Total purchase price</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,425</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.68%; border-bottom:solid 0.75pt transparent;"> Less cash and cash equivalents acquired</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:75.68%; border-bottom:double 2.5pt transparent;"> Total purchase price, net of cash acquired</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,408</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:75.68%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.02%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">  </td> </tr> </table></div>  </div>

<div> The following table summarizes the final allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the NorMedix acquisition: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.7%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.98%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Fair Value <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(In years)</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.7%;"> Net current assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.7%;"> Property and equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.7%;"> Developed technology</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,850</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.0-14.0</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.7%;"> Customer relationships</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">900</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.0</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.7%;"> Deferred tax asset</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">690</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.7%;"> Other noncurrent asset</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.7%;"> Accounts payable</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(187</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.7%; border-bottom:solid 0.75pt transparent;"> Deferred tax liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,483</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.78%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.7%;"> Net assets acquired</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,956</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.78%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.7%; border-bottom:solid 0.75pt transparent;"> Goodwill</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,452</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.78%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.7%; border-bottom:double 2.5pt transparent;"> Total purchase price, net of cash acquired</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,408</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.78%; border-bottom:double 2.5pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2016:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.8%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Active Markets <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">for Identical <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Instruments <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Significant Other Observable Inputs <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Significant Unobservable Inputs <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.28%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Total Fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Value as of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.8%;"> Assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.8%;"> Cash equivalents</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,775</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,775</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.8%; border-bottom:solid 0.75pt transparent;"> Available-for-sale securities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,474</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,474</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.8%; border-bottom:double 2.5pt transparent;"> Total assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,249</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,249</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.8%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%; border-top:double 2.5pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%; border-top:double 2.5pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.8%;"> Liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.44%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.8%; border-bottom:solid 0.75pt transparent;"> Contingent consideration</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,291</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,291</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.8%; border-bottom:double 2.5pt transparent;"> Total liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.66%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,291</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.28%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,291</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> )</td> </tr> </table></div> The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2016:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.74%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Active Markets <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">for Identical <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Instruments <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Significant Other Observable Inputs <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Significant Unobservable Inputs <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.24%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.68%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Total Fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Value as of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%;"> Assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%;"> Cash equivalents</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,160</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,160</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.74%; border-bottom:solid 0.75pt transparent;"> Available-for-sale securities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,954</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,954</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.74%; border-bottom:double 2.5pt transparent;"> Total assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,114</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,114</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-top:double 2.5pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%; border-top:double 2.5pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%;"> Liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.56%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.38%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.74%; border-bottom:solid 0.75pt transparent;"> Contingent consideration</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,517</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%; border-bottom:solid 0.75pt #000000;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,517</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.74%; border-bottom:double 2.5pt transparent;"> Total liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.56%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.36%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,517</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,517</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> )</td> </tr> </table></div>  </div>

<div> The following table summarizes the changes in the contingent consideration liabilities measured at fair value using Level 3 inputs for the three months ended December 31, 2016 and 2015:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.98%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.98%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.98%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.98%;"> Beginning balance</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,517</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.98%;"> Additions</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,064</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.98%;"> Fair value adjustments</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.98%;"> Settlements</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.98%;"> Interest accretion</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">437</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.98%; border-bottom:solid 0.75pt transparent;"> Foreign currency translation (gain) loss</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(663</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.98%; border-bottom:double 2.5pt transparent;"> Ending balance</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,291</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,308</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>  </div>

<div> The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows:     <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:solid 0.75pt transparent;"> Commercial paper and corporate bonds</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,487</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,474</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:double 2.5pt transparent;"> Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,487</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,474</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:solid 0.75pt transparent;"> Commercial paper and corporate bonds</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,954</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.54%; border-bottom:double 2.5pt transparent;"> Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,954</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>  </div>

<div> The following table summarizes sales of available-for-sale debt securities:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from maturities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,071</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross realized gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross realized losses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Inventories consisted of the following components:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,724</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,766</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work-in process</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">449</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">492</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished products</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,299</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,321</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,472</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,579</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Other assets consist of the following: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> ViaCyte, Inc.</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">479</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">479</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> Other noncurrent assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> Other assets, net</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">721</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">628</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>  </div>

<div> Intangible assets consisted of the following: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Original Life (Years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Gross Carrying Amount</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Amortization</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Net</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;"> Definite-lived intangible assets:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer lists and relationships</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,979</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,434</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,545</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Core technology</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">530</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(530</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developed technology</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,610</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(800</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,810</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-compete</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents and other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,322</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,312</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,010</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,671</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,145</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,526</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;"> Unamortized intangible assets:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-process research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">927</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">927</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trademarks and trade names</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">641</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">641</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,239</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,145</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,094</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.42%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.42%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average Original Life (Years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Gross Carrying Amount</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-top:solid 0.75pt #000000;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Amortization</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-top:solid 0.75pt #000000;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Net</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.42%;"> Definite-lived intangible assets:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.42%;"> Customer lists and relationships</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.9</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,692</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,123</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,569</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.42%;"> Core technology</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">530</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(530</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.42%;"> Developed technology</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.8</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,724</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(618</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,106</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.42%;"> Non-compete</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.42%; border-bottom:solid 0.75pt transparent;"> Patents and other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,321</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,275</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,046</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.42%;"> Subtotal</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,497</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,604</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,893</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.42%;"> Unamortized intangible assets:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.42%;"> In-process research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">987</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.58%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">987</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.42%; border-bottom:solid 0.75pt transparent;"> Trademarks and trade names</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">645</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">645</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.42%; border-bottom:double 2.5pt transparent;"> Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:13.96%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,129</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,604</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.58%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,525</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>  </div>

<div> Based on the intangible assets in service as of December 31, 2016, excluding any possible future amortization associated with acquired in-process research and development (“IPR&D”), which has not met technological feasibility as of December 31, 2016, estimated amortization expense for the remainder of fiscal 2017 and each of the next five fiscal years is as follows: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> Remainder of 2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,864</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,439</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,439</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,264</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,125</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,085</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The change in the carrying amount of goodwill by segment for the three months ended December 31, 2016 was as follows: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">In Vitro Diagnostics</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.98%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Medical Device</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.18%;"> Balance as of  September 30, 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,010</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,545</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,555</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:solid 0.75pt transparent;"> Translation adjustment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(861</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(861</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.18%; border-bottom:double 2.5pt transparent;"> Balance as of  December 31, 2016</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,010</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,684</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,694</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>  </div>

<div> The Company’s stock-based compensation expenses were allocated to the following expense categories:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.86%;"> Product costs</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.86%;"> Research and development</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:solid 0.75pt transparent;"> Selling, general and administrative</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">651</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">619</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:double 2.5pt transparent;"> Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">789</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">684</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>  </div>

<div> The assumptions used as inputs in the model were as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.52%;"> Risk-free interest rates</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> %</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> %</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.52%;"> Expected life (years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.52%;"> Expected volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> %</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36.7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> %</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.52%;"> Dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> %</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> %</td> </tr> </table></div>  </div>

<div> The aggregate number of shares that could be awarded to our executives if the minimum, target and maximum performance goals are met, based on the fair value at the date of grant is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%; border-bottom:solid 0.75pt #000000;"> Performance Period</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Minimum Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Target Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Maximum Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%; border-top:solid 0.75pt #000000;"> Fiscal 2015 – 2017</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,440</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,199</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,398</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;"> Fiscal 2016 – 2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,268</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,338</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,676</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51%;"> Fiscal 2017 – 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,437</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,185</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,370</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;">  </td> </tr> </table></div>  </div>

<div> The following table sets forth the denominator for the computation of basic and diluted net income per share (in thousands): <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> Net income available to common shareholders</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,300</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,653</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> Basic weighted average shares outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,200</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,966</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> Dilutive effect of outstanding stock options, non-vested    restricted stock, restricted stock units, deferred stock    units and performance shares</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">246</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> Diluted weighted average shares outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,446</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,186</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>  </div>

<div> The tables below present segment revenue, operating income and depreciation and amortization, as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:solid 0.75pt transparent;"> (Dollars in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.86%;"> Revenue:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.86%;"> Medical Device</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,757</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,247</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:solid 0.75pt transparent;"> In Vitro Diagnostics</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,004</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,294</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:double 2.5pt transparent;"> Total revenue</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,761</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,541</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.86%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.86%;"> Operating income:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.86%;"> Medical Device</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,719</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,830</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:solid 0.75pt transparent;"> In Vitro Diagnostics</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,456</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,643</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.86%;"> Total segment operating income</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,175</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,473</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:solid 0.75pt transparent;"> Corporate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,907</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,534</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:double 2.5pt transparent;"> Total operating income</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,268</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,939</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.86%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.86%;"> Depreciation and amortization:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.86%;"> Medical Device</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,004</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.86%;"> In Vitro Diagnostics</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:solid 0.75pt transparent;"> Corporate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.86%; border-bottom:double 2.5pt transparent;"> Total depreciation and amortization</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,282</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">909</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>  </div>

-100000

100000

0.01

100000

1.00

30000000

32000000

18000000

19300000

12000000

12800000

2400000

500000

-300000

18449000

761000

9064000

28274000

251000

28023000

896000

634000

75000

1787000

942000

11119000

81000

942000

9000

14583000

13440000

P7Y

P1Y

P10Y

P7Y

P10Y

1.00

14000000

7000000

100000

6905000

3520000

10425000

17000

10408000

113000

60000

6850000

900000

690000

13000

187000

2483000

5956000

4452000

P4Y

P10Y

P14Y

17600000

4200000

0.32 400000

300000

2500000

300000

13775000

27474000

41249000

14291000

22160000

21954000

44114000

14517000

9064000

437000 109000 -663000 135000

14291000

9308000

0.056

0.067

0.141

0.228

0.65 0.95

700000

-100000

27487000

13000

27474000

22019000

65000

21954000

1724000

1766000

449000

492000

1299000

1321000

479000

242000

149000

5300000

4800000

500000

0.01

600000

400000

P8Y10M24D

P8Y

P11Y9M18D

P5Y

P16Y6M

927000

641000

16979000

530000

8610000

230000

2322000

28671000

6434000

530000

800000

69000

1312000

9145000

10545000

7810000

161000

1010000

19526000

30239000

9145000

P8Y10M24D

P8Y

P11Y9M18D

P5Y

P16Y6M

987000

645000

17692000

530000

8724000

230000

2321000

29497000

6123000

530000

618000

58000

1275000

8604000

11569000

8106000

172000

1046000

20893000

31129000

8604000

1864000

2439000

2264000

2125000

2085000

8010000

18545000

-861000

8010000

17684000

13000

6000

125000

59000

651000

619000

789000

684000

6200000

P2Y6M

2600000

7.59

6.87

0.017

0.020

P4Y7M6D

0.344

0.367

0.000

P7Y

P10Y

P1Y

0.25

P4Y

300000

100000

P3Y

2015 2017 2016 2018 2017 2019

0.20

2.00

200000

38505

78606

1200000

1300000

900000

8440 13268 10437 42199 66338 52185 84398 132676 104370

600000

0.10 25000 100000 100000

100000

6570

8916

100000

35378

32101

900000

1971

1842

100000

23048

21077

600000

30000000

P3Y

5000000

0.0100

0.0175

0.0015

5000000 20000000 2019-11

2300000

2653000

246000

220000

300000

400000

30000000

0.429

0.303

0.350

1200000

13757000

12247000

4004000

4294000

3719000

3830000

1456000

1643000

5175000

5473000

-1907000

-1534000

1004000

487000

103000

222000

175000

200000

2006-03

211000

200000

1.0536 2027-09 2700000

EX-101.SCH 8 srdx-20161231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Income link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Comprehensive Income link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - New Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Business Combinations link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Investments link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Inventories link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Other Assets link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Intangible Assets link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Goodwill link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Stock-based Compensation link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Revolving Credit Facility link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Net Income Per Share Data link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Segment and Geographical Information link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - New Accounting Pronouncements (Policies) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Business Combinations (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Investments (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Inventories (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Other Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Goodwill (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Stock-based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Net Income Per Share Data (Tables) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Segment and Geographical Information (Tables) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - New Accounting Pronouncements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Business Combinations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Business Combinations - Summary of Purchase Price (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Business Combinations - Summary of Purchase Price Allocation to the Fair Values Assigned to the Assets Acquired and Liabilities Assumed (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Fair Value Measurements - Schedule of Contingent Consideration Liabilities Measured at Fair Value (Detail) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Investments - Amortized Cost, Unrealized Holding Gains and (Losses) and Fair Value of Available-for-sale Securities (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Investments - Sales of Available-for-Sale Securities (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Inventories - Components of Inventories (Detail) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Other Assets - Summary of Other Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Other Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Intangible Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Intangible Assets - Estimated Amortization Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Goodwill - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Goodwill - Schedule Of Carrying Amount of Goodwill by Segment (Detail) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Stock-based Compensation - Stock-based Compensation Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Stock-based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Stock-based Compensation - Assumptions Used in Stock Option Plans (Detail) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Stock-based Compensation - Schedule of Fair Value at the Date of Grant (Detail) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Revolving Credit Facility - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Net Income Per Share Data - Denominator for Computation of Basic and Diluted Net Income Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Net Income Per Share Data - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100570 - Disclosure - Segment and Geographical Information - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100580 - Disclosure - Segment and Geographical Information - Segment Revenue, Operating Income and Depreciation and Amortization (Detail) link:calculationLink link:presentationLink link:definitionLink 100590 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 9 srdx-20161231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 srdx-20161231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 srdx-20161231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Statement Of Financial Position [Abstract] ASSETS Assets [Abstract] Current Assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Available-for-sale securities Available For Sale Securities Current Accounts receivable, net of allowance for doubtful accounts of $10 and $19 as of December 31, 2016 and September 30, 2016, respectively Accounts Receivable Net Current Inventories Inventory Net Income tax receivable Income Taxes Receivable Prepaids and other Prepaid Expense And Other Assets Current Total Current Assets Assets Current Property and equipment, net Property Plant And Equipment Net Deferred tax assets Deferred Tax Assets Net Noncurrent Intangible assets, net Intangible Assets Net Excluding Goodwill Goodwill Goodwill Other assets Other Assets Noncurrent Total Assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities And Stockholders Equity [Abstract] Current Liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued liabilities: Accrued Liabilities Current [Abstract] Compensation Employee Related Liabilities Current Due to customers Payables To Customers Accrued other Other Accrued Liabilities Current Contingent consideration Business Combination Contingent Consideration Liability Current Deferred revenue Deferred Revenue Current Total Current Liabilities Liabilities Current Contingent consideration, less current portion Business Combination Contingent Consideration Liability Noncurrent Deferred revenue, less current portion Deferred Revenue Noncurrent Other long-term liabilities Other Liabilities Noncurrent Total Liabilities Liabilities Commitments and Contingencies (Note 15) Commitments And Contingencies Stockholders’ Equity: Stockholders Equity [Abstract] Series A Preferred stock- $.05 par value, 450,000 shares authorized; no shares issued and outstanding Preferred Stock Value Common stock- $.05 par value, 45,000,000 shares authorized; 13,268,530 and 13,208,443 shares issued and outstanding, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income Loss Net Of Tax Retained earnings Retained Earnings Accumulated Deficit Total Stockholders’ Equity Stockholders Equity Total Liabilities and Stockholders’ Equity Liabilities And Stockholders Equity Accounts receivable, allowance for doubtful accounts Allowance For Doubtful Accounts Receivable Current Series A Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Series A Preferred stock, shares authorized Preferred Stock Shares Authorized Series A Preferred stock, shares issued Preferred Stock Shares Issued Series A Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Research development and other revenue. Acquisition related intangible asset amortization. Income Statement [Abstract] Revenue: Revenues [Abstract] Product sales Sales Revenue Goods Net Royalties and license fees Royalty Revenue Research, development and other Research Development And Other Revenue Total revenue Revenues Operating costs and expenses: Costs And Expenses [Abstract] Product costs Cost Of Goods Sold Research and development Research And Development Expense Selling, general and administrative Selling General And Administrative Expense Acquisition transaction, integration and other costs Business Combination Integration Related Costs Acquired intangible asset amortization Acquisition Related Intangible Asset Amortization Contingent consideration accretion expense Accretion Expense Including Asset Retirement Obligations Total operating costs and expenses Costs And Expenses Operating income Operating Income Loss Other income (loss): Nonoperating Income Expense [Abstract] Investment income, net Investment Income Net Foreign exchange gain (loss) Foreign Currency Transaction Gain Loss Before Tax Other income (loss), net Nonoperating Income Expense Income before income taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income tax provision Income Tax Expense Benefit Net income Net Income Loss Basic net income per share Earnings Per Share Basic Diluted net income per share Earnings Per Share Diluted Weighted average number of shares outstanding: Weighted Average Number Of Shares Outstanding [Abstract] Basic Weighted Average Number Of Shares Outstanding Basic Diluted Weighted Average Number Of Diluted Shares Outstanding Statement Of Income And Comprehensive Income [Abstract] Net income Other comprehensive (loss) income: Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Unrealized holding gains (losses) on available-for-sale securities, net of tax Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Foreign currency translation adjustments Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Other comprehensive (loss) income Other Comprehensive Income Loss Net Of Tax Comprehensive income Comprehensive Income Net Of Tax Payment of contingent consideration. Noncash transaction - acquisition of property and equipment on account. Noncash transaction deferred financing costs in accounts payable. Noncash Transactions related to issuance of performance shares, restricted stock units, and deferred stock units in current year. Statement Of Cash Flows [Abstract] Statement [Table] Statement [Table] Business Acquisition Business Acquisition [Axis] Business Acquisition, Acquiree Business Acquisition Acquiree [Domain] Creagh Medical Ltd. Creagh Medical Ltd [Member] Creagh Medical Ltd [Member] Statement [Line Items] Statement [Line Items] Operating Activities: Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation Depletion And Amortization Stock-based compensation Share Based Compensation Contingent consideration accretion Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 Unrealized foreign exchange (income) loss Foreign Currency Transaction Gain Loss Unrealized Deferred taxes Deferred Income Tax Expense Benefit Other Other Noncash Income Expense Change in operating assets and liabilities, net of acquisitions: Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Inventories Increase Decrease In Inventories Prepaids and other Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable and accrued liabilities Increase Decrease In Accounts Payable And Accrued Liabilities Income taxes Increase Decrease In Accrued Income Taxes Payable Deferred revenue Increase Decrease In Deferred Revenue Net cash provided by operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Investing Activities: Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Purchases of property and equipment Payments To Acquire Property Plant And Equipment Purchases of available-for-sale securities Payments To Acquire Available For Sale Securities Maturities of available-for-sale securities Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities Payments for acquisition, net of cash acquired Payments To Acquire Businesses Net Of Cash Acquired Net cash used in investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Financing Activities: Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Issuance of common stock Proceeds From Issuance Of Common Stock Payments for taxes related to net share settlement of equity awards Payments Related To Tax Withholding For Share Based Compensation Payment of deferred financing costs Payments Of Financing Costs Payment of contingent consideration Payment Of Contingent Consideration Net cash used in financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Effect of exchange rate changes on cash Effect Of Exchange Rate On Cash And Cash Equivalents Net change in cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Cash and Cash Equivalents: Cash And Cash Equivalents At Carrying Value [Abstract] Beginning of period End of period Supplemental Information: Supplemental Cash Flow Information [Abstract] Cash paid for income taxes Income Taxes Paid Net Noncash transactions from investing and financing activities: Noncash Investing And Financing Items [Abstract] Acquisition of property and equipment on account Noncash Transaction Acquisition Of Property Plant And Equipment On Account Deferred financing costs in accounts payable Noncash Transaction Deferred Financing Costs In Accounts Payable Contingent consideration and debt assumed in Creagh Medical transaction Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 Issuance of performance shares, restricted and deferred stock units Noncash Transactions Issuance Of Performance Shares Restricted And Deferred Stock Units Accounting Policies [Abstract] Basis of Presentation Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] New Accounting Pronouncements New Accounting Pronouncements And Changes In Accounting Principles [Text Block] Business Combinations [Abstract] Business Combinations Business Combination Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Investments Debt And Equity Securities [Abstract] Investments Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Inventory Disclosure [Abstract] Inventories Inventory Disclosure [Text Block] Investments All Other Investments [Abstract] Other Assets Investments And Other Noncurrent Assets [Text Block] Goodwill And Intangible Assets Disclosure [Abstract] Intangible Assets Intangible Assets Disclosure [Text Block] Goodwill Goodwill Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Revolving line of credit. Text Block [Abstract] Revolving Credit Facility Revolving Line Of Credit [Text Block] Earnings Per Share [Abstract] Net Income Per Share Data Earnings Per Share [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Segment Reporting [Abstract] Segment and Geographical Information Segment Reporting Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] New Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Schedule Of Business Acquisitions By Acquisition [Table] Schedule Of Business Acquisitions By Acquisition [Table] NorMedix, Inc. NorMedix, Inc. [Member] Nor Medix Inc [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Summary of Purchase Price Schedule Of Business Acquisitions By Acquisition [Text Block] Schedule of Purchase Price to the Fair Values Assigned to the Assets Acquired and Liabilities Assumed Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed Table [Text Block] Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Schedule of Contingent Consideration Liabilities Measured at Fair Value Schedule Of Business Acquisitions By Acquisition Contingent Consideration [Text Block] Amortized Cost, Unrealized Holding Gains and (Losses) and Fair Value of Available-for-sale Securities Available For Sale Securities [Text Block] Sales of Available-for-Sale Debt Securities Schedule Of Available For Sale Securities Reconciliation Table [Text Block] Components of Inventories Schedule Of Inventory Current Table [Text Block] Summary of Other Assets Schedule Of Other Assets Noncurrent [Text Block] Schedule of Intangible Assets Schedule Of Intangible Assets And Goodwill Table [Text Block] Estimated Amortization Expense Schedule Of Finite Lived Intangible Assets Table [Text Block] Schedule Of Carrying Amount Of Goodwill By Segment Schedule Of Goodwill [Text Block] Stock-Based Compensation Expenses Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Assumptions Used in Stock Option Plans Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Schedule of number of shares awarded to key employees. Schedule of Fair Value at the Date of Grant Schedule Of Number Of Shares Awarded To Key Employees Table [Text Block] Denominator for Computation of Basic and Diluted Net Income Per Share Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Segment Revenue, Operating Income and Depreciation and Amortization Schedule Of Segment Reporting Information By Segment [Text Block] New accounting pronouncement or change in accounting principle effect of change on income tax provision. New accounting pronouncement or change in accounting principle effect of change on net income of basic and diluted earnings per share. New Accounting Pronouncements Or Change In Accounting Principle [Table] New Accounting Pronouncements Or Change In Accounting Principle [Table] Adjustments for New Accounting Pronouncements Adjustments For New Accounting Pronouncements [Axis] Type of Adoption Type Of Adoption [Member] Accounting standards update two thousand sixteen zero nine. ASU 2016-09 [Member] Accounting Standards Update Two Thousand Sixteen Zero Nine [Member] EX-101.PRE 12 srdx-20161231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Dec. 31, 2016	Jan. 31, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Trading Symbol	SRDX
Entity Registrant Name	SURMODICS INC
Entity Central Index Key	0000924717
Current Fiscal Year End Date	--09-30
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		13,266,526

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016
Current Assets:
Cash and cash equivalents	$ 17,653	$ 24,987
Available-for-sale securities	27,474	21,954
Accounts receivable, net of allowance for doubtful accounts of $10 and $19 as of December 31, 2016 and September 30, 2016, respectively	6,504	6,869
Inventories	3,472	3,579
Income tax receivable	358	697
Prepaids and other	1,183	472
Total Current Assets	56,644	58,558
Property and equipment, net	20,186	19,601
Deferred tax assets	4,286	5,027
Intangible assets, net	21,094	22,525
Goodwill	25,694	26,555
Other assets	721	628
Total Assets	128,625	132,894
Current Liabilities:
Accounts payable	1,611	1,622
Accrued liabilities:
Compensation	1,364	5,418
Due to customers	340	881
Accrued other	1,563	1,109
Contingent consideration	925	925
Deferred revenue	131	180
Total Current Liabilities	5,934	10,135
Contingent consideration, less current portion	13,366	13,592
Deferred revenue, less current portion	258	188
Other long-term liabilities	1,884	2,146
Total Liabilities	21,442	26,061
Commitments and Contingencies (Note 15)
Stockholders’ Equity:
Series A Preferred stock- $.05 par value, 450,000 shares authorized; no shares issued and outstanding
Common stock- $.05 par value, 45,000,000 shares authorized; 13,268,530 and 13,208,443 shares issued and outstanding, respectively	663	660
Additional paid-in capital	7,009	6,754
Accumulated other comprehensive (loss) income	(935)	1,273
Retained earnings	100,446	98,146
Total Stockholders’ Equity	107,183	106,833
Total Liabilities and Stockholders’ Equity	$ 128,625	$ 132,894

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016
Statement Of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 10	$ 19
Series A Preferred stock, par value	$ 0.05	$ 0.05
Series A Preferred stock, shares authorized	450,000	450,000
Series A Preferred stock, shares issued	0	0
Series A Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.05	$ 0.05
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	13,268,530	13,208,443
Common stock, shares outstanding	13,268,530	13,208,443

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue:
Product sales	$ 7,701	$ 7,181
Royalties and license fees	8,001	7,954
Research, development and other	2,059	1,406
Total revenue	17,761	16,541
Operating costs and expenses:
Product costs	2,628	2,366
Research and development	5,970	3,634
Selling, general and administrative	4,862	3,648
Acquisition transaction, integration and other costs		2,491
Acquired intangible asset amortization	596	354
Contingent consideration accretion expense	437	109
Total operating costs and expenses	14,493	12,602
Operating income	3,268	3,939
Other income (loss):
Investment income, net	85	1
Foreign exchange gain (loss)	674	(135)
Other income (loss), net	759	(134)
Income before income taxes	4,027	3,805
Income tax provision	(1,727)	(1,152)
Net income	$ 2,300	$ 2,653
Basic net income per share	$ 0.17	$ 0.20
Diluted net income per share	$ 0.17	$ 0.20
Weighted average number of shares outstanding:
Basic	13,200	12,966
Diluted	13,446	13,186

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 2,300	$ 2,653
Other comprehensive (loss) income:
Unrealized holding gains (losses) on available-for-sale securities, net of tax	46	(2)
Foreign currency translation adjustments	(2,254)	408
Other comprehensive (loss) income	(2,208)	406
Comprehensive income	$ 92	$ 3,059

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 18 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Operating Activities:
Net income	$ 2,300	$ 2,653
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,282	909
Stock-based compensation	789	684
Contingent consideration accretion	437	109
Unrealized foreign exchange (income) loss	(663)	135
Deferred taxes	742	753
Other	(5)	(3)
Change in operating assets and liabilities, net of acquisitions:
Accounts receivable	345	2,194
Inventories	73	(83)
Prepaids and other	(746)	(75)
Accounts payable and accrued liabilities	(2,713)	(1,354)
Income taxes	82	356
Deferred revenue	28
Net cash provided by operating activities	1,951	6,278
Investing Activities:
Purchases of property and equipment	(1,545)	(384)
Purchases of available-for-sale securities	(12,541)
Maturities of available-for-sale securities	7,071
Payments for acquisition, net of cash acquired		(18,166)
Net cash used in investing activities	(7,015)	(18,550)
Financing Activities:
Issuance of common stock	13	10
Payments for taxes related to net share settlement of equity awards	(2,129)	(353)
Payment of deferred financing costs	(38)
Payment of contingent consideration		(305)
Net cash used in financing activities	(2,154)	(648)
Effect of exchange rate changes on cash	(116)
Net change in cash and cash equivalents	(7,334)	(12,920)
Cash and Cash Equivalents:
Beginning of period	24,987	55,588
End of period	17,653	42,668
Supplemental Information:
Cash paid for income taxes	897	42
Noncash transactions from investing and financing activities:
Acquisition of property and equipment on account	227	54
Deferred financing costs in accounts payable	45
Issuance of performance shares, restricted and deferred stock units	$ 2,414	1,073
Creagh Medical Ltd [Member]
Operating Activities:
Net income		(300)
Noncash transactions from investing and financing activities:
Contingent consideration and debt assumed in Creagh Medical transaction		$ 9,857

XML 19 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation	3 Months Ended
Basis of Presentation	Dec. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation	1. Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S.”) (“GAAP”) and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, needed to fairly present the financial results of Surmodics, Inc. and subsidiaries (“Surmodics” or the “Company”) for the periods presented. These financial statements include some amounts that are based on management’s best estimates and judgments. These estimates may be adjusted as more information becomes available, and any adjustment could be significant. The impact of any change in estimates is included in the determination of net income in the period in which the change in estimate is identified. The results of operations for the three months ended December 31, 2016 are not necessarily indicative of the results that may be expected for the entire 2017 fiscal year. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), the Company has omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited consolidated financial statements of the Company. These unaudited condensed consolidated financial statements should be read together with the audited consolidated financial statements for the fiscal year ended September 30, 2016, and footnotes thereto included in the Company’s Form 10-K as filed with the SEC on December 2, 2016.

XML 20 R8.htm IDEA: XBRL DOCUMENT

New Accounting Pronouncements	3 Months Ended
New Accounting Pronouncements	Dec. 31, 2016
Accounting Policies [Abstract]
New Accounting Pronouncements	2. New Accounting Pronouncements Accounting Standards to be Implemented In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) Update No. 2014-09, Revenue from Contracts with Customers (ASC Topic 606). Principles of this guidance require entities to recognize revenue in a manner that depicts the transfer of goods or services to customers in amounts that reflect the consideration an entity expects to be entitled to in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting standard will be effective for the Company beginning in the first quarter of fiscal year 2019 (October 1, 2018) using one of two prescribed retrospective methods. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s business model and consolidated results of operations, cash flows and financial position. The Company expects to complete its evaluation during fiscal 2017. Based on a preliminary assessment, the Company currently estimates the impact may be material due to the potential acceleration of minimum license fees and a one quarter acceleration of royalty revenue pursuant to our hydrophilic license agreements. In February 2016, the FASB issued Accounting Standards Update ASU 2016-02, Leases (ASC Topic 842). The new guidance primarily affects lessee accounting, while accounting by lessors will not be significantly impacted by the update. The update maintains two classifications of leases: finance leases, which replace capital leases, and operating leases. Lessees will need to recognize a right-of-use asset and a lease liability on the statement of financial position for those leases previously classified as operating leases under the old guidance. The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for direct costs. The accounting standard will be effective for the Company beginning the first quarter of fiscal year 2020 (October 1, 2019) and will be applied using a modified retrospective approach. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s results of operations, cash flows and financial position. In June 2016, the FASB issued ASU No 2016-13, Financial Instruments – Credit Losses (ASC Topic 326), Measurement of Credit Losses on Financial Statements. This ASU requires a financial asset (or a group of financial assets) measured at an amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The accounting standard will be effective for the Company beginning in the first quarter of fiscal 2020 (October 1, 2019). Early adoption is permitted and the guidance will be applied using a modified retrospective approach. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s results of operations, cash flows and financial position. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new guidance clarifies requirements for presentation and classification of the following items within the statement of cash flows: debt prepayments, settlement of zero coupon debt instruments, contingent consideration payments, insurance proceeds, securitization transactions and distributions from equity method investees. The update also addresses classification of transactions that have characteristics of more than one class of cash flows. The accounting standard will be effective for the Company beginning in the first quarter of fiscal 2018. Early adoption is permitted, including adoption in an interim period, and the guidance will be applied retrospectively. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s condensed consolidated statements of cash flows. In January 2017, the FASB issued ASU No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The new guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The accounting standard will be effective for the Company beginning in its fiscal 2020. Early adoption is permitted, and the guidance will be applied prospectively. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s condensed consolidated financial statements. Accounting Standards Implemented In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (ASC Topic 718): Improvements to Employee Share-Based Payment Accounting. The accounting standard intends to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The accounting standard is effective for the Company beginning in the first quarter of fiscal 2018 (October 1, 2017), and early adoption is permitted. The Company elected to early-adopt this accounting standard in the fourth quarter of fiscal 2016, for the fiscal year ended September 30, 2016. As a result of the adoption, the Company records excess tax benefits and certain tax deficiencies as income tax expense or benefit in the condensed consolidated statements of income, whereas such excess tax benefits or tax deficiencies were previously recorded in additional paid-in capital. As this guidance was applied retroactively to the beginning of the fiscal year ended September 30, 2016, previously reported quarterly income tax and net income for interim periods therein were adjusted for the effects of the adoption. This resulted in an adjustment to reduce the income tax provision and increase net income by $0.1 million in the three months ended December 31, 2015, with a corresponding increase in net income per basic and diluted share of $0.01 per share. The guidance also requires presentation of excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. Prior to the adoption of ASU No. 2016-09, cash flows resulting from the tax benefits generated by tax deductions in excess of the compensation cost recognized for those options (excess tax benefits) are classified as financing cash flows. During the three months ended December 31, 2015, the Company realized tax benefits from stock options resulting in approximately $0.1 million of gross excess tax benefits, which are included as a component of cash flows from operating activities for the three months ended December 31, 2015 in the accompanying condensed consolidated statements of cash flows. This amount was previously reported as a component of cash flows from financing activities, but has been reclassified to conform to current accounting guidance. No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s condensed consolidated financial statements.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6510796

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e725-108305

+ Details

XML 21 R9.htm IDEA: XBRL DOCUMENT

Business Combinations

3 Months Ended

Dec. 31, 2016

Business Combinations [Abstract]

Business Combinations

3. Business Combinations

Creagh Medical Ltd.

On November 20, 2015, the Company acquired 100% of the outstanding common shares and voting shares of Creagh Medical Ltd. (“Creagh Medical”) located in Ballinasloe, Ireland. The acquisition was financed with cash on hand and contingent seller financing. The Company acquired Creagh Medical for up to €30 million (approximately $32 million as of the acquisition date), including an upfront payment of €18 million (approximately $19.3 million as of the acquisition date), and up to €12 million (approximately $12.8 million as of the acquisition date) based on achievement of revenue and value-creating operational milestones through September 30, 2018. The payment of the milestones, if any, will occur in the quarter ending December 31, 2018. Total transaction, integration and other costs associated with the Creagh Medical acquisition aggregated $2.4 million for the quarter ended December 31, 2015. The operating results of Creagh Medical have been included in the Company’s Medical Device segment since the acquisition date. The Company realized $0.5 million of revenue and a loss of $0.3 million from the Creagh Medical operations for the three months ended December 31, 2015.

The purchase price of Creagh Medical consisted of the following:

(Dollars in thousands)
Cash paid	$	18,449
Debt assumed		761
Contingent consideration		9,064
Total purchase price		28,274
Less cash and cash equivalents acquired		(251	)
Total purchase price, net of cash acquired	$	28,023

The following table summarizes the final allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the Creagh Medical acquisition:

	Fair Value (Dollars in thousands)			Estimated Useful Life (In years)
Current assets	$	896		N/A
Property and equipment		634		1.0-10.0
Trade name		75		N/A
Developed technology		1,787		7.0
In-process research and development		942		N/A
Customer relationships		11,119		7.0-10.0
Other noncurrent assets		81		N/A
Current liabilities		(942	)	N/A
Deferred tax liabilities		(9	)	N/A
Net assets acquired		14,583
Goodwill		13,440		N/A
Total purchase price, net of cash acquired	$	28,023

NorMedix, Inc.

The purchase price of NorMedix consisted of the following:

(Dollars in thousands)
Cash paid	$	6,905
Contingent consideration		3,520
Total purchase price		10,425
Less cash and cash equivalents acquired		(17	)
Total purchase price, net of cash acquired	$	10,408

The following table summarizes the final allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the NorMedix acquisition:

	Fair Value (Dollars in thousands)			Estimated Useful Life (In years)
Net current assets	$	113		N/A
Property and equipment		60		N/A
Developed technology		6,850		10.0-14.0
Customer relationships		900		4.0
Deferred tax asset		690		N/A
Other noncurrent asset		13		N/A
Accounts payable		(187	)	N/A
Deferred tax liabilities		(2,483	)	N/A
Net assets acquired		5,956
Goodwill		4,452		N/A
Total purchase price, net of cash acquired	$	10,408

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

XML 22 R10.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurements

4. Fair Value Measurements

Fair Value Hierarchy

Accounting guidance on fair value measurements requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1 — Quoted (unadjusted) prices in active markets for identical assets or liabilities.

The Company did not have any Level 1 assets as of December 31, 2016 and September 30, 2016.

The Company’s Level 2 assets as of December 31, 2016 and September 30, 2016 consisted of money market funds, commercial paper instruments and corporate bonds.

In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2016:

(Dollars in thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)			Total Fair Value as of December 31, 2016
Assets
Cash equivalents	$	—	$	13,775	$	—		$	13,775
Available-for-sale securities		—		27,474		—			27,474
Total assets	$	—	$	41,249	$	—		$	41,249

Liabilities
Contingent consideration	$	—	$	—	$	(14,291	)	$	(14,291	)
Total liabilities	$	—	$	—	$	(14,291	)	$	(14,291	)

The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2016:

(Dollars in thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)			Total Fair Value as of September 30, 2016
Assets
Cash equivalents	$	—	$	22,160	$	—		$	22,160
Available-for-sale securities		—		21,954				$	21,954
Total assets	$	—	$	44,114	$	—		$	44,114

Liabilities
Contingent consideration	$	—	$	—	$	(14,517	)	$	(14,517	)
Total liabilities	$	—	$	—	$	(14,517	)	$	(14,517	)

The following table summarizes the changes in the contingent consideration liabilities measured at fair value using Level 3 inputs for the three months ended December 31, 2016 and 2015:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016			2015
Beginning balance	$	14,517		$	—
Additions		—			9,064
Fair value adjustments		—			—
Settlements		—			—
Interest accretion		437			109
Foreign currency translation (gain) loss		(663	)		135
Ending balance	$	14,291		$	9,308

There were no transfers of assets or liabilities to or from amounts measured using Level 3 fair value measurements during fiscal 2017 or 2016.

Valuation Techniques

The valuation techniques used to measure the fair value of assets are as follows:

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 23 R11.htm IDEA: XBRL DOCUMENT

Investments

3 Months Ended

Dec. 31, 2016

Investments Debt And Equity Securities [Abstract]

Investments

5. Investments

The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows:

	December 31, 2016
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial paper and corporate bonds	$	27,487	$	—	$	(13	)	$	27,474
Total	$	27,487	$	—	$	(13	)	$	27,474

	September 30, 2016
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial paper and corporate bonds	$	22,019	$	—	$	(65	)	$	21,954
Total	$	22,019	$	—	$	(65	)	$	21,954

The following table summarizes sales of available-for-sale debt securities:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016		2015
Proceeds from maturities	$	7,071	$	—
Gross realized gains	$	—	$	—
Gross realized losses	$	—	$	—

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

XML 24 R12.htm IDEA: XBRL DOCUMENT

Inventories

3 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

Inventories

6. Inventories

	December 31,		September 30,
(Dollars in thousands)	2016		2016
Raw materials	$	1,724	$	1,766
Work-in process		449		492
Finished products		1,299		1,321
Total	$	3,472	$	3,579

XML 25 R13.htm IDEA: XBRL DOCUMENT

Other Assets

3 Months Ended

Dec. 31, 2016

Investments All Other Investments [Abstract]

Other Assets

7. Other Assets

Other assets consist of the following:

	December 31,		September 30,
(Dollars in thousands)	2016		2016
ViaCyte, Inc.	$	479	$	479
Other noncurrent assets		242		149
Other assets, net	$	721	$	628

XML 26 R14.htm IDEA: XBRL DOCUMENT

Intangible Assets

3 Months Ended

Dec. 31, 2016

Goodwill And Intangible Assets Disclosure [Abstract]

Intangible Assets

8. Intangible Assets

Intangible assets consisted of the following:

	December 31, 2016
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	16,979	$	(6,434	)	$	10,545
Core technology		8.0		530		(530	)		—
Developed technology		11.8		8,610		(800	)		7,810
Non-compete		5.0		230		(69	)		161
Patents and other		16.5		2,322		(1,312	)		1,010
Subtotal				28,671		(9,145	)		19,526
Unamortized intangible assets:
In-process research and development				927		—			927
Trademarks and trade names				641		—			641
Total			$	30,239	$	(9,145	)	$	21,094

	September 30, 2016
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	17,692	$	(6,123	)	$	11,569
Core technology		8.0		530		(530	)		—
Developed technology		11.8		8,724		(618	)		8,106
Non-compete		5.0		230		(58	)		172
Patents and other		16.5		2,321		(1,275	)		1,046
Subtotal				29,497		(8,604	)		20,893
Unamortized intangible assets:
In-process research and development				987		—			987
Trademarks and trade names				645		—			645
Total			$	31,129	$	(8,604	)	$	22,525

(Dollars in thousands)
Remainder of 2017	$	1,864
2018		2,439
2019		2,439
2020		2,264
2021		2,125
2022		2,085

The Company defines IPR&D as the value of technology acquired for which the related projects have substance and are incomplete. IPR&D acquired in a business acquisition is recognized at fair value and requires the IPR&D to be capitalized as an indefinite-lived intangible asset until completion of the IPR&D project or abandonment. Upon completion of the development project (generally when regulatory approval to market the product is obtained), an impairment assessment is performed prior to amortizing the asset over its estimated useful life. If the IPR&D projects are abandoned, the related IPR&D assets would be written off.

XML 27 R15.htm IDEA: XBRL DOCUMENT

Goodwill

3 Months Ended

Dec. 31, 2016

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill

9. Goodwill

The change in the carrying amount of goodwill by segment for the three months ended December 31, 2016 was as follows:

(Dollars in thousands)	In Vitro Diagnostics		Medical Device			Total
Balance as of September 30, 2016	$	8,010	$	18,545		$	26,555
Translation adjustment		—		(861	)		(861	)
Balance as of December 31, 2016	$	8,010	$	17,684		$	25,694

XML 28 R16.htm IDEA: XBRL DOCUMENT

Stock-based Compensation

3 Months Ended

Dec. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-based Compensation

10. Stock-based Compensation

The Company’s stock-based compensation expenses were allocated to the following expense categories:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016		2015
Product costs	$	13	$	6
Research and development		125		59
Selling, general and administrative		651		619
Total	$	789	$	684

Stock Option Awards

	Three Months Ended
	December 31,
	2016			2015
Risk-free interest rates		1.7	%		2.0	%
Expected life (years)		4.6			4.6
Expected volatility		34.4	%		36.7	%
Dividend yield		0.0	%		0.0	%

Restricted Stock Awards

Performance Share Awards

The fair values of the Performance Shares, at target, were $1.2 million, $1.3 million and $0.9 million in each fiscal year for awards granted in fiscal 2017, 2016 and 2015, respectively.

The aggregate number of shares that could be awarded to our executives if the minimum, target and maximum performance goals are met, based on the fair value at the date of grant is as follows:

Performance Period	Minimum Shares		Target Shares		Maximum Shares
Fiscal 2015 – 2017		8,440		42,199		84,398
Fiscal 2016 – 2018		13,268		66,338		132,676
Fiscal 2017 – 2019		10,437		52,185		104,370

1999 Employee Stock Purchase Plan

Restricted Stock and Deferred Stock Units

XML 29 R17.htm IDEA: XBRL DOCUMENT

Revolving Credit Facility	3 Months Ended
Revolving Credit Facility	Dec. 31, 2016
Text Block [Abstract]
Revolving Credit Facility	11. Revolving Credit Facility On November 2, 2016, the Company amended and restated the revolving credit facility. The new agreement increased the available principal to $30.0 million and extended the maturity of the previous facility by three years to November 2019. In addition, the agreement includes a $5.0 million multi-currency overdraft facility in Ireland. Borrowings under the credit facility, if any, will bear interest at a benchmark rate plus a margin ranging from 1.00% to 1.75% based on the Company’s leverage ratio, as defined in the loan agreement. A facility fee is payable quarterly on unused commitments at a rate of 0.15% per annum. The Company has the option to increase the credit facility in increments of $5.0 million up to an additional $20.0 million, subject to approval of the lender. The Company’s obligations under the credit facility are secured by substantially all of its assets, other than intellectual property and real estate, as well as the majority of its equity interest in its subsidiaries. In connection with the credit facility, the Company is required to comply with certain financial and non-financial covenants. As of December 31, 2016, the Company has no debt outstanding and was in compliance with all financial covenants.

XML 30 R18.htm IDEA: XBRL DOCUMENT

Net Income Per Share Data

3 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Net Income Per Share Data

12. Net Income Per Share Data

The following table sets forth the denominator for the computation of basic and diluted net income per share (in thousands):

	Three Months Ended
	December 31,
	2016		2015
Net income available to common shareholders	$	2,300	$	2,653
Basic weighted average shares outstanding		13,200		12,966
Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units, deferred stock units and performance shares		246		220
Diluted weighted average shares outstanding		13,446		13,186

The Company’s Board of Directors has authorized the repurchase of up to $30.0 million of the Company’s outstanding common stock. This authorization does not have an expiration date.

XML 31 R19.htm IDEA: XBRL DOCUMENT

Income Taxes	3 Months Ended
Income Taxes	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes The Company recorded income tax provisions of $1.7 million and $1.2 million for the three months ended December 31, 2016 and 2015, respectively, representing effective tax rates of 42.9% and 30.3%, respectively. The Company’s effective tax reflects the impact of state income taxes, permanent tax items and discrete tax benefits. The effective income tax rate for the three month periods ended December 31, 2016 and 2015 differs from the U.S. federal statutory tax rate of 35.0% primarily due to transaction costs and contingent consideration accretion associated with the Creagh Medical and NorMedix acquisitions, the domestic production manufacturing deduction and the U.S. federal research and development income tax credit , operating losses in a jurisdiction where tax benefits are offset by a valuation allowance, and discrete tax expense related to expiring stock option awards. The total amount of unrecognized tax benefits, excluding interest and penalties that, if recognized, would affect the effective tax rate is $1.2 million as of both December 31, 2016 and September 30, 2016. Currently, the Company does not expect the liability for unrecognized tax benefits to change significantly in the next 12 months with the above balances classified on the condensed consolidated balance sheets in other long-term liabilities. Interest and penalties related to unrecognized tax benefits are recorded in income tax provision. The Company files income tax returns, including returns for its subsidiaries, in the U.S. federal jurisdiction and in various state jurisdictions as well as several non-U.S. jurisdictions. Uncertain tax positions are related to tax years that remain subject to examination. The Internal Revenue Service (“IRS”) completed an examination of the Company’s U.S. income tax return for fiscal 2012 in the fourth quarter of fiscal 2014 with a payment made associated with a timing adjustment. U.S. income tax returns for years prior to fiscal 2013 are no longer subject to examination by federal tax authorities. For tax returns for state and local jurisdictions, the Company is no longer subject to examination for tax years generally before fiscal 2006. For tax returns for non-U.S. jurisdictions, the Company is no longer subject to income tax examination for years prior to 2011. Additionally, the Company has been indemnified of liability for any taxes relating to Creagh Medical and NorMedix for periods prior to the respective acquisition dates, pursuant to the terms of the related share purchase agreements. As of December 31, 2016 and September 30, 2016 there were no undistributed earnings in foreign subsidiaries.

XML 32 R20.htm IDEA: XBRL DOCUMENT

Segment and Geographical Information

3 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Segment and Geographical Information

14. Segment and Geographical Information

During fiscal 2016, the Company acquired Creagh Medical and NorMedix, which are included in the Medical Device segment subsequent to the respective acquisition dates, as further discussed in Note 3.

The tables below present segment revenue, operating income and depreciation and amortization, as follows:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016			2015
Revenue:
Medical Device	$	13,757		$	12,247
In Vitro Diagnostics		4,004			4,294
Total revenue	$	17,761		$	16,541

Operating income:
Medical Device	$	3,719		$	3,830
In Vitro Diagnostics		1,456			1,643
Total segment operating income		5,175			5,473
Corporate		(1,907	)		(1,534	)
Total operating income	$	3,268		$	3,939

Depreciation and amortization:
Medical Device	$	1,004		$	487
In Vitro Diagnostics		103			222
Corporate		175			200
Total depreciation and amortization	$	1,282		$	909

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

XML 33 R21.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Dec. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	15. Commitments and Contingencies Litigation. From time to time, the Company has been, and may become, involved in various legal actions involving its operations, products and technologies, including intellectual property and employment disputes. The outcomes of these legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages as well as other relief, including injunctions barring the sale of products that are the subject of the lawsuit, which if granted, could require significant expenditures or result in lost revenue. The Company records a liability in the condensed consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate, the minimum amount of the range is accrued. If a loss is possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded. InnoCore Technologies BV. In March 2006, the Company entered into a license agreement whereby Surmodics obtained an exclusive license to a drug delivery coating for licensed products within the vascular field which included peripheral, coronary and neurovascular biodurable stent products. The license requires an annual minimum payment of 200,000 euros (equivalent to $211,000 using a euro to US dollar exchange rate of 1.0536 to the Euro as of December 31, 2016) until the last patent expires which is currently estimated to be September 2027. The total minimum future payments associated with this license are approximately $2.7 million. The license is currently utilized by one of the Company’s drug delivery customers.

XML 34 R22.htm IDEA: XBRL DOCUMENT

New Accounting Pronouncements (Policies)	3 Months Ended
New Accounting Pronouncements (Policies)	Dec. 31, 2016
Accounting Policies [Abstract]
New Accounting Pronouncements	Accounting Standards to be Implemented In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) Update No. 2014-09, Revenue from Contracts with Customers (ASC Topic 606). Principles of this guidance require entities to recognize revenue in a manner that depicts the transfer of goods or services to customers in amounts that reflect the consideration an entity expects to be entitled to in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting standard will be effective for the Company beginning in the first quarter of fiscal year 2019 (October 1, 2018) using one of two prescribed retrospective methods. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s business model and consolidated results of operations, cash flows and financial position. The Company expects to complete its evaluation during fiscal 2017. Based on a preliminary assessment, the Company currently estimates the impact may be material due to the potential acceleration of minimum license fees and a one quarter acceleration of royalty revenue pursuant to our hydrophilic license agreements. In February 2016, the FASB issued Accounting Standards Update ASU 2016-02, Leases (ASC Topic 842). The new guidance primarily affects lessee accounting, while accounting by lessors will not be significantly impacted by the update. The update maintains two classifications of leases: finance leases, which replace capital leases, and operating leases. Lessees will need to recognize a right-of-use asset and a lease liability on the statement of financial position for those leases previously classified as operating leases under the old guidance. The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for direct costs. The accounting standard will be effective for the Company beginning the first quarter of fiscal year 2020 (October 1, 2019) and will be applied using a modified retrospective approach. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s results of operations, cash flows and financial position. In June 2016, the FASB issued ASU No 2016-13, Financial Instruments – Credit Losses (ASC Topic 326), Measurement of Credit Losses on Financial Statements. This ASU requires a financial asset (or a group of financial assets) measured at an amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The accounting standard will be effective for the Company beginning in the first quarter of fiscal 2020 (October 1, 2019). Early adoption is permitted and the guidance will be applied using a modified retrospective approach. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s results of operations, cash flows and financial position. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new guidance clarifies requirements for presentation and classification of the following items within the statement of cash flows: debt prepayments, settlement of zero coupon debt instruments, contingent consideration payments, insurance proceeds, securitization transactions and distributions from equity method investees. The update also addresses classification of transactions that have characteristics of more than one class of cash flows. The accounting standard will be effective for the Company beginning in the first quarter of fiscal 2018. Early adoption is permitted, including adoption in an interim period, and the guidance will be applied retrospectively. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s condensed consolidated statements of cash flows. In January 2017, the FASB issued ASU No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The new guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The accounting standard will be effective for the Company beginning in its fiscal 2020. Early adoption is permitted, and the guidance will be applied prospectively. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s condensed consolidated financial statements. Accounting Standards Implemented In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (ASC Topic 718): Improvements to Employee Share-Based Payment Accounting. The accounting standard intends to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The accounting standard is effective for the Company beginning in the first quarter of fiscal 2018 (October 1, 2017), and early adoption is permitted. The Company elected to early-adopt this accounting standard in the fourth quarter of fiscal 2016, for the fiscal year ended September 30, 2016. As a result of the adoption, the Company records excess tax benefits and certain tax deficiencies as income tax expense or benefit in the condensed consolidated statements of income, whereas such excess tax benefits or tax deficiencies were previously recorded in additional paid-in capital. As this guidance was applied retroactively to the beginning of the fiscal year ended September 30, 2016, previously reported quarterly income tax and net income for interim periods therein were adjusted for the effects of the adoption. This resulted in an adjustment to reduce the income tax provision and increase net income by $0.1 million in the three months ended December 31, 2015, with a corresponding increase in net income per basic and diluted share of $0.01 per share. The guidance also requires presentation of excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity. Prior to the adoption of ASU No. 2016-09, cash flows resulting from the tax benefits generated by tax deductions in excess of the compensation cost recognized for those options (excess tax benefits) are classified as financing cash flows. During the three months ended December 31, 2015, the Company realized tax benefits from stock options resulting in approximately $0.1 million of gross excess tax benefits, which are included as a component of cash flows from operating activities for the three months ended December 31, 2015 in the accompanying condensed consolidated statements of cash flows. This amount was previously reported as a component of cash flows from financing activities, but has been reclassified to conform to current accounting guidance. No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s condensed consolidated financial statements.

XML 35 R23.htm IDEA: XBRL DOCUMENT

Business Combinations (Tables)

3 Months Ended

Dec. 31, 2016

Creagh Medical Ltd [Member]

Business Acquisition [Line Items]

Summary of Purchase Price

The purchase price of Creagh Medical consisted of the following:

(Dollars in thousands)
Cash paid	$	18,449
Debt assumed		761
Contingent consideration		9,064
Total purchase price		28,274
Less cash and cash equivalents acquired		(251	)
Total purchase price, net of cash acquired	$	28,023

Schedule of Purchase Price to the Fair Values Assigned to the Assets Acquired and Liabilities Assumed

The following table summarizes the final allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the Creagh Medical acquisition:

	Fair Value (Dollars in thousands)			Estimated Useful Life (In years)
Current assets	$	896		N/A
Property and equipment		634		1.0-10.0
Trade name		75		N/A
Developed technology		1,787		7.0
In-process research and development		942		N/A
Customer relationships		11,119		7.0-10.0
Other noncurrent assets		81		N/A
Current liabilities		(942	)	N/A
Deferred tax liabilities		(9	)	N/A
Net assets acquired		14,583
Goodwill		13,440		N/A
Total purchase price, net of cash acquired	$	28,023

NorMedix, Inc. [Member]

Business Acquisition [Line Items]

Summary of Purchase Price

The purchase price of NorMedix consisted of the following:

(Dollars in thousands)
Cash paid	$	6,905
Contingent consideration		3,520
Total purchase price		10,425
Less cash and cash equivalents acquired		(17	)
Total purchase price, net of cash acquired	$	10,408

Schedule of Purchase Price to the Fair Values Assigned to the Assets Acquired and Liabilities Assumed

The following table summarizes the final allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the NorMedix acquisition:

	Fair Value (Dollars in thousands)			Estimated Useful Life (In years)
Net current assets	$	113		N/A
Property and equipment		60		N/A
Developed technology		6,850		10.0-14.0
Customer relationships		900		4.0
Deferred tax asset		690		N/A
Other noncurrent asset		13		N/A
Accounts payable		(187	)	N/A
Deferred tax liabilities		(2,483	)	N/A
Net assets acquired		5,956
Goodwill		4,452		N/A
Total purchase price, net of cash acquired	$	10,408

XML 36 R24.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

3 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2016:

(Dollars in thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)			Total Fair Value as of December 31, 2016
Assets
Cash equivalents	$	—	$	13,775	$	—		$	13,775
Available-for-sale securities		—		27,474		—			27,474
Total assets	$	—	$	41,249	$	—		$	41,249

Liabilities
Contingent consideration	$	—	$	—	$	(14,291	)	$	(14,291	)
Total liabilities	$	—	$	—	$	(14,291	)	$	(14,291	)

The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2016:

(Dollars in thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)			Total Fair Value as of September 30, 2016
Assets
Cash equivalents	$	—	$	22,160	$	—		$	22,160
Available-for-sale securities		—		21,954				$	21,954
Total assets	$	—	$	44,114	$	—		$	44,114

Liabilities
Contingent consideration	$	—	$	—	$	(14,517	)	$	(14,517	)
Total liabilities	$	—	$	—	$	(14,517	)	$	(14,517	)

Schedule of Contingent Consideration Liabilities Measured at Fair Value

The following table summarizes the changes in the contingent consideration liabilities measured at fair value using Level 3 inputs for the three months ended December 31, 2016 and 2015:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016			2015
Beginning balance	$	14,517		$	—
Additions		—			9,064
Fair value adjustments		—			—
Settlements		—			—
Interest accretion		437			109
Foreign currency translation (gain) loss		(663	)		135
Ending balance	$	14,291		$	9,308

XML 37 R25.htm IDEA: XBRL DOCUMENT

Investments (Tables)

3 Months Ended

Dec. 31, 2016

Investments Debt And Equity Securities [Abstract]

Amortized Cost, Unrealized Holding Gains and (Losses) and Fair Value of Available-for-sale Securities

The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows:

	December 31, 2016
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial paper and corporate bonds	$	27,487	$	—	$	(13	)	$	27,474
Total	$	27,487	$	—	$	(13	)	$	27,474

	September 30, 2016
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial paper and corporate bonds	$	22,019	$	—	$	(65	)	$	21,954
Total	$	22,019	$	—	$	(65	)	$	21,954

Sales of Available-for-Sale Debt Securities

The following table summarizes sales of available-for-sale debt securities:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016		2015
Proceeds from maturities	$	7,071	$	—
Gross realized gains	$	—	$	—
Gross realized losses	$	—	$	—

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

XML 38 R26.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

3 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

Components of Inventories

Inventories consisted of the following components:

	December 31,		September 30,
(Dollars in thousands)	2016		2016
Raw materials	$	1,724	$	1,766
Work-in process		449		492
Finished products		1,299		1,321
Total	$	3,472	$	3,579

XML 39 R27.htm IDEA: XBRL DOCUMENT

Other Assets (Tables)

3 Months Ended

Dec. 31, 2016

Investments All Other Investments [Abstract]

Summary of Other Assets

Other assets consist of the following:

	December 31,		September 30,
(Dollars in thousands)	2016		2016
ViaCyte, Inc.	$	479	$	479
Other noncurrent assets		242		149
Other assets, net	$	721	$	628

XML 40 R28.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

3 Months Ended

Dec. 31, 2016

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets consisted of the following:

	December 31, 2016
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	16,979	$	(6,434	)	$	10,545
Core technology		8.0		530		(530	)		—
Developed technology		11.8		8,610		(800	)		7,810
Non-compete		5.0		230		(69	)		161
Patents and other		16.5		2,322		(1,312	)		1,010
Subtotal				28,671		(9,145	)		19,526
Unamortized intangible assets:
In-process research and development				927		—			927
Trademarks and trade names				641		—			641
Total			$	30,239	$	(9,145	)	$	21,094

	September 30, 2016
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	17,692	$	(6,123	)	$	11,569
Core technology		8.0		530		(530	)		—
Developed technology		11.8		8,724		(618	)		8,106
Non-compete		5.0		230		(58	)		172
Patents and other		16.5		2,321		(1,275	)		1,046
Subtotal				29,497		(8,604	)		20,893
Unamortized intangible assets:
In-process research and development				987		—			987
Trademarks and trade names				645		—			645
Total			$	31,129	$	(8,604	)	$	22,525

Estimated Amortization Expense

(Dollars in thousands)
Remainder of 2017	$	1,864
2018		2,439
2019		2,439
2020		2,264
2021		2,125
2022		2,085

XML 41 R29.htm IDEA: XBRL DOCUMENT

Goodwill (Tables)

3 Months Ended

Dec. 31, 2016

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule Of Carrying Amount Of Goodwill By Segment

The change in the carrying amount of goodwill by segment for the three months ended December 31, 2016 was as follows:

(Dollars in thousands)	In Vitro Diagnostics		Medical Device			Total
Balance as of September 30, 2016	$	8,010	$	18,545		$	26,555
Translation adjustment		—		(861	)		(861	)
Balance as of December 31, 2016	$	8,010	$	17,684		$	25,694

XML 42 R30.htm IDEA: XBRL DOCUMENT

Stock-based Compensation (Tables)

3 Months Ended

Dec. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation Expenses

The Company’s stock-based compensation expenses were allocated to the following expense categories:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016		2015
Product costs	$	13	$	6
Research and development		125		59
Selling, general and administrative		651		619
Total	$	789	$	684

Assumptions Used in Stock Option Plans

The assumptions used as inputs in the model were as follows:

	Three Months Ended
	December 31,
	2016			2015
Risk-free interest rates		1.7	%		2.0	%
Expected life (years)		4.6			4.6
Expected volatility		34.4	%		36.7	%
Dividend yield		0.0	%		0.0	%

Schedule of Fair Value at the Date of Grant

The aggregate number of shares that could be awarded to our executives if the minimum, target and maximum performance goals are met, based on the fair value at the date of grant is as follows:

Performance Period	Minimum Shares		Target Shares		Maximum Shares
Fiscal 2015 – 2017		8,440		42,199		84,398
Fiscal 2016 – 2018		13,268		66,338		132,676
Fiscal 2017 – 2019		10,437		52,185		104,370

XML 43 R31.htm IDEA: XBRL DOCUMENT

Net Income Per Share Data (Tables)

3 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Denominator for Computation of Basic and Diluted Net Income Per Share

The following table sets forth the denominator for the computation of basic and diluted net income per share (in thousands):

	Three Months Ended
	December 31,
	2016		2015
Net income available to common shareholders	$	2,300	$	2,653
Basic weighted average shares outstanding		13,200		12,966
Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units, deferred stock units and performance shares		246		220
Diluted weighted average shares outstanding		13,446		13,186

XML 44 R32.htm IDEA: XBRL DOCUMENT

Segment and Geographical Information (Tables)

3 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Segment Revenue, Operating Income and Depreciation and Amortization

The tables below present segment revenue, operating income and depreciation and amortization, as follows:

	Three Months Ended
	December 31,
(Dollars in thousands)	2016			2015
Revenue:
Medical Device	$	13,757		$	12,247
In Vitro Diagnostics		4,004			4,294
Total revenue	$	17,761		$	16,541

Operating income:
Medical Device	$	3,719		$	3,830
In Vitro Diagnostics		1,456			1,643
Total segment operating income		5,175			5,473
Corporate		(1,907	)		(1,534	)
Total operating income	$	3,268		$	3,939

Depreciation and amortization:
Medical Device	$	1,004		$	487
In Vitro Diagnostics		103			222
Corporate		175			200
Total depreciation and amortization	$	1,282		$	909

XML 45 R33.htm IDEA: XBRL DOCUMENT

New Accounting Pronouncements - Additional Information (Detail) - ASU 2016-09 [Member] $ / shares in Units, $ in Millions	3 Months Ended
	Dec. 31, 2015 USD ($) $ / shares
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Adjustment to reduce income tax provision	$ 0.1
Adjustment to increase net income	$ 0.1
Increase in net income per basic and diluted share \| $ / shares	$ 0.01
Excess tax benefit from stock-based compensation plans	$ 0.1

XML 46 R34.htm IDEA: XBRL DOCUMENT

Business Combinations - Additional Information (Detail) $ / shares in Units, $ in Thousands, € in Millions				3 Months Ended
	Jan. 08, 2016 USD ($)	Nov. 20, 2015 USD ($)	Nov. 20, 2015 EUR (€)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($) $ / shares	Nov. 20, 2015 EUR (€)
Business Acquisition [Line Items]
Acquisition transaction, integration and other costs					$ 2,491
Business acquisition, revenue recognized				$ 17,761	16,541
Business acquisition, loss recognized				2,300	2,653
Creagh Medical Ltd [Member]
Business Acquisition [Line Items]
Outstanding common shares and voting shares percentage		100.00%				100.00%
Payments to acquire business				28,274
Upfront payments		$ 19,300	€ 18	18,449
Contingent milestone payments		12,800				€ 12
Acquisition transaction, integration and other costs					2,400
Business acquisition, revenue recognized					500
Business acquisition, loss recognized					(300)
Creagh Medical Ltd [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Payments to acquire business		$ 32,000	€ 30
NorMedix, Inc. [Member]
Business Acquisition [Line Items]
Outstanding common shares and voting shares percentage	100.00%
Payments to acquire business				10,425
Upfront payments	$ 7,000			$ 6,905
Contingent milestone payments	7,000
Acquisition transaction, integration and other costs					100
NorMedix, Inc. [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Payments to acquire business	$ 14,000
Creagh Medical and NorMedix [Member]
Business Acquisition [Line Items]
Consolidated pro forma revenue					17,600
Consolidated pro forma net income					$ 4,200
Basic and diluted earnings per share \| $ / shares					$ 0.32
Creagh Medical and NorMedix [Member] \| Unaudited Pro Forma [Member]
Business Acquisition [Line Items]
Amortization expense on intangible assets					$ 400
Contingent consideration accretion expense					300
Non-recurring professional fees					2,500
Tax effect impact					$ 300

XML 47 R35.htm IDEA: XBRL DOCUMENT

Business Combinations - Summary of Purchase Price (Detail) $ in Thousands, € in Millions				3 Months Ended
	Jan. 08, 2016 USD ($)	Nov. 20, 2015 USD ($)	Nov. 20, 2015 EUR (€)	Dec. 31, 2016 USD ($)
Creagh Medical Ltd [Member]
Business Acquisition [Line Items]
Cash Paid		$ 19,300	€ 18	$ 18,449
Debt assumed				761
Contingent consideration				9,064
Total purchase price				28,274
Less cash and cash equivalents acquired				(251)
Total purchase price, net of cash acquired				28,023
NorMedix, Inc. [Member]
Business Acquisition [Line Items]
Cash Paid	$ 7,000			6,905
Contingent consideration				3,520
Total purchase price				10,425
Less cash and cash equivalents acquired				(17)
Total purchase price, net of cash acquired				$ 10,408

XML 48 R36.htm IDEA: XBRL DOCUMENT

Business Combinations - Summary of Purchase Price Allocation to the Fair Values Assigned to the Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016
Business Acquisition [Line Items]
Goodwill	$ 25,694	$ 26,555
Developed Technology [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	11 years 9 months 18 days	11 years 9 months 18 days
Creagh Medical Ltd [Member]
Business Acquisition [Line Items]
Current assets	$ 896
Property and equipment	634
Other noncurrent assets	81
Current liabilities	(942)
Deferred tax liabilities	(9)
Net assets acquired	14,583
Goodwill	13,440
Total purchase price, net of cash acquired	$ 28,023
Creagh Medical Ltd [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	1 year
Creagh Medical Ltd [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	10 years
Creagh Medical Ltd [Member] \| Developed Technology [Member]
Business Acquisition [Line Items]
Intangible assets	$ 1,787
Estimated Useful Life (In years)	7 years
Creagh Medical Ltd [Member] \| In-Process Research and Development [Member]
Business Acquisition [Line Items]
Intangible assets	$ 942
Creagh Medical Ltd [Member] \| Customer Relationship [Member]
Business Acquisition [Line Items]
Intangible assets	$ 11,119
Creagh Medical Ltd [Member] \| Customer Relationship [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	7 years
Creagh Medical Ltd [Member] \| Customer Relationship [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	10 years
Creagh Medical Ltd [Member] \| Trade Name [Member]
Business Acquisition [Line Items]
Intangible assets	$ 75
NorMedix, Inc. [Member]
Business Acquisition [Line Items]
Current assets	113
Property and equipment	60
Deferred tax asset	690
Other noncurrent assets	13
Accounts payable	(187)
Deferred tax liabilities	(2,483)
Net assets acquired	5,956
Goodwill	4,452
Total purchase price, net of cash acquired	10,408
NorMedix, Inc. [Member] \| Developed Technology [Member]
Business Acquisition [Line Items]
Intangible assets	$ 6,850
NorMedix, Inc. [Member] \| Developed Technology [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	10 years
NorMedix, Inc. [Member] \| Developed Technology [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	14 years
NorMedix, Inc. [Member] \| Customer Relationship [Member]
Business Acquisition [Line Items]
Intangible assets	$ 900
Estimated Useful Life (In years)	4 years

XML 49 R37.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Assets and Liabilities Measured at Fair Value on a Recurring Basis [Member] - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	$ 41,249	$ 44,114
Liabilities measured at fair value	(14,291)	(14,517)
Available-for-sale securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	27,474	21,954
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	41,249	44,114
Significant Other Observable Inputs (Level 2) [Member] \| Available-for-sale securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	27,474	21,954
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	(14,291)	(14,517)
Cash equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	13,775	22,160
Cash equivalents [Member] \| Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	13,775	22,160
Contingent consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	(14,291)	(14,517)
Contingent consideration [Member] \| Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	$ (14,291)	$ (14,517)

XML 50 R38.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Contingent Consideration Liabilities Measured at Fair Value (Detail) - Contingent Consideration [Member] - Significant Unobservable Inputs (Level 3) [Member] - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 14,517
Additions		$ 9,064
Interest accretion	437	109
Foreign currency translation (gain) loss	(663)	135
Ending balance	$ 14,291	$ 9,308

XML 51 R39.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2017	Sep. 30, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfers in or out Level 3, Assets				$ 0
Transfers in or out Level 3, Liabilities				$ 0
Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Percentage of Probability Achievement of Contingent Consideration payment.	65.00%
Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Percentage of Probability Achievement of Contingent Consideration payment.	95.00%
Contingent Consideration [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Foreign currency gain (loss)	$ 700,000	$ (100,000)
Contingent Consideration [Member] \| Minimum [Member] \| Non Revenue Based Milestones [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Inputs, Discount Rate	5.60%
Contingent Consideration [Member] \| Minimum [Member] \| Revenue Based Milestones [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Inputs, Discount Rate	14.10%
Contingent Consideration [Member] \| Maximum [Member] \| Non Revenue Based Milestones [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Inputs, Discount Rate	6.70%
Contingent Consideration [Member] \| Maximum [Member] \| Revenue Based Milestones [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Inputs, Discount Rate	22.80%
Scenario Forecast [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfers in or out Level 3, Assets			$ 0
Transfers in or out Level 3, Liabilities			$ 0

XML 52 R40.htm IDEA: XBRL DOCUMENT

Investments - Amortized Cost, Unrealized Holding Gains and (Losses) and Fair Value of Available-for-sale Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 27,487	$ 22,019
Unrealized Losses	(13)	(65)
Fair Value	27,474	21,954
Commercial paper and corporate bonds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	27,487	22,019
Unrealized Losses	(13)	(65)
Fair Value	$ 27,474	$ 21,954

XML 53 R41.htm IDEA: XBRL DOCUMENT

Investments - Sales of Available-for-Sale Securities (Detail) $ in Thousands	3 Months Ended
	Dec. 31, 2016 USD ($)
Investments Debt And Equity Securities [Abstract]
Proceeds from maturities	$ 7,071

XML 54 R42.htm IDEA: XBRL DOCUMENT

Inventories - Components of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 1,724	$ 1,766
Work-in process	449	492
Finished products	1,299	1,321
Total	$ 3,472	$ 3,579

XML 55 R43.htm IDEA: XBRL DOCUMENT

Other Assets - Summary of Other Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016
Schedule of Investments [Line Items]
Other assets, net	$ 721	$ 628
ViaCyte, Inc. [Member]
Schedule of Investments [Line Items]
Other assets, net	479	479
Other Noncurrent Assets [Member]
Schedule of Investments [Line Items]
Other assets, net	$ 242	$ 149

XML 56 R44.htm IDEA: XBRL DOCUMENT

Other Assets - Additional Information (Detail) - ViaCyte, Inc. [Member] $ in Millions	3 Months Ended
	Dec. 31, 2016 USD ($)
Schedule of Investments [Line Items]
Equity method investment	$ 5.3
Other than temporary impairment loss on investment	4.8
Cost method of investment	$ 0.5
Maximum [Member]
Schedule of Investments [Line Items]
Company's ownership percentage	1.00%

XML 57 R45.htm IDEA: XBRL DOCUMENT

Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization expense	$ 0.6	$ 0.4

XML 58 R46.htm IDEA: XBRL DOCUMENT

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016
Intangible Assets [Line Items]
Definite-lived intangible assets, Accumulated Amortization	$ (9,145)	$ (8,604)
Intangible assets, Gross Carrying Amount	30,239	31,129
Intangible assets, Net	$ 21,094	$ 22,525
Customer Lists and Relationships [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	8 years 10 months 24 days	8 years 10 months 24 days
Definite-lived intangible assets, Gross Carrying Amount	$ 16,979	$ 17,692
Definite-lived intangible assets, Accumulated Amortization	(6,434)	(6,123)
Definite-lived intangible assets, Net	$ 10,545	$ 11,569
Core Technology [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	8 years	8 years
Definite-lived intangible assets, Gross Carrying Amount	$ 530	$ 530
Definite-lived intangible assets, Accumulated Amortization	$ (530)	$ (530)
Developed Technology [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	11 years 9 months 18 days	11 years 9 months 18 days
Definite-lived intangible assets, Gross Carrying Amount	$ 8,610	$ 8,724
Definite-lived intangible assets, Accumulated Amortization	(800)	(618)
Definite-lived intangible assets, Net	$ 7,810	$ 8,106
Non-compete [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	5 years	5 years
Definite-lived intangible assets, Gross Carrying Amount	$ 230	$ 230
Definite-lived intangible assets, Accumulated Amortization	(69)	(58)
Definite-lived intangible assets, Net	$ 161	$ 172
Patents and Other [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	16 years 6 months	16 years 6 months
Definite-lived intangible assets, Gross Carrying Amount	$ 2,322	$ 2,321
Definite-lived intangible assets, Accumulated Amortization	(1,312)	(1,275)
Definite-lived intangible assets, Net	1,010	1,046
Definite-Lived Intangible Assets [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Gross Carrying Amount	28,671	29,497
Definite-lived intangible assets, Accumulated Amortization	(9,145)	(8,604)
Definite-lived intangible assets, Net	19,526	20,893
In-Process Research and Development [Member]
Intangible Assets [Line Items]
Indefinite-lived intangible assets, Net	927	987
Trademarks and Trade Names [Member]
Intangible Assets [Line Items]
Indefinite-lived intangible assets, Net	$ 641	$ 645

XML 59 R47.htm IDEA: XBRL DOCUMENT

Intangible Assets - Estimated Amortization Expense (Detail) $ in Thousands	Dec. 31, 2016 USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Remainder of 2017	$ 1,864
2018	2,439
2019	2,439
2020	2,264
2021	2,125
2022	$ 2,085

XML 60 R48.htm IDEA: XBRL DOCUMENT

Goodwill - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	$ 25,694	$ 26,555

XML 61 R49.htm IDEA: XBRL DOCUMENT

Goodwill - Schedule Of Carrying Amount of Goodwill by Segment (Detail) $ in Thousands	3 Months Ended
	Dec. 31, 2016 USD ($)
Goodwill [Line Items]
Balance as of September 30, 2016	$ 26,555
Translation adjustment	(861)
Balance as of December 31, 2016	25,694
In Vitro Diagnostics [Member]
Goodwill [Line Items]
Balance as of September 30, 2016	8,010
Balance as of December 31, 2016	8,010
Medical Device [Member]
Goodwill [Line Items]
Balance as of September 30, 2016	18,545
Translation adjustment	(861)
Balance as of December 31, 2016	$ 17,684

XML 62 R50.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Stock-based Compensation Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 789	$ 684
Product costs [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	13	6
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	125	59
Selling, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 651	$ 619

XML 63 R51.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015
Stock-Based Compensation Activity [Line Items]
Unrecognized compensation costs related to non-vested awards	$ 6,200,000
Weighted average period for recognition of compensation costs related to non-vested awards	2 years 6 months
Performance share awards fully expensed	$ 2,600,000
Weighted average per share fair value of stock options	$ 7.59	$ 6.87
Dividend yield	0.00%	0.00%
Vesting period				3 years	3 years
Stock compensation expenses recognized	$ 789,000	$ 684,000
Fiscal 2015 (2015 - 2017) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year	2015
Performance period end year	2017
Fiscal 2016 (2016 - 2018) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year	2016
Performance period end year	2018
Fiscal 2017 (2017 - 2019) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year	2017
Performance period end year	2019
Scenario Forecast [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period			3 years
Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Total pre-tax intrinsic value of options exercised	$ 100,000	100,000
Performance Level [Member] \| Minimum [Member]
Stock-Based Compensation Activity [Line Items]
Vesting percentage	20.00%
Performance Level [Member] \| Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Performance share awards, estimated vesting percentage	200.00%
Nonqualified Stock Options [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized	$ 300,000	300,000
Nonqualified Stock Options [Member] \| Board of Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock option exercisable on a pro-rata basis	1 year
Nonqualified Stock Options [Member] \| Employee [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period	4 years
Nonqualified Stock Options [Member] \| Minimum [Member] \| Board of Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock option expiration term upon expiration of employment or service	7 years
Nonqualified Stock Options [Member] \| Maximum [Member] \| Board of Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock option expiration term upon expiration of employment or service	10 years
Nonqualified Stock Options [Member] \| Vesting Anniversary [Member] \| Employee [Member]
Stock-Based Compensation Activity [Line Items]
Vesting percentage	25.00%
Restricted Stock Awards
Stock-Based Compensation Activity [Line Items]
Restricted stock expense	$ 100,000	100,000
Performance Shares [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized	$ 200,000	200,000
Issuance of shares	38,505
Performance Shares [Member] \| Fiscal 2015 (2015 - 2017) [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of performance shares for grants awarded					$ 900,000
Performance Shares [Member] \| Fiscal 2016 (2016 - 2018) [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of performance shares for grants awarded				$ 1,300,000
Performance Shares [Member] \| Scenario Forecast [Member] \| Fiscal 2017 (2017 - 2019) [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of performance shares for grants awarded			$ 1,200,000
Performance Shares [Member] \| Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Issuance of shares	78,606
1999 Employee Stock Purchase Plan [Member]
Stock-Based Compensation Activity [Line Items]
Annual compensation withheld, maximum limit	$ 25,000
Employee contributions	100,000			$ 100,000
1999 Employee Stock Purchase Plan [Member] \| Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized	$ 100,000	$ 100,000
Common stock authorized, shares	600,000
Annual compensation withheld	10.00%
Restricted Stock Units (RSUs) [Member] \| 2009 Equity Incentive Plan [Member]
Stock-Based Compensation Activity [Line Items]
Number of stock units awarded	6,570	8,916
Number of stock units forfeited	74
Number of stock units outstanding	35,378			32,101
Number of stock units outstanding estimated fair value	$ 900,000			$ 900,000
Restricted Stock Units (RSUs) [Member] \| Maximum [Member] \| 2009 Equity Incentive Plan [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized	$ 100,000	$ 100,000
Deferred Stock Units [Member] \| 2009 Equity Incentive Plan [Member] \| Director [Member]
Stock-Based Compensation Activity [Line Items]
Number of stock units awarded	1,971	1,842
Number of stock units outstanding	23,048			21,077
Number of stock units outstanding estimated fair value	$ 600,000			$ 600,000
Deferred Stock Units [Member] \| Maximum [Member] \| 2009 Equity Incentive Plan [Member] \| Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized	100,000	$ 100,000
Number of stock units outstanding estimated fair value	$ 100,000	$ 100,000

XML 64 R52.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Assumptions Used in Stock Option Plans (Detail)	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Risk-free interest rates	1.70%	2.00%
Expected life (years)	4 years 7 months 6 days	4 years 7 months 6 days
Expected volatility	34.40%	36.70%
Dividend yield	0.00%	0.00%

XML 65 R53.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Schedule of Fair Value at the Date of Grant (Detail)	3 Months Ended
	Dec. 31, 2016 shares
Fiscal 2015 (2015 - 2017) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum Shares	8,440
Target Shares	42,199
Maximum Shares	84,398
Fiscal 2016 (2016 - 2018) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum Shares	13,268
Target Shares	66,338
Maximum Shares	132,676
Fiscal 2017 (2017 - 2019) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum Shares	10,437
Target Shares	52,185
Maximum Shares	104,370

XML 66 R54.htm IDEA: XBRL DOCUMENT

Revolving Credit Facility - Additional Information (Detail) - Revolving Credit Facility [Member] - USD ($)		3 Months Ended
	Nov. 02, 2016	Dec. 31, 2016
Line Of Credit Facility [Line Items]
Revolving credit facility amount	$ 30,000,000
Line of credit facility, expiration period	3 years
Credit facility fee percentage	0.15%
Line of credit facility expiration month and year		2019-11
Debt outstanding		$ 0
Minimum [Member]
Line Of Credit Facility [Line Items]
Credit facility interest rate	1.00%
Maximum [Member]
Line Of Credit Facility [Line Items]
Credit facility interest rate	1.75%
Multi-currency Overdraft Facility [Member] \| Ireland
Line Of Credit Facility [Line Items]
Line of credit facility additional borrowing capacity	$ 5,000,000
Credit facility incremental of additional borrowings	5,000,000
Multi-currency Overdraft Facility [Member] \| Maximum [Member] \| Ireland
Line Of Credit Facility [Line Items]
Line of credit facility additional borrowing capacity	$ 20,000,000

XML 67 R55.htm IDEA: XBRL DOCUMENT

Net Income Per Share Data - Denominator for Computation of Basic and Diluted Net Income Per Share (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
Net income available to common shareholders	$ 2,300	$ 2,653
Basic weighted average shares outstanding	13,200	12,966
Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units, deferred stock units and performance shares	246	220
Diluted weighted average shares outstanding	13,446	13,186

XML 68 R56.htm IDEA: XBRL DOCUMENT

Net Income Per Share Data - Additional Information (Detail) - USD ($) shares in Millions	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Nov. 05, 2014
Earnings Loss Per Share [Line Items]
Weighted average diluted shares outstanding excluded outstanding stock options	0.3	0.4
Accelerated Share Repurchase Program [Member]
Earnings Loss Per Share [Line Items]
Maximum payments for repurchase of common stock			$ 30,000,000

XML 69 R57.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income tax provisions	$ 1,727,000	$ 1,152,000
Effective tax rates	42.90%	30.30%
U.S. federal statutory tax rate	35.00%	35.00%
Unrecognized tax benefits excluding interest and penalties that would impact effective tax rate	$ 1,200,000		$ 1,200,000
Undistributed earnings in foreign subsidiaries	$ 0		$ 0

XML 70 R58.htm IDEA: XBRL DOCUMENT

Segment and Geographical Information - Additional Information (Detail)	3 Months Ended
	Dec. 31, 2016 Segment
Segment Reporting [Abstract]
Number of operating segments	2

XML 71 R59.htm IDEA: XBRL DOCUMENT

Segment and Geographical Information - Segment Revenue, Operating Income and Depreciation and Amortization (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Revenue	$ 17,761	$ 16,541
Operating income	3,268	3,939
Depreciation and amortization	1,282	909
Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income	5,175	5,473
Operating Segments [Member] \| Medical Device [Member]
Segment Reporting Information [Line Items]
Revenue	13,757	12,247
Operating income	3,719	3,830
Depreciation and amortization	1,004	487
Operating Segments [Member] \| In Vitro Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue	4,004	4,294
Operating income	1,456	1,643
Depreciation and amortization	103	222
Corporate [Member]
Segment Reporting Information [Line Items]
Operating income	(1,907)	(1,534)
Depreciation and amortization	$ 175	$ 200

XML 72 R60.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail)	3 Months Ended
	Dec. 31, 2016 USD ($) € / $	Dec. 31, 2016 EUR (€)
Commitments And Contingencies [Line Items]
License agreement commencement date	2006-03	2006-03
Annual minimum payments for licenses	$ 211,000	€ 200,000
Exchange rate relating to license payment \| € / $	1.0536
Future minimum payments associated with license \| $	$ 2,700,000
Patents [Member]
Commitments And Contingencies [Line Items]
Patent expiry date	2027-09	2027-09

EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 74 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 77 FilingSummary.xml IDEA: XBRL DOCUMENT 3.6.0.2 html 174 257 1 false 57 0 false 7 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.surmodics.com/20161231/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.surmodics.com/20161231/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.surmodics.com/20161231/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Income Sheet http://www.surmodics.com/20161231/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome Condensed Consolidated Statements of Income Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.surmodics.com/20161231/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.surmodics.com/20161231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 100060 - Disclosure - Basis of Presentation Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureBasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 100070 - Disclosure - New Accounting Pronouncements Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureNewAccountingPronouncements New Accounting Pronouncements Notes 8 false false R9.htm 100080 - Disclosure - Business Combinations Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureBusinessCombinations Business Combinations Notes 9 false false R10.htm 100090 - Disclosure - Fair Value Measurements Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 100100 - Disclosure - Investments Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureInvestments Investments Notes 11 false false R12.htm 100110 - Disclosure - Inventories Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureInventories Inventories Notes 12 false false R13.htm 100120 - Disclosure - Other Assets Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureOtherAssets Other Assets Notes 13 false false R14.htm 100130 - Disclosure - Intangible Assets Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureIntangibleAssets Intangible Assets Notes 14 false false R15.htm 100140 - Disclosure - Goodwill Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureGoodwill Goodwill Notes 15 false false R16.htm 100150 - Disclosure - Stock-based Compensation Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureStockBasedCompensation Stock-based Compensation Notes 16 false false R17.htm 100160 - Disclosure - Revolving Credit Facility Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureRevolvingCreditFacility Revolving Credit Facility Notes 17 false false R18.htm 100170 - Disclosure - Net Income Per Share Data Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureNetIncomePerShareData Net Income Per Share Data Notes 18 false false R19.htm 100180 - Disclosure - Income Taxes Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 19 false false R20.htm 100190 - Disclosure - Segment and Geographical Information Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureSegmentAndGeographicalInformation Segment and Geographical Information Notes 20 false false R21.htm 100200 - Disclosure - Commitments and Contingencies Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 21 false false R22.htm 100210 - Disclosure - New Accounting Pronouncements (Policies) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureNewAccountingPronouncementsPolicies New Accounting Pronouncements (Policies) Policies http://www.surmodics.com/20161231/taxonomy/role/DisclosureNewAccountingPronouncements 22 false false R23.htm 100220 - Disclosure - Business Combinations (Tables) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureBusinessCombinationsTables Business Combinations (Tables) Tables http://www.surmodics.com/20161231/taxonomy/role/DisclosureBusinessCombinations 23 false false R24.htm 100230 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.surmodics.com/20161231/taxonomy/role/DisclosureFairValueMeasurements 24 false false R25.htm 100240 - Disclosure - Investments (Tables) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureInvestmentsTables Investments (Tables) Tables http://www.surmodics.com/20161231/taxonomy/role/DisclosureInvestments 25 false false R26.htm 100250 - Disclosure - Inventories (Tables) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureInventoriesTables Inventories (Tables) Tables http://www.surmodics.com/20161231/taxonomy/role/DisclosureInventories 26 false false R27.htm 100260 - Disclosure - Other Assets (Tables) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureOtherAssetsTables Other Assets (Tables) Tables http://www.surmodics.com/20161231/taxonomy/role/DisclosureOtherAssets 27 false false R28.htm 100270 - Disclosure - Intangible Assets (Tables) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureIntangibleAssetsTables Intangible Assets (Tables) Tables http://www.surmodics.com/20161231/taxonomy/role/DisclosureIntangibleAssets 28 false false R29.htm 100280 - Disclosure - Goodwill (Tables) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureGoodwillTables Goodwill (Tables) Tables http://www.surmodics.com/20161231/taxonomy/role/DisclosureGoodwill 29 false false R30.htm 100290 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureStockBasedCompensationTables Stock-based Compensation (Tables) Tables http://www.surmodics.com/20161231/taxonomy/role/DisclosureStockBasedCompensation 30 false false R31.htm 100300 - Disclosure - Net Income Per Share Data (Tables) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureNetIncomePerShareDataTables Net Income Per Share Data (Tables) Tables http://www.surmodics.com/20161231/taxonomy/role/DisclosureNetIncomePerShareData 31 false false R32.htm 100310 - Disclosure - Segment and Geographical Information (Tables) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureSegmentAndGeographicalInformationTables Segment and Geographical Information (Tables) Tables http://www.surmodics.com/20161231/taxonomy/role/DisclosureSegmentAndGeographicalInformation 32 false false R33.htm 100320 - Disclosure - New Accounting Pronouncements - Additional Information (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureNewAccountingPronouncementsAdditionalInformationDetail New Accounting Pronouncements - Additional Information (Detail) Details 33 false false R34.htm 100330 - Disclosure - Business Combinations - Additional Information (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformationDetail Business Combinations - Additional Information (Detail) Details 34 false false R35.htm 100340 - Disclosure - Business Combinations - Summary of Purchase Price (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfPurchasePriceDetail Business Combinations - Summary of Purchase Price (Detail) Details 35 false false R36.htm 100350 - Disclosure - Business Combinations - Summary of Purchase Price Allocation to the Fair Values Assigned to the Assets Acquired and Liabilities Assumed (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureBusinessCombinationsSummaryOfPurchasePriceAllocationToFairValuesAssignedToAssetsAcquiredAndLiabilitiesAssumedDetail Business Combinations - Summary of Purchase Price Allocation to the Fair Values Assigned to the Assets Acquired and Liabilities Assumed (Detail) Details 36 false false R37.htm 100360 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) Details 37 false false R38.htm 100370 - Disclosure - Fair Value Measurements - Schedule of Contingent Consideration Liabilities Measured at Fair Value (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfContingentConsiderationLiabilitiesMeasuredAtFairValueDetail Fair Value Measurements - Schedule of Contingent Consideration Liabilities Measured at Fair Value (Detail) Details 38 false false R39.htm 100380 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 39 false false R40.htm 100390 - Disclosure - Investments - Amortized Cost, Unrealized Holding Gains and (Losses) and Fair Value of Available-for-sale Securities (Details) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureInvestmentsAmortizedCostUnrealizedHoldingGainsAndLossesAndFairValueOfAvailableForSaleSecuritiesDetails Investments - Amortized Cost, Unrealized Holding Gains and (Losses) and Fair Value of Available-for-sale Securities (Details) Details 40 false false R41.htm 100400 - Disclosure - Investments - Sales of Available-for-Sale Securities (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureInvestmentsSalesOfAvailableForSaleSecuritiesDetail Investments - Sales of Available-for-Sale Securities (Detail) Details 41 false false R42.htm 100410 - Disclosure - Inventories - Components of Inventories (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureInventoriesComponentsOfInventoriesDetail Inventories - Components of Inventories (Detail) Details 42 false false R43.htm 100420 - Disclosure - Other Assets - Summary of Other Assets (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureOtherAssetsSummaryOfOtherAssetsDetail Other Assets - Summary of Other Assets (Detail) Details 43 false false R44.htm 100430 - Disclosure - Other Assets - Additional Information (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureOtherAssetsAdditionalInformationDetail Other Assets - Additional Information (Detail) Details 44 false false R45.htm 100440 - Disclosure - Intangible Assets - Additional Information (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail Intangible Assets - Additional Information (Detail) Details 45 false false R46.htm 100450 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail Intangible Assets - Schedule of Intangible Assets (Detail) Details 46 false false R47.htm 100460 - Disclosure - Intangible Assets - Estimated Amortization Expense (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureIntangibleAssetsEstimatedAmortizationExpenseDetail Intangible Assets - Estimated Amortization Expense (Detail) Details 47 false false R48.htm 100470 - Disclosure - Goodwill - Additional Information (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureGoodwillAdditionalInformationDetail Goodwill - Additional Information (Detail) Details 48 false false R49.htm 100480 - Disclosure - Goodwill - Schedule Of Carrying Amount of Goodwill by Segment (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureGoodwillScheduleOfCarryingAmountOfGoodwillBySegmentDetail Goodwill - Schedule Of Carrying Amount of Goodwill by Segment (Detail) Details 49 false false R50.htm 100490 - Disclosure - Stock-based Compensation - Stock-based Compensation Expenses (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesDetail Stock-based Compensation - Stock-based Compensation Expenses (Detail) Details 50 false false R51.htm 100500 - Disclosure - Stock-based Compensation - Additional Information (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail Stock-based Compensation - Additional Information (Detail) Details 51 false false R52.htm 100510 - Disclosure - Stock-based Compensation - Assumptions Used in Stock Option Plans (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedInStockOptionPlansDetail Stock-based Compensation - Assumptions Used in Stock Option Plans (Detail) Details 52 false false R53.htm 100520 - Disclosure - Stock-based Compensation - Schedule of Fair Value at the Date of Grant (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueAtDateOfGrantDetail Stock-based Compensation - Schedule of Fair Value at the Date of Grant (Detail) Details 53 false false R54.htm 100530 - Disclosure - Revolving Credit Facility - Additional Information (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureRevolvingCreditFacilityAdditionalInformationDetail Revolving Credit Facility - Additional Information (Detail) Details 54 false false R55.htm 100540 - Disclosure - Net Income Per Share Data - Denominator for Computation of Basic and Diluted Net Income Per Share (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureNetIncomePerShareDataDenominatorForComputationOfBasicAndDilutedNetIncomePerShareDetail Net Income Per Share Data - Denominator for Computation of Basic and Diluted Net Income Per Share (Detail) Details 55 false false R56.htm 100550 - Disclosure - Net Income Per Share Data - Additional Information (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureNetIncomePerShareDataAdditionalInformationDetail Net Income Per Share Data - Additional Information (Detail) Details 56 false false R57.htm 100560 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 57 false false R58.htm 100570 - Disclosure - Segment and Geographical Information - Additional Information (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureSegmentAndGeographicalInformationAdditionalInformationDetail Segment and Geographical Information - Additional Information (Detail) Details 58 false false R59.htm 100580 - Disclosure - Segment and Geographical Information - Segment Revenue, Operating Income and Depreciation and Amortization (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureSegmentAndGeographicalInformationSegmentRevenueOperatingIncomeAndDepreciationAndAmortizationDetail Segment and Geographical Information - Segment Revenue, Operating Income and Depreciation and Amortization (Detail) Details 59 false false R60.htm 100590 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.surmodics.com/20161231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 60 false false All Reports Book All Reports srdx-20161231.xml srdx-20161231.xsd srdx-20161231_cal.xml srdx-20161231_def.xml srdx-20161231_lab.xml srdx-20161231_pre.xml true true ZIP 79 0001564590-17-000937-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-17-000937-xbrl.zip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�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